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Christoph P. Hornik: Application of Pharmacometric Methods to Optimize Trial Design and Dosing in 
Critically Ill Infants 
(Under the direction of Daniel Gonzalez) 
Drug development in critically ill infants is challenging. Limited number of eligible trial participants, 
low consent rates, inability to perform or tolerate trial assessments, and ethical considerations all 
contribute to a low rate of successful clinical trials in this population. As a result, drugs administered to 
infants are often incompletely studied to ensure their efficacy and safety, and administered without a US 
Food and Drug Administration (FDA)-approved indication (off-label). Off-label drug use is associated with 
increased risk of unwanted drug toxicities or therapeutic failures, which can result in poor infant 
outcomes. To improve infant outcomes, innovative strategies in drug development are needed to 
generate the data necessary to identify safe and effective drug dosing regimens. The work performed in 
this dissertation provides 3 examples of innovative approaches to drug development in critically ill infants. 
Central to these innovations is leveraging pharmacometric methods to address 3 common obstacles: 
(1) sample size determination of infant pharmacokinetic (PK) trials; (2) characterization of the relationship 
between drug exposure and efficacy to identify efficacious doses; and (3) evaluation of the association 
between drug exposure and safety to identify safe doses. Each of these 3 obstacles is overcome with the 
help of a specific pharmacometric approach. In aim 1, populationPK (popPK) modeling and simulation is 
applied to determine optimal sample sizes for various infant PK trial designs. In aim 2, 
popPK/pharmacodynamic (PD) modeling is used to characterize the exposure response relationship 
between methylprednisolone and antiinflammatory changes in neonates undergoing cardiac surgery on 
cardiopulmonary bypass (CPB). In aim 3, popPK models are combined with electronic health record 
(EHR)-derived real-world data (RWD) sources to develop a novel platform to study the relationship 
between predicted drug exposures and safety events captured during routine clinical care. 
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 INTRODUCTION: CHALLENGES OF AND OPPORTUNITIES ASSOCIATED WITH DRUG 
DEVELOPMENT IN CRITICALLY ILL INFANTS 
 
INTRODUCTION 
For decades, children have been largely excluded from clinical drug trials, resulting in a critical 
knowledge gap in drug efficacy, safety, and dosing data. As a result, when treating pediatric patients, 
practicing clinicians are often forced to prescribe off-label drugs (up to 60% of drugs in children and up to 
90% of drugs in neonates).1,2 This practice can result in therapeutic failure and unnecessary toxicity.3 
Lack of safety and efficacy data on therapeutics and devices in infants (less than 2 years of age) and 
children (12 years of age or older) is largely due to the challenges associated with conducting clinical 
trials in this vulnerable population. 
Numerous legislative efforts in the US (starting with the Pediatric Labeling Rule in 1994) and 
European Union (EU) (2006) were created to promote the conduct of clinical trials in children, including 
the Best Pharmaceuticals for Children Act; the Pediatric Research Equity Act; and the EU pediatric 
regulation on pediatric medicinal products (FDAMA, Food and Drug Administration Modernization Act; 
FDASIA, Food and Drug Administration Safety and Innovation Act [Figure 1-1]). As a result, both the US 
Food and Drug Administration (FDA) and the European Medicines Agency now require pediatric trial 
plans, the Pediatric Study Plan and Pediatric Investigation Plan, respectively, as part of the approval 
process for new drugs. Since the initiation of these programs, which were permanently reauthorized in the 
US in 2012, there have been 687 US pediatric labeling changes. However, despite this success, over 
40% of trials under these legislative efforts in the US and EU have failed to support a regulatory-approved 
indication in children.4 Further, of the 24 neonatal (children less than 28 days of life) label changes 
approved by the FDA from 1997 to 2010, 13 were for "lack of neonatal indication, which effectively does 
not provide further guidance to clinicians."5 The most common reasons for pediatric trials failures included 
lack of efficacy (86%) and safety issues (16%).4,6 A review published by FDA scientists identified the 
following common factors contributing to pediatric trial failure:  
• Suboptimal dosing of pediatric studies
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• Difference between adult and pediatric diseases 
• Placebo response 
• Suboptimal design 
 
FDAMA, Food and Drug Administration Modernization Act; FDASIA: Food and Drug Administration Safety and 
Innovation Act 
Figure 1-1. Overview of US pediatric drug development legislation [adapted from 1]  
 
Critically ill infants and children are a particularly vulnerable and challenging pediatric 
subpopulation to study. As a result, 60 to 70% of drugs received by children during intensive care unit 
hospitalization are administered off-label.7,8 During a 2-month review period at a 26-bed academic 
pediatric intensive care unit, none of the 25 most frequently administered drugs were approved for the 
indication or age group for which they were being used. Similarly, a retrospective review of electronic 
health record (EHR)–derived real-world date (RWD) found that less than 0.5% of all infant drug 
exposures in the neonatal intensive care unit were for drugs approved for use in neonates as a result of 
federal legislation.9 
Off-label prescribing is associated with adverse events in critically ill and other pediatric 
populations. Catastrophic adverse events have occurred as a result of off-label drug use in critically ill 
neonates and infants.10–13 At a single academic tertiary-care center, the majority (53-70%) of adverse 
drug events requiring corrective interventions in children occurred in critical care units.14 Similarly, review 
1994       Pediatric Labeling Rule 
FDAMA [Pediatric Exclusivity Provision]       1997
1998       Pediatric Rule
Best Pharmaceuticals for Children Act         2002
2003      Pediatric Research Equity Act
FDASIA Creating Hope Act         2012
2016       21st Century Cures Act
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of adverse drug reactions in 5 pediatric inpatient wards in the United Kingdom found the highest rate of 
events among children admitted to the cardiac intensive care unit (35%) or intensive care unit (18%).15 In 
this study, the overall rate of adverse events was twice as high following off-label compared to on-label 
drug administration.16 
Improving pediatric labeling through extrapolation  
The FDA, the European Medicines Agency, and other regulatory agencies are committed to 
improving the state of pediatric drug labeling.17–20 One approach is to better leverage existing adult data. 
In order to ensure the most efficient use of adult data, regulatory agencies have endorsed the concept of 
extrapolation, whereby proof of drug efficacy may be borrowed from well-controlled studies in adults. 
Even when full extrapolation of drug efficacy is permissible, which is dependent upon meeting 
assumptions about disease and drug exposure-response similarities between adults and children, 
pediatric pharmacokinetic (PK) and safety trials are still needed to inform labeling. When extrapolation of 
efficacy is not permissible or only partial extrapolation is possible, efficacy trials or trials characterizing 
drug exposure-response relationships (also known as PK/pharmacodynamics [PD] trials) need to be 
performed (Figure 1-2). As a result, pediatric PK, safety, and PK/PD trials are likely to be the most 
impactful studies in terms of overall pediatric drug development. 
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Figure 1-2. Food and Drug Administration Pediatric Extrapolation Decision Tree [redrawn from 
12]  
 
CHALLENGES TO DRUG DEVELOPMENT IN CRITICALLY ILL INFANTS 
Several key hurdles have historically limited drug development in critically ill infants and children, 
in particular the conduct of PK, safety, and PK/PD trials:  
• Limited number of eligible trial participants 
• Limitations with blood  sampling for PK/PD analyses 
• Complex interplay of ontogeny and critical illness affecting ability to detect exposure-
response and exposure-safety relationships 
• Limited number and highly heterogeneous critically ill infants eligible for trial inclusion21  
Though more than 5.7 million Americans are admitted to intensive care units annually, only about 
315,000 US infants and children are treated for critical illness each year.19 Infants and children admitted 
to intensive care units often have complex conditions, including a combination of complex congenital 
malformations, trauma or postoperative physiologic alterations, infections, fluid and electrolyte 
derangements, and others,20,22 which may affect eligibility for trial participation. In addition to this 
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underlying complexity, pediatric critical illness is a highly dynamic process, which may rapidly change 
eligibility status and trial participation risk, further limiting the number of potential subjects.  
Blood sampling limitations 
In addition to the low number of eligible participants, pediatric PK/PD trials are further hampered 
by a limited ability to gather study data in children. Traditional PK studies in adults involve the collection of 
multiple (10-15 samples/subject) large-volume (greater than 10 mL) blood samples. Because the 
circulating blood volume of a newborn infant is closer to 85 mL/kg (~300 mL), such sample collection is 
not feasible in infants. While the ultimate decision on allowable blood volumes lies with institutional review 
boards (IRBs), most typically allow approximately 3% of the total blood volume to be drawn for all study 
activities over an approximately 2-week period.6 Age-appropriate sampling strategies including sparse 
sampling (2-6 samples/subject) with ultra-low sample volume (less than 100 µL) have successfully helped 
characterize the PK of antimicrobials in critically ill infants.23–26 Similarly, scavenged sampling is a 
minimal-risk method to obtain PK samples from plasma collected as part of the normal clinical care of 
infants. Blood sent to laboratories is often in excess of what is needed for the laboratory assay, and this 
surplus can be “scavenged” for PK analysis. Advantages include avoiding the need for separate blood 
draws specifically for the study, higher rates of parental consent, availability of several samples per infant; 
and avoidance of time-specific sampling.27,28 In addition to blood-volume limitations, infants may also not 
tolerate repeat phlebotomy, which can further reduce the number of available blood samples per subject. 
While sparse, opportunistic, and scavenge sampling approaches may overcome blood-volume and 
phlebotomy limitations, the data generated by these are not adequate for traditional compartmental PK 
data analysis. 
Impact of developmental changes on pharmacokinetics/pharmacodynamics 
Human growth and maturation greatly affect the PK/PD properties of drugs.29 Complex and 
rapidly changing physiologic parameters that alter drug exposures and response throughout childhood 
include, among others:  
1) Alteration in volume and function of extravascular drug-absorption sites, including intestinal 
function, epidermal barrier function, and intramuscular (IM) capillary density 
 6  
 
2) Larger relative extracellular fluid volume as a percentage of body weight (WT) that changes 
between premature infants, term infants, early childhood, and adolescents 
3) Immature renal and hepatic function that develop at varying rates across different ages in 
early childhood 
4) Changes in amount and composition of drug-binding proteins 
5) Unique and developing drug barriers in multiple organ systems, including intestine luminal 
blood and blood-brain barriers  
As a result of these changes, when therapeutics are evaluated in pediatric PK trials, the dosing is often 
substantially different from adults and/or there are significant safety issues identified.30–32  
Similar to differences in PK, PD drug response may display significant variability across the 
pediatric age continuum as a result of growth, maturation, and disease-specific effects. Age-dependent 
differences in the expression of drug targets may alter PD. Differences in the prokinetic effects of 
erythromycin in preterm infants, for example, may be mediated by age-dependent alterations of intestinal 
motilin receptor expression.33 Age-dependent differences in the interaction of drugs and receptors have 
also been shown to alter PD response to drugs such as warfarin and cyclosporine.34,35 Even when drug-
receptor expression and initial interaction remain constant, age-dependent alterations of downstream 
effects of drug-receptor interactions can alter drug effects across the pediatric age continuum, as seen, 
for example, with different sedation levels following administration of midazolam.36,37 Importantly, age-
dependent exposure-response relationships may also alter the safety profile of drugs administered across 
the pediatric age continuum. Finally, interindividual differences mediated by pharmacogenomics may 
further alter these relationships, adding an additional level of complexity.38  
There are several additional barriers to successful pediatric drug development not discussed in 
detail here but previously reviewed by others.39–42 These include the need for age-appropriate 
formulations, including excipients; the need for age-appropriate drug assay development and validation, 
taking into account both sample-volume limitations and age-specific quantification ranges; and the need 
for study of age-specific drug-drug interactions.43–45  
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SOLUTIONS AND INNOVATIONS IN INFANT DRUG DEVELOPMENT 
Despite significant obstacles and past failures, drug development in critically ill children is an area 
ripe for innovation. While the role played by specific interventions and innovations will depend on the 
specific drug-development challenge to be addressed, 2 strategies that may overcome several challenges 
are discussed here—the role of PK/PD modeling and simulation to help guide pediatric drug development 
programs and the use of EHR-derived RWD to characterize exposure-response and exposure-safety 
relationships in pediatric patients.  
Pharmacokinetic/pharmacodynamic modeling and simulation  
Mathematical modeling and simulation approaches have become essential to successful pediatric 
drug development and are endorsed by the FDA and the European Medicines Agency.17,18 There are 
numerous examples of both “bottom up” modeling approaches using physiologically based PK models 
and “top down” modeling approaches using population PK (popPK) modeling influencing essential 
pediatric drug development steps, including dose selection and trial design.46,47  
The optimal type of model for pediatric drug development depends largely on the planned 
regulatory strategy and extrapolation path as well as the available in vitro and in vivo data (Figure 1-2). 
Under the full extrapolation option (“Option C”), a PK model that incorporates the effects of size and 
maturation on drug disposition for the pediatric population of interest is ideally suited to conduct dosing 
simulations aimed at matching the exposures associated with efficacy in  populations from which efficacy 
is extrapolated. Chapter 4 illustrates the development of 2 popPK models developed, in part, for this use. 
For partial extrapolation (“Option B”) a PK/PD model developed to account for size and maturation will be 
needed to perform dosing simulations that will achieve target concentrations based on the PK/PD 
relationship. The PK/PD approach is particularly attractive to the study of drugs in the critically ill child, 
where alterations in PK/PD can be a result of developmental changes as well as pathophysiological 
alterations due to critical illness. Under the circumstances of critical illness, traditional PK methods may 
be limited in their ability to account for the variety of physiologic changes that may alter both drug 
disposition and efficacy. PK/PD models can include physiologic parameters as covariates to evaluate the 
potentially complex interactions between drug dosing, exposure, and efficacy. Characterization of PK/PD 
properties can help uncover complex exposure-response relationships likely to occur in critically ill 
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children as a result of target organ dysfunction or altered drug metabolism. When these conditions are 
present, PK/PD characterization and derived dosing guidance stand to be more informative than a 
description of drug exposure alone. For this reason, the FDA Draft Guidance Document for Pediatric 
Studies for Drugs and Biological Products recommends that PK/PD data should be collected in pediatric 
studies.18 Chapter 3 illustrates the utility of a popPK/PD model to identify optimal dosing of 
methylprednisolone in neonates undergoing cardiac surgery. Because the exposure targets of 
methylprednisolone in this population are unknown, dosing simulations are designed to optimize pro- and 
anti-inflammatory cytokine profiles while minimizing overall drug exposure.48,49 
Regardless of the planned regulatory strategy and subsequent trial design, optimizing sample 
size of pediatric trials is essential. Unfortunately, even though PK or PK/PD model development is 
commonly the primary objective of pediatric trials, robust methods to compute the necessary sample size 
to successfully meet this objective are still lacking. As a result, numerous approaches to sample size 
determination for pediatric PK and PK/PD trials are used by sponsors. The pragmatic and flexible 
approach of modeling and simulations can once again be leveraged to help address this limitation. 
Chapter 2 illustrates how sample size determinations for neonatal PK trials can be conducted for specific 
PK study designs using a modeling and simulation approach.  
Real-world data utilization 
Safety assessments of pediatric drugs, mandated through the entire FDA pediatric extrapolation 
decision tree, continue to require robust sample sizes.15,16 Because the number of critically ill infants 
eligible for trial enrollment is limited, novel approaches are needed. RWD is a promising approach to help 
augment pediatric safety data.50 Section 505F(b) of the federal Food, Drug, and Cosmetic Act defines 
RWD as "data regarding the usage, or the potential benefits or risks, of a drug derived from sources other 
than traditional clinical trials." Real-world evidence (RWE) is clinical evidence about the usage and 
potential risks of a medical product derived from analysis of RWD. The FDA created its RWE framework 
with the specific intent of evaluating the potential for RWE to support the approval of a new indication for 
a drug.51 A promising example of an RWD source, particularly for pediatric drug safety assessment, is the 
use of EHRs.  
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EHRs are nearing universal adoption in the US healthcare system.52,53 Though designed to 
optimize the provision of clinical care, EHRs hold great potential for the assessment of pediatric drug 
safety.54 Common pediatric drug adverse events, including diagnoses, laboratory abnormalities, or 
changes in vital signs, are recorded for routine clinical care and have become more readily accessible. 
Despite its strengths, a common limitation to the use of EHRs for the assessment of pediatric drug safety 
is the lack of drug-exposure data. With the exception of the rare drugs that undergo routine therapeutic 
drug monitoring, assessment of the relationship between drug exposure and safety (or efficacy) cannot 
be conducted using EHR data alone. Chapter 4 illustrates how a combination of EHRs and exposure 
simulations derived from popPK models developed using opportunistically collected data can be used to 
evaluate exposure-safety relationships. 
CONCLUSIONS 
Despite substantial efforts in recent years, pediatric drug development continues to lag behind 
adult programs. Importantly, the most vulnerable pediatric subpopulations, including critically ill infants, 
are most neglected when it comes to studying drug efficacy and safety. Fortunately, innovative 
approaches to pediatric drug development offer an opportunity to address this public health challenge. 
The following work illustrates how innovative approaches can address specific challenges of drug 
development in critically ill infants. In addition to presenting practical solutions to specific problems, each 
approach also serves as a proof of concept for a broader platform to support drug development in this 
vulnerable population. Specifically: 
• Chapter 2 illustrates the use of a simulation-based approach to optimize sample size for 
neonatal PK trials, addressing both the challenges of a small eligible population and limited 
tolerance for plasma-sampling for analysis.  
• Chapter 3 illustrates the role of popPK/PD modeling to identify optimal drug dosing in critically 
ill postoperative neonates, based on relationships between predicted exposures and 
interleukin response.  
• Chapter 4 illustrates how combining opportunistically derived popPK modeling and simulation 
with RWD collected in the EHR can create a novel, innovative, and efficient platform for the 
characterization of drug exposure-safety relationships. 
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The majority of drugs received by neonates are prescribed off-label.1 Off-label prescribing is 
associated with increased risk of unwanted drug side effects and therapeutic failures.2 Lack of neonatal 
drug labeling is a direct result of insufficient or inadequate clinical trial data. Pharmacokinetic (PK) trials 
are the foundation of clinical drug development, and are essential to identify appropriate doses for 
administration in neonates.3 Failed PK trials may result in the development and application of 
misspecified or imprecise PK models, and the resulting selection of inappropriate drug doses leading to 
over- or under-exposure.4 An inadequately small sample size may lead to failure of PK trials, but 
enrollment in studies including infants is challenging.5–7 Neonates and infants are especially difficult to 
enroll in PK trials, due to the overall small eligible population, increased risk from trial participation 
(because of low blood volume and increased risk associated with phlebotomy, among others), and 
generally low (< 10%) consent rate. These challenges are accentuated when enrolling premature 
neonates. Adequately sizing PK trials without enrolling unnecessarily large number of subjects is 
therefore paramount to study success in neonates. 
Guidance from the US Food and Drug Administration (FDA) suggests that PK trials be 
prospectively powered to target a 95% CI within 60% to 140% of the geometric mean estimate of 
clearance (CL) and volume of distribution (V) for the study drug in each pediatric subgroup with at least 
80% power.8 Clarifications published by FDA scientists provide further methodological detail on how to 
achieve this precision-based sample size requirement.9 These methods are easily implemented when 
                                                     
1 This chapter previously appeared in a manuscript prepared for submission to Journal of Clinical 
Pharmacology. Sample Size estimation of Neonatal Pharmacokinetic Trials: A Simulation Based 
Approach. Christoph P. Hornik, MD, MPH; Todd Schwartz, DrPH; Michael Cohen-Wolkowiez, MD, PhD; 
Daniel Gonzalez PharmD, PhD. 
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conducting traditional noncompartmental PK analysis. However, when population pharmacokinetics 
(popPK) is planned as the PK analysis method, as is most often the case in neonatal PK trials, the 
proposed methods are more complex and rely on assumed values of population parameters and the 
variance-covariance matrix to compute 95% CIs around parameter estimates, followed by clinical trial 
simulations to calculate power. While robust, this method lacks intuitive incorporation of several factors 
essential to neonatal PK trial design, including the number and timing of PK samples obtained per 
subject, the effects of growth and maturation on drug disposition, and other potential sources of 
variability. As a result, the FDA recommends that whenever possible, clinical trial simulations be 
performed to assess the effect of these factors on sample size determination.  
In this report, we leveraged existing neonatal PK data to perform simulations and compute the 
precision and accuracy of estimated values of CL and V for commonly encountered neonatal clinical trial 
scenarios. By including prematurity, number of samples per subject, assumed between-subject variability 
(BSV), and drugs with different primary elimination routes, we provide relevant and practical sample size 
estimates to support the optimal design of neonatal PK trials. 
METHODS 
Brief overview of the approach and workflow 
We used a simulation-based approach to estimate sample size requirements for neonatal popPK 
modeling. The workflow outlined here was followed for the sample size estimation of 2 probe drugs—the 
renally eliminated drug, meropenem, and the hepatically eliminated drug, clindamycin (Figure 2-1). In 
addition to their differing routes of elimination, both drugs have been previously studied in neonatal 
(sub)populations of varying sizes, and popPK models with differing numbers of covariates have been 
developed for each drug.10,11 The PK of meropenem was characterized in a subpopulation of 
130 neonates, while that of clindamycin was characterized in a subpopulation of 30 neonates. 
First, we selected 2 reference popPK models previously developed from plasma PK data 
prospectively collected in separate reference PK trials.10,11 
 
 
The approach outlined was repeated for each of the 2 probe drugs. 
BSV, between-subject variability; PK, pharmacokinetics 




Next we created separate neonatal virtual populations of 1000 preterm and 1000 term neonates 
for each probe drug. The virtual populations mimic the clinical characteristics, dosing scheme, and PK 
sampling times of the neonates included in both trials. Using the reference covariate models (see below 
for details of parameterization), we simulated individual predicted plasma concentrations (IPREDs) of 
each probe drug in each virtual population at the protocol-specified sampling times, following the protocol-
specified dosing regimen. 
From the virtual populations, we created subpopulations of interest, termed clinical trial 
populations. These clinical trial populations are defined based on factors known to potentially affect 
reliability of PK models, including gestational age (GA) of subjects, number of PK samples drawn per 
subject, and the amount of BSV incorporated into the plasma concentration simulations (see Figure 2-1). 
For each of the clinical trial populations, we sampled without replacement 1000 analysis datasets of a 
prespecified sample size. 
We then separately fit the reference popPK models in each of the 1000 analysis datasets to 
generate individual empirical Bayesian estimates (EBEs) of CL (CLi) and V (Vi) for each virtual subject. 
We used these individual estimates to determine the precision of the geometric mean of CLi and Vi 
estimates in each analysis dataset. We computed power as the percentage of successful analysis 
datasets, defined as analysis datasets for which the 95% CI around the geometric mean of both CLi and 
Vi were within 60% to 140% of the point estimates.   
Reference population pharmacokinetics models and parameter estimates 
We chose meropenem as the first probe to simulate sample size requirements. The meropenem 
reference popPK model was developed in a population of 188 hospitalized infants less than 91 days 
postnatal age (PNA), including 130 neonates less than 30 days PNA, who received intravenous (IV) 
meropenem at doses of 20 to 30 mg/kg/dose every 8 to 12 hours.10 The equations for typical values of CL 
and V defining the reference popPK model of meropenem were: 
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where WTi is body weight in kg, ALBi is plasma albumin concentration in g/dL, SCRi is serum creatinine 
concentration in mg/dL, and PMAi is postmenstrual age in weeks. 
We chose clindamycin as the second probe to simulate sample size requirements. The 
clindamycin reference popPK model was developed in a population of 220 children, including 
30 neonates less than 30 days PNA, who received IV clindamycin at doses of 10 to 15 mg/kg/dose every 
6 to 8 hours.11 The equations for typical values of CL and V defining the reference popPK model of 
clindamycin were:      






















where WTi is body weight in kg, ALBi is plasma albumin concentration in g/dL, AAGi is alpha-1 acid 
glycoprotein in mg/mL, and PMAi is postmenstrual age in weeks.  
Virtual populations 
To create the virtual populations of neonates, we sampled without replacement from an electronic 
health recored (EHR) data source: the Pediatrix Medical Group Clinical Data Warehouse.12 This EHR-
derived real-world data (RWD) source includes inpatient neonatal intensive care unit admission records 
from more than 300 sites in North America. Daily deidentified data from the EHR are transferred to the 
data warehouse for quality improvement and research purposes. For our analysis, extracted data 
included GA and PNA, daily WT, and plasma serum creatinine and albumin concentrations obtained per 
routine clinical care. Because alpha-1 acid glycoprotein concentration measurement is not routinely 
performed in clinical practice, values were not available in the data warehouse and were instead 
simulated using the ontogeny function built in to PK-Sim.13 We separately sampled the data warehouse to 
create virtual populations for simulations of meropenem and clindamycin. Within each virtual population, 
the sample was stratified by prematurity (GA < 37 weeks vs GA ≥37 weeks), and by PNA (0-7 days, 
7-14 days, 14-28 days). In total, we created 1000 preterm and 1000 term neonates for each drug, for a 
total of 4000 subjects. We added dosing and PK sampling records to the virtual population to mimic the 
conditions of the reference PK trials.  
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Dosing was based on the recommended clinical trial dose, and PK sample times were selected 
based on the protocol-recommended sampling times following both first dose and at steady state (Table 
2-1). The maximum number of PK samples allowed per each study protocol (7 samples) was selected. 
We then used reference popPK models developed for each drug to simulate individual plasma 
concentrations (IPREDs) of meropenem and clindamycin at each of the PK sampling times. For the 
simulation, population estimates were fixed at the final values estimated in the models, but BSV for both 
CL and V were jointly fixed at 1 of 3 coefficient of variation (CV) % values: 20%, 40%, or 60%. Residual 
variability was not incorporated into the simulations.   
To define the clinical trial populations, we systematically modified the characteristics of the virtual 
populations as follows. First, we separated premature from term infants. We then separated simulated 
concentrations by the amount of incorporated BSV. Next, we specified the number of PK samples 
obtained in each subject by randomly sampling time points from the 7 simulated PK samples. We created 
3 categories of PK sample numbers: sparse sampling, defined as 1 to 3 samples per subject; moderate 
sampling, defined as 4 to 5 samples per subject; and rich sampling, defined as 6 to 7 samples per 
subject. Within each category, an equal number of subjects were assigned to each number of samples. 
Lastly, we created a total of 1000 analysis datasets with a prespecified number of subjects for each 
clinical trial population. We varied the number of subjects included in each of the 1000 analysis datasets 
in increments of 2 subjects.  
Table 2-1. Suggested sampling times in the POP01 protocol 
Sample name Time points after start of continuous infusion or end of 
single-dose administration (hours) 
Sample #1 0-0.25 
Sample #2 0.15-0.5 
Sample #3 1-3 
Sample #4 4-8 
POP01, Pharmacokinetics of Understudied Drugs Administered to Children per Standard of Care trial 
 
Sample size estimate 
To estimate sample size, we fit the reference popPK model in each of the 1000 analysis datasets 
of decreasing number of subjects. Following reestimation of the models in the analysis datasets, we 
computed within each of the 1000 replicates the geometric mean and associated 95% CI of CLi and Vi. 
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We then considered each of the 1000 replicates a success if the 95% CI around the geometric mean 
estimate of both CLi and Vi was within 60% to 140% of the respective geometric mean point estimate. 
Model runs with greater than 20% shrinkage on BSV terms for CL or V were considered failures, while 
model runs that did not minimize successfully were excluded from the analysis. We computed power as 
the percentage of successful analysis datasets for each scenario. Finally, the minimal required sample 
size for each clinical trial population was defined as the sample size at which the power to precisely 
estimate both CLi and Vi was 80% or greater, per the FDA guidance.  
Accuracy at minimal sample size 
To evaluate the accuracy of our model at the proposed sample size for each clinical trial scenario, 
we computed the mean absolute difference between the estimated population parameter estimates from 
the reference popPK model for both CL and V from each of the 1000 replicates at the proposed minimal 
sample size and the population estimate obtained when fitting the models in the entire corresponding 
virtual population (ie, N = 1000 neonates with the same GA and included BSV for simulated 







|𝜃𝜃�𝑗𝑗𝑗𝑗 − 𝜃𝜃�𝑗𝑗′ |
𝜃𝜃�𝑗𝑗′
∗ 100) 
where 𝜃𝜃�𝑗𝑗𝑗𝑗  is the population estimate for CL or V estimated in the jth run for each clinical trial population, 
and 𝜃𝜃�𝑗𝑗′  is the population estimate for CL or V estimated in the entire virtual population with the same 
clinical characteristics. 
RESULTS 
Virtual population characteristics 
Weight, age, and covariate values were within the range of the neonatal subpopulation enrolled in 
the meropenem and clindamycin trials (Table 2-2). Per design, half of the population were premature 
neonates. Alpha-1 acid glycoprotein and serum creatinine concentrations were only included for the 
clindamycin and meropenem virtual populations, respectively, as they were not included as covariates in 
the popPK model for the other drug.  
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N = 30 
GA, weeks 36.5 (24-40) 28.1 (22.5-40) 36.5 (24-40) 31 (23-40) 
Premature (< 37 
weeks GA) 1000 (50%) 112 (86%) 1000 (50%) 21 (70%) 
PNA, days 16 (1-30) 12 (1-30) 16 (1-30) 13 (5-30) 
PMA, weeks 38 (24.1-44.3) 30.7 (23.6-43.7) 38 (24-44) 33 (24-42) 
Weight, grams 3111 (450-4799) 1200 (425-4768) 3200 (535-8420) 1440 (460-4400) 
Creatinine, mg/dL 0.5 (0.1-3.05) 0.6 (0.2-2.9) N/Ab N/Ab 




N/Ab N/Ab 2.0 (0.5-3.8) 1.8  (0.5-.8) 
GA, gestational age; N/A, not applicable; PMA, postmenstrual age; PNA, postnatal age 
a Data shown as median (range) or counts (%). 
b N/A, as these covariates were not included in the popPK model for this drug. Alpha1 acid glycoprotein 
concentrations were simulated using the ontogeny function algorithm built in to PK-Sim® and previously 
published.13 
 
Sample size requirement  
Across all scenarios, the minimal required sample size was lower for meropenem than for 
clindamycin (Table 2-3). The required sample size in term neonates was up to 80% lower compared to 
the required sample size in preterm neonates with otherwise similar clinical trial scenarios (4-24 subjects 
vs 14-36 subjects). The difference was most pronounced for clinical trial populations with a large number 
of samples per subject and low BSV. 
In general, the required sample size decreased with increasing number of samples drawn per 
subject, ranging from 6 to 20 subjects with 6 to 7 PK samples to 24 to 36 subjects with 1 to 3 PK samples.  
The largest increases in sample size were seen when the BSV was (60%). At a fixed number of samples 
per subject, the required sample size increased with increasing BSV in all scenarios.   
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Table 2-3. Minimal sample size requirements stratified by gestational age, samples per 
subject, and degree of between-subject variability derived from simulations performed using final 




age Samples per subject 
  6 – 7 4 – 5 1 – 3 
Between subject variability 
(CV%) 20 40 60 20 40 60 20 40 60 
Meropenem < 37 weeks 14 18 24 16 18 24 18 20 26 
 ≥ 37 weeks 6 12 18 8 12 16 8 14 24 
Clindamycin < 37 weeks 20 26 30 20 24 30 20 28 36 
 ≥ 37 weeks 4 6 8 6 8 10 8 12 14 
CV, coefficient of variation 
  
Accuracy of estimates 
Accuracy of population parameter estimates of both CL and V estimated from the covariate 
popPK model varied across simulations (Table 2-4). Accuracy decreased with increased BSV and 
decreasing number of samples per subject. Accuracy was generally best (< 20%) for meropenem 
simulations in preterm infants, while it was greater than 20% for several simulated clindamycin scenarios.   
CL was generally estimated more accurately than V, except in the meropenem model for term infants, 




Table 2-4. Accuracy of population parameter estimates from the covariate population 
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CL, clearance; CV, coefficient of variation; GA, gestational age; V, volume; wks., weeks  
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DISCUSSION 
We computed simulation-based estimates of minimal sample size requirements for neonatal PK 
trials analyzed using a popPK approach. Our approach was based on the FDA-defined precision criterion 
for the estimation of CL and V.9 As expected, we found that prematurity, number of samples drawn per 
subject, and magnitude of BSV affected sample size estimates. Further, estimated sample size also 
differed between the 2 probe drugs studied: clindamycin required greater sample sizes to precisely 
estimate CL and V parameters compared to meropenem, particularly in premature infants. The novelty of 
our approach included the sole focus on the neonatal population and the inclusion of premature infants, 
the use of RWD to create the virtual populations used for simulation, the estimation of sample size at 
different magnitudes of BSV and for different numbers of samples drawn per subject, and the use of 
individual estimates of both CLi and Vi to compute the power and necessary sample size.  
Clarification published by FDA scientists in support of the agency’s proposed approach to power 
pediatric PK trials to precisely estimate PK parameters of interest provides example results and scripts for 
direct computation of sample size when noncompartmental analysis methods are used.9 When, as is 
frequently the case in children in general and neonates in particular, a popPK analysis method is planned, 
simulations to obtain the power to estimate the CI of a particular parameter within a prespecified precision 
limit with stepwise increases in sample size are needed. This simulation-based approach has been 
previously implemented to calculate the necessary sample size for theoretical scenarios and in 
preparation for an actual pediatric PK trial.14,15 A key advantage of this pragmatic simulation-based 
approach is its flexibility, which allows for estimation of the precision of any model parameter, regardless 
of model structure or complexity. Because the model relies on imputing estimates of population 
parameter values and their standard error, the source of these estimates can significantly affect estimated 
sample size. Indeed, varying the source of the initial estimate of PK parameter variability has been shown 
to increase the required sample size by greater than 100%.16 Of note, this prior study did not detect any 
obvious additional trends in sample size requirements based on study drug or subject characteristics, 
including age. While the limitations of imputed initial parameter estimates applies regardless of the 
planned PK analysis method (noncompartmental or popPK), a limitation specific to the popPK analysis 
approach is the requirement to compute parameter standard errors to calculate 95% CIs. Unfortunately, 
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widely used popPK software such as NONMEM does not always produce standard errors of popPK 
parameter estimates; even then models minimize successfully.17 We attempted to address both of these 
limitations in our simulation design. We relied on existing pediatric popPK models to inform the values of 
the fixed-effects parameters included in our simulation and fixed BSV at 3 different a priori specified 
values of 20%, 40%, and 60% CV. This approach allowed us to systematically show the effect that BSV 
may have on sample size requirements. To avoid the need to rely on population parameter standard 
errors, we opted to compute precision of the geometric mean of individual estimates CLi and Vi. Despite 
these differences in approach, our simulated sample sizes were generally consistent with those 
previously reported for popPK analysis using the precision-based approach.14,15 Further, we confirmed 
that our minimal recommended sample sizes in all scenarios were sufficient to precisely estimate the 
population parameter values of both CL and V with a 95% CI within 60% to 140% of the point estimates.   
Standard errors of parameter estimates can also be asymptotically estimated by computing the 
Fisher information matrix (FIM) for a given model. Multiple approaches to compute the FIM, and software 
packages that implement these methods, have been developed, with only minor differences observed 
among them.18 This approach has several advantages over simulation-based methods, including 
computational efficiency, and is increasingly relied upon for study design. While a comparison of FIM vs 
estimation-based computation of standard errors was not within the scope of this work, a single scenario 
of a neonatal PK trial using a 1-compartment model and BSV of 45% on both CL and V, a sample size of 
24 subjects, well within the range of our estimates, was sufficient to precisely estimate both CL and V 
(results not shown).  
We observed different sample size requirements for the 2 probe drugs studied. Across all 
simulated scenarios, but particularly among neonates less than 37 weeks GA clindamycin required 
greater sample sizes to achieve similar PK parameter precision compared to meropenem. We believe this 
difference highlights the limitation of simulation-based sample size estimations that depend upon the 
characteristics of the underlying popPK model used for simulation. The clindamycin reference popPK 
model included a greater number of covariates and parameters. Ultimately, the magnitude of covariate 
effects, both as a function of strength of covariate effects and range of covariate values, observed in our 
virtual populations determine the variability in Cli and Vi and therefore the recommended sample size. 
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Illustrating the greater magnitude of covariate effects in the clindamycin model, the CV% of Cli estimates 
in the entire virtual population was greater for clindamycin compared to meropenem: 74% vs 60%.  
Our simulation results also suggested a greater sample- size requirement in the preterm relative 
to the term population. Again, the magnitude of covariate effects likely drives this difference. In particular, 
the range for postmenstrual age (PMA) is much wider in a population of premature neonates compared to 
term neonates. As a result, estimates for Cli and Vi that incorporate PMA, as is the case in the model for 
both of our probe drugs, would be expected to show greater variability in the preterm population. Also as 
a result, the sample size requirement to precisely estimate the geometric mean of Cli and Vi would be 
expected to be greater in premature neonates.  
A major objective of our approach was to provide highly relevant and usable sample size 
estimates for neonatal PK trials. We therefore simulated scenarios that incorporated several factors 
known to affect PK model commonly encountered during PK trial design, including assumptions about the 
anticipated BSV, the number of samples drawn per subject, and the inclusion of premature neonates. We 
also chose to increase sample size in each simulation in increments of 2, to allow for more precise 
selection of sample size, given the challenges to enroll even a single neonate in a PK trial. We leveraged 
our access to RWD sources to sample the virtual populations, rather than relying on distribution of 
characteristics. Lastly, we based our final sample size requirement on the ability to precisely estimate 
both CL and V parameters, rather than a single parameter only, which would be necessary to fully 
estimate the disposition characteristics of a drug. Finally, it is important to note that while we selected 
sample sizes based on an 80% threshold for power, our approach could be applied to any prespecified 
threshold (eg, 90% power). 
Despite its strengths, our approach has several limitations in addition to the ones outlined above. 
We relied on a specific drug popPK model and population characteristics for simulation. As a result, the 
simulation findings themselves may not be applicable to the study of other drugs or populations. 
However, the approach is generalizable and easily implemented in NONMEM to compute sample size 
requirements for drugs or study populations. We also limited our simulation to the study of covariate 
models and did not evaluate the sample sizes required to detect statistically significant covariates. 
However, our approach can easily be implemented in both covariate and "base" popPK models without 
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covariates to compare sample size requirements. Because the approach relies on estimates of Cli and Vi, 
both the magnitude of covariate effects and the range of covariate values observed in the simulation 
population will drive the difference in required sample size. In our case, the covariate effects for both 
drugs were relatively weak, and the range of observed values was small in this neonatal population, 
limiting the impact of covariates on sample size requirements. Other limitations of our approach in 
addition to the ones outlined above include the use of only 1 estimation method in NONMEM (first order 
conditional estimation method with interaction), despite the known effect that different estimation methods 
may have on simulated parameter values.15 We also based our simulations on popPK models previously 
developed in children, not just neonates, which confers real-world plausibility to our estimates, but is 
limited to a 1-compartment model with IV administration of drug. Additional simulations would be required 
to evaluate sample size requirement for more complex models. Finally, we used 1000 replicates of 
analysis datasets to compute power and associated sample size. More precise estimates may be 
obtained with larger simulations, albeit at a greater computational expense.   
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 POPULATION PHARMACOKINETIC/PHARMACODYNAMIC MODELING OF 
METHYLPREDNISOLONE IN NEONATES UNDERGOING CARDIOPULMONARY BYPASS2 
 
INTRODUCTION 
Congenital heart diseases (CHDs) are the most common birth defects, affecting approximately 
40,000 live births annually in the US.1,2 The most severe forms of CHDs need life-saving surgery in the 
neonatal period, which requires the use of CPB to perform cardiac and pulmonary functions and allow for 
open-heart surgery on a nonbeating and bloodless heart.3 CPB induces systemic inflammation modulated 
by multiple cytokines, including proinflammatory interleukin (IL)-6 and antiinflammatory IL-10. CPB-
induced inflammation leads to postoperative complications (eg, pulmonary, renal, and myocardial 
dysfunction; coagulopathy) and increased mortality. Suppression of IL-mediated inflammation may be 
achieved with antiinflammatory drugs such as methylprednisolone and could improve outcomes, though a 
clinical benefit has not been demonstrated in neonates.    
Methylprednisolone is administered to more than 60% of neonates undergoing cardiac surgery on 
CPB, despite a lack of population-specific dosing, efficacy, and safety data.4 Intravenous (IV) 
methylprednisolone is administered in the form of phosphate or succinate ester prodrugs, which are both 
rapidly converted to active drug. Methylprednisolone is a lipophilic drug (volume of distribution at steady 
state [Vss] in adults 24-29 L), moderately bound to plasma albumin, and exhibits linear elimination via 
                                                     
2 This chapter previously appeared in a manuscript prepared for submission to CPT: Pharmacometrics & 
Systems Pharmacology. Population Pharmacokinetic/Pharmacodynamic Modeling of Methylprednisolone 
in Neonates Undergoing Cardiopulmonary Bypass. Christoph P. Hornik, MD MPH; Daniel Gonzalez, 
PharmD, PhD; Julie Dumond, PharmD MS; Huali Wu, PhD; Eric M. Graham, MD; Kevin Hill, MD, MS; 




oxidation and conjugation in the liver. Intravenous methylprednisolone sodium succinate is a high-
extraction-ratio drug at lower doses, with reported clearance (CL) in adults of 82 to 97 L/h.5,6 CPB may 
alter drug disposition through multiple pathophysiologic mechanisms, including blood pH and cardiac 
output changes, drug sequestration in the CPB circuit, hemodilution and hypoproteinemia, iatrogenic 
hypothermia, and inflammation.7–10 For example, in adults undergoing CPB, methylprednisolone CL was 
reduced approximately 2-fold compared to healthy controls, likely resulting from impaired hepatic blood 
flow in the perioperative period. The PK of methylprednisolone has never been studied in neonates 
undergoing CPB, and extrapolation of adult PK data is infeasible given developmental and disease-
specific changes in drug disposition, as well as differences in CPB execution in neonates. 
Methylprednisolone exposure-targets associated with reduction of CPB-mediated inflammation 
are unknown. Because of this uncertainty, prior trials studying the relationship between 
methylprednisolone dosing and clinical endpoints have yielded conflicting results.11–16 Interleukin-6 and 
IL-10 are elevated during CPB in neonates, and the degree of elevation can be modulated by 
methylprednisolone therapy.12 Given this finding and their known role in the inflammatory cascade, IL-6 
and IL-10 may represent a biomarker surrogate for methylprednisolone efficacy. Indirect-response 
PK/pharmacodynamic (PD) models have characterized methylprednisolone effects in adults and were 
found to be generally more consistent than effect compartment models.17,18  
The goal of the analyses described herein is to address both knowledge gaps in the PK and 
PK/PD relationships of methylprednisolone in neonates undergoing CPB. Using plasma samples 
collected in a previously conducted trial in neonates undergoing CPB,11 we developed separate 
population PK (popPK)/PD) models for IL-6 and IL-10 and leveraged the models to conduct 
methylprednisolone dosing simulations to achieve optimal suppression of IL-6 and induction of IL-10. 
METHODS 
Study design 
The plasma samples and clinical data for this analysis were collected in a prospective, 
randomized study of methylprednisolone sodium succinate administered as 1 or 2 doses of 30 mg/kg via 
IV infusion over 1 hour to neonates 30 days of age or older before CPB.11,19 In the 2-dose arm, subjects 
received methylprednisolone approximately 12 hours before CPB and at CPB induction via injection into 
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the pump prime fluid. In the 1-dose arm, subjects received methylprednisolone at CPB induction via 
injection into the pump prime fluid. Blood samples were collected before the first dose of 
methylprednisolone; approximately 8 hours after the first dose (for the 2-dose group) and before CPB 
initiation and the second dose (2-dose group); and at 0, 4, 12, and 24 hours after the end of CPB. 
Samples were stored at -80 degrees Celsius, without intermittent thawing/refreezing, for up to 7 years 
before analysis. Pharmacokinetic profiles based on these samples have not been previously published. 
Bioanalysis 
Concentrations of methylprednisolone in plasma were quantified using high-performance liquid 
chromatography tandem mass spectrometry assay (OpAns LLP, Durham NC). Methylprednisolone and 
the internal standard were extracted using liquid-liquid extraction from human plasma with methyl tert-
butyl ether. Reversed-phase high-performance liquid chromatography separation was achieved with a 
Phenomenex Synergi Polar-RP 80Å, (50 x 2.0 mm, 4 micron) column (Torrance CA). Tandem mass 
spectrometry detection was set at mass transitions of m/z 375.2→253.2 for methylprednisolone and m/z 
378.3→255.4 for methylprednisolone-d3 (internal standard) in Turbolon Spray Probepositive mode. The 
linear concentration range of methylprednisolone was from 20 to 10,000 mcg/mL, with a lower limit of 
quantification (LLOQ) of 1 ng/mL. Inter- and intra-run precision and accuracy were within standards 
established by the US Food and Drug Administration (FDA) (< 15% coefficient of variation [CV] and bias). 
Concentrations of IL-6 and IL-10 in plasma were determined via commercially available multiplex 
suspension array assays (R&D Systems, Minneapolis MN) as previously described.11 
Population pharmacokinetic/pharmacodynamic model development 
Sequential population PK/PD models were developed to characterize the time course of IL-6 and 
IL-10 responses separately after IV administration of methylprednisolone. The nonlinear mixed effects 
modeling software NONMEM (version 7.2, Icon Development Solutions, Ellicott City MD) with the first-
order conditional estimate method with interaction estimation method was used for all model runs.  
To develop the popPK component of the popPK/PD model, 1- and 2-compartment structural 
models and proportional, additive, and proportional plus additive residual error models were explored. 
Because methylprednisolone was administered to subjects as methylprednisolone sodium succinate, the 
formation of methylprednisolone from methylprednisolone sodium succinate was tested for inclusion in 
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the model as a linear kinetic process, as previously described.20 Weight was included a priori as a 
covariate for structural model parameters, centered to 3.2 kg median WT in our study cohort, and 
allometrically scaled. We tested both fixed (0.75 for all CL parameters and 1 for all V parameters) and 
estimated allometric coefficients.  
Upon successful development of the popPK model, individual PK parameter estimates from the 
final model were fixed in the PD analysis to predict methylprednisolone plasma concentrations at the time 
of IL-6 and IL-10 measurement and fit the population PD component of the popPK/PD model. Based on 
visual inspection of the observed PK/PD data and a previously published PD model for 
methylprednisolone, direct and indirect effect models were tested for both IL-6 and IL-10.17 Due to the 
known induction of both IL-6 and IL-10 production by CPB, we tested different methods to include CPB 
onset in the model. This included the CPB effect as a covariate on the maximum drug effect (eg, 
maximum stimulating drug effect [Smax], maximum inhibition [Imax]), and CPB as a separate effect on the 
formation rate constant (Kin) of IL-6 and IL-10 in parallel with the drug effect, with or without complete or 
partial interactions between the CPB and drug effects. Based on the delayed change in the observed IL-6 
and IL-10 concentrations after the start of CPB, a delay of 0.5 hours in the onset of CPB effect was 
implemented in the model. Because the observed data showed a protracted decline in IL-6 
concentrations after CPB, a half-life for the withdrawal of CPB effect was estimated for IL-6.  
The change in IL-6 concentration over time in a model without interaction between the CPB and 
drug effects, with interaction between CPB effect and drug effect, and with partial interaction between 
CPB and drug effects were described using equations 1, 2, and 3, respectively. The relationship between 
IL-6 formation and decline is shown in equation 4, and the parameterization of CPB effect is shown in 
equation 5.  
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)    (5)        
where kin is the zero-order rate constant for production of IL-6, kout is the first-order rate constant for 
decline of IL-6, IL-6base is the model-predicted IL-6 baseline plasma concentration in subjects before the 
first dose of methylprednisolone (equation 4). Imax is the maximum-fold change in production of IL-6 as a 
response to drug exposure; IC50 is the methylprednisolone concentration that produces 50% of maximum 
attainable inhibition; HILL is the Hill coefficient; Cp is the predicted plasma concentration of 
methylprednisolone; CPBE is the fold-change in IL-6 as a response to CPB procedure; CPBV is a 
variable to indicate presence of CPB effect; ONCPB is 1 during CPB and 0 for pre- and post-CPB time 
periods; CPBES, used to represent the delay in CPB effect onset, is 0 for the first 30 minutes after start of 
CPB and 1 thereafter; STRT is 0 before start of CPB and 1 thereafter; ENDT is 0 post-CPB stop and 1 
before CPB stop; TACPB is the time after the end of CPB; and CPBH is the half-life of CPB effect 
(equation 5).  
The changes in IL-10 plasma concentrations over time were characterized using equations 
similar to those for IL-6 except that Smax was used instead of Imax to account for the stimulation effect of 
methylprednisolone on kin for IL-10.   
Clinical covariates were analyzed for inclusion in the PK and PD components of the model. Visual 
inspection was performed using scatter and box plots (for continuous and categorical covariates, 
respectively) of individual deviations from the typical population values of the PK and PD parameters 
(ETAs) against covariates. In the popPK model, the covariates explored were: gestational age (GA) at 
birth (weeks); postnatal age (PNA) (days) at the time of first sample; postmenstrual age (PMA) (weeks), 
defined as GA plus PNA age at the time of first sample; CPB time (minutes); use of aortic cross-clamp 
(yes/no) and  aortic cross-clamp time (minutes); lowest CPB flow rate (L/h) and time at lowest CPB flow 
rate (minutes); and use of deep hypothermic circulatory arrest (yes/no) and time at deep hypothermic 
circulatory arrest  (minutes). In the PopPD model, the covariates explored were: GA (weeks), PNA (days) 
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at the time of first sample, PMA (weeks), CPB time (minutes), use of aortic cross-clamp (yes/no) and 
aortic cross-clamp time (minutes), surgical case complexity as defined by the Risk Adjustment in 
Congenital Heart Surgery scoring system (RACHS-1),21 and inotrope score calculated as previously 
described. Covariates with a discernible graphical relationship to ETAs were evaluated for inclusion in the 
final model. A forward inclusion (p < 0.05 and Δ objective function value [OFV] > 3.8) followed by a 
backward elimination (p < 0.01 and ΔOFV > 6.6) approach was used to evaluate statistical significance of 
relevant covariates. After the final model was identified, simultaneous fitting of all PK and PD parameters 
was performed and results compared to the sequential fitting approach. 
Population pharmacokinetics/pharmacodynamics model evaluation  
Standard diagnostic methods applied for the assessment of the popPK/PD model performance 
were successful minimization, diagnostic plots, plausibility and precision of parameter estimates, OFV, 
and shrinkage values. To further guide model development, IL-6 and IL-10 concentration time profiles 
were simulated from the popPK/PD model at methylprednisolone doses of 30 mg/kg and in the absence 
of drug and visually compared to previously published concentration time plots of observed data in infants 
exposed to 30 mg/kg of methylprednisolone or placebo, respectively. Nonparametric bootstrapping 
(500 replicates) was performed to evaluate the precision of the final popPK and PD model parameter 
estimates and to generate the 95% CIs for parameter estimates.  
Prediction-corrected visual predictive checks (pcVPCs) and standardized visual predictive checks 
(SVPCs) were performed for the final popPK and popPK/PD models, respectively, by generating 
1000 Monte Carlo simulation replicates per time point. Simulated results were compared with those 
observed in the study, including calculating and plotting the percentile of each observed concentration in 
relation to its 1000 simulated observations derived from the final model for the SVPC.22 The dosing and 
covariate values used to generate the predictions were the same as those used in the study population. 
The number of observed concentrations outside of the 90% prediction interval for each time point was 
quantified for both pcVPCs and SVPCs. 
Dosing simulation 
The final popPK/PD models were used to simulate IL-6 and IL-10 concentration time profiles in 
virtual subjects mimicking clinically relevant scenarios. Using the software PK-Sim®, a virtual population of 
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1000 term infants (GA 40 weeks) with 50% female and 85% white American (15% black American) were 
generated for equally distributed age groups: PNA of 0 to 7 days, inclusive; more than 7 to 14 days; more 
than 14 to 28 days; and 0 to 28 days. For IL-6 simulations, RACHS-1 scores less than 4 or 4 or greater 
were randomly assigned in equal distribution to the virtual subjects regardless of PNA. This cut-off was 
chosen because RACHS-1 scores of 4 or greater have been previously associated with 5-fold or greater 
odds of mortality compared to RACHS-1 scores of less than 4,23 and because subjects with scores of 4 or 
greater had mostly positive deviations of individual CL estimates from the population mean compared to 
scores of less than 4, which had mostly negative deviations. Within each RACHS-1 group (< 4 vs ≥ 4), 
CPB durations of 1 to less than 2 hours, 2 to less than 3 hours, and 3 to 4 hours were randomly assigned. 
For each RACHS-1 and CPB time group, 3 different dose levels of methylprednisolone (0, 10, and 
30 mg/kg) were assigned. For each RACHS-1, CPB time, and dose group, 2 dosing regimens were 
tested: 1 dose at CPB initiation, 1 dose at CPB, and a dose 8 hours before CPB initiation. For IL-10 
simulations, 3 different time lengths of CPB (1-< 2 hours, 2-< 3 hours, and 3-4 hours) were assigned to 
each of 3 distinct age groups: PNA 0 to 7 or fewer days, 8 to 14 days, greater than 14 to 28 days. Two 
different dose levels of methylprednisolone (10 and 30 mg/kg) and a scenario without methylprednisolone 
were assigned to each age and CPB time group. For each age, CPB time, and dose group, 2 dosing 
regimens were tested: 1 dose at CPB initiation, and 1 dose at CPB plus an additional dose 8 hours before 
CPB initiation. Simulated concentration time curves of IL-6 and IL-10 were plotted and visually compared 
across the different dosing simulation scenarios. The area under the concentration–time curve from time 
0 to 24 hours (AUC0-24) after CPB start  was calculated in NONMEM for IL-6 and IL-10 using the 
simulated concentrations of IL-6 and IL-10 for each scenario. The equation for calculating AUC0-24 is 
shown below (equation 6).  
𝐴𝐴𝐴𝐴𝐶𝐶0−24 =  ∫ 𝐶𝐶𝐶𝐶𝐶𝐶
𝑑𝑑1+24
𝑑𝑑1                      (6)  
where C is the concentration of IL-6 or IL-10, t1 is time of the CPB start relative to time of the first dose, 
and t is time after the first dose. 
Summary statistics including mean, SD, median, minimum, maximum, and 95% CI were 
calculated for AUC0-24 by number of doses and dose level. 




Sixty-four neonates with a median (range) GA at birth of 39 weeks (35-42) and PNA and WT at 
the time of PK sampling of 7 days (3-30) and 3.2 kg (2.2-4.3), respectively, contributed 
290 methylprednisolone plasma concentrations (Figure 3-1). There were no samples below the limit of 
quantification (BQL). The median number of samples per neonate was 5 (4-5). Median plasma 
concentration of methylprednisolone was 849 ng/mL (range 1.07-12,700). A single dose of 
methylprednisolone of 30 mg/kg at the start of CPB was administered to 29/64 (45%) of neonates, while 
35/64 (55%) received an additional dose of methylprednisolone approximately 12 hours before CPB 
(Table 3-1). During popPK base model development, the OFV of a 2-compartment model was 198 points 
lower than that of a 1-compartment model. Including the first-order Kin of methylprednisolone from 
methylprednisolone sodium succinate further decreased the OFV by 66 units. Estimation of the allometric 
coefficient on CL resulted in better model fit than fixing the exponent to a value of 0.75, while estimating 
the allometric coefficient on V did not improve model fit. A 2-compartment model with first-order Kin to 
methylprednisolone and estimation of the allometric coefficient on CL was selected as the base model 
(Figure 3-2). No obvious trends were observed in the standard goodness-of-fit plots of the base model. 
  




Methylprednisolone concentration vs time after last dose with concentration on log scale (A), methylprednisolone 
concentration vs time after last dose with concentration on linear scale (B), methylprednisolone concentration vs time 
after first dose with concentration on log scale (C), and methylprednisolone concentration vs time after first dose with 
concentration on linear scale (D). 
Figure 3-1. Observed concentration-time plots 
 
Table 3-1. Clinical data* of N = 64 subjects included in the analysis 
Characteristic N = 64 infants 
Gestational age at birth (weeks) 39 (34.6-42) 
Postnatal age at 1st sample (days) 7 (3-30) 
Postmenstrual age at 1st sample (weeks) 40 (36-44) 
Body weight at 1st sample (kg) 3.2 (2.2-4.3) 
Serum creatinine at 1st sample (mg/dL) 0.5 (0.1-1) 
Cardiopulmonary bypass time (minutes) 156.5 (64-251) 
Lowest cardiopulmonary bypass flow rate (L/h) 0.1 (0-0.54) 
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Characteristic N = 64 infants 
Cross-clamp time (minutes) 71 (0-132) 
Deep hypothermic circulatory arrest time 
(minutes) 4.5 (0-42) 
Time at low flow (minutes) 30 (4-119) 
Plasma lactate at 1st sample (mmol/L) 1.8 (0.5-4.1) 
Inotrope score 11.3 (2.5-20) 
RACHS-1  
    < 4 42% 
    ≥ 4   58% 
Female sex 47% 
Race  
    White 58% 
    Black 25% 
    Asian 2% 
    Latino 13% 
    Latino/Black 2% 
    Latino/White 2% 
RACHS-1, Risk Adjustment for Congenital Heart Surgery 
*Data were represented as median (range) for continuous data and percent for categorical data. Where applicable, 
data were at the time of first dose.  
 




Observed vs individual prediction (A) and population prediction (B), conditional weighted residuals vs population 
predictions (C) and time after last dose (D). The solid line in A and B is the line of identity. The solid line in C and D is 
a reference line at y = 0. The dashed lines in A, B, C, and D are smooth lines. 
Figure 3-2. Base population pharmacokinetic model diagnostic plots 
 
Plots of deviations of the individual CL estimates from the average value (ETAs) vs covariates 
suggested relationships between CL and cross-clamp time and CL and CPB time (Figure 3-3). Addition of 
CPB time on CL resulted in a significant drop in OFV (p < 0.01), and CPB time on CL was retained after 
backward elimination. Addition of cross-clamp time and time at low-flow rate on CL also resulted in a 
significant drop in OFV (p < 0.001); however, because both variables were correlated with CPB time and 
because not all neonates included in the analysis underwent cross-clamping during CPB, they were not 
further considered for the final model. No other significant covariates were identified for 
methylprednisolone PK parameters (Table 3-2). Covariates were not tested Vc because of high shrinkage 
of the parameter estimate in the base model (46%). 




Note: Each closed circle represents a subject. 
Figure 3-3. ETA for clearance vs postmenstrual age (A), postnatal age (B), cross-clamp time 
(C), and cardiopulmonary bypass time (D) for the base population pharmacokinetic model 
 
Table 3-2. Summary of covariate selection for the population pharmacokinetic model 
Description Model OFV ΔOFVa 
Univariable analysis 




Q = θQ x (WT/3.2)1.16 
3501.5 - 








Time at low-flow rate on 
CL 
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Description Model OFV ΔOFVa 
Univariable analysis 
Post-CPB vs pre-CPB and 





























PMA on CL, maturation 
function CL = θCL x (WT/3.2)
1.16 x (PMA26/(20.6 26+PMA26)) 3501.4 -0.1 
PMA on CL, power 




 3501.4 -0.1 






 3501.4 -0.1 






 3501.4 -0.1 
















+ Time at low flow rate on 
CL 





0.35x(Timeatlowflow/30)-0.15 ) x(WT/3.2)1.45 
3477.3 -4.7 
+ CPB time on CL 
 
CL = (θCLx(1-POSTCPB)+ θCLxPOSTCPBx(1-CRC)x 
(CPBtime/156.5)0.19 + 
θCLxPOSTCPBxCRCx(Crossclamp/71)-
0.51x(CPBtime/156.5)0.19 ) x(WT/3.2)1.37 
3481.5 -0.5 
Backward elimination 
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Description Model OFV ΔOFVa 
Univariable analysis 





CL, clearance; CPB, cardiopulmonary bypass; DHCA, deep hypothermic circulatory arrest; GA, gestational age; 
OFV, objective function value; PMA, postmenstrual age; PNA, postnatal age; WT, body weight 
 
Diagnostic plots for the final popPK model did not show any obvious bias (Figure 3-4). Parameter 
estimates and their precision derived from the final popPK model are shown in Table 3-3. Median (range) 
posthoc empirical Bayesian estimates (EBEs) of CL before CPB and post-CPB were 1.28 L/h/kg (0.25-
2.71) and 1.24 L/h/kg (0.20-3.60), respectively. The final popPK model was evaluated using a 1000-set 
bootstrap analysis. Seventy-two percent of bootstrap datasets converged to greater than 3 significant 
digits. The median of bootstrap fixed-effects parameter estimates were within 10% of population 
estimates from the original dataset for all parameters. The pcVPC revealed a reasonable fit between the 
observed and predicted methylprednisolone concentrations (Figure 3-5), with 11% of observed 
concentrations outside the 90% prediction interval. 
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Observed vs individual predictions (A) and population predictions (B), conditional weighted residuals vs population 
predictions (C) and time after last dose (D). The solid lines in A and B are the lines of identity. The solid line in C and 
D is a reference line at y = 0. The dashed lines in A, B, C, and D are smooth lines. 
Figure 3-4. Final population pharmacokinetics model diagnostic plots 
 
Table 3-3. Parameter estimates for the final population pharmacokinetic model 
Parameter Estimate RSE (%) Shrinkage (%) 
Bootstrap CI 
2.5% Median 97.5% 
Structural PK model 
CL/F (L/h, 3.2kg) 3.88 8  3.32 3.90 4.57 
Vc/F (L, 3.2kg) 8.92 9  7.25 8.87 10.41 
Q/F (L/h, 3.2kg) 0.10 24  0.045 0.096 0.13 
Vp/F (L, 3.2kg) 16.81 51  3.14 16.51 19.97 
Kf (1/h) 0.41 9  0.35 0.41 0.46 
WT exponent on CL 1.24 46  0.01 1.34 2.35 
CPB time on CL -0.47 47  -0.86 -0.46 0.079 
Interindividual variability (%CV) 
IIV (CL) 47.2 31 4 32.6 45.7 59.8 
IIV (Vc) 26.4 90 45 0.3 24.3 43.9 
IIV (Q) 32.6 66 39 0.3 31.0 48.2 
Residual variability       
Proportional error (%) 42.8 17 14 35.1 42.5 50.4 
CPB, cardiopulmonary bypass; CL/F, apparent clearance; IIV, interindividual variability; Kf, formation rate 
constant of methylprednisolone from methylprednisolone sodium succinate; PK, pharmacokinetic; Q/F, apparent 
distribution clearance; RSE, relative standard error; Vc/F, apparent volume of distribution for central compartment; 
Vp/F, apparent volume of distribution for peripheral compartment; WT, body weight 
CL (L/h/kg) = (3.88 x [1-POSTCPB] + 3.88 x POSTCPB x [CPBtime/156.5]-0.47) x (WT/3.2)1.24, where POSTCPB 
is a dummy variable =1 during and after CPB, and = 0 in the pre-CPB time period. 
 45  
 
 
Open circles represent prediction-corrected observed data. Dashed lines represent the 5th, 50th, and 95th 
percentiles (bottom, middle, and top, respectively) of prediction-corrected observed data. Solid lines represent the 
5th, 50th, and 95th percentiles (bottom, middle, and top, respectively) of prediction-corrected model predicted data. 
Figure 3-5. Prediction-corrected visual predictive check of methylprednisolone for the final 
population pharmacokinetic model 
 
Pharmacodynamics 
Three hundred and fourteen IL-6 data points from 62 neonates and 324 IL-10 data points from 
64 neonates were used for popPK/PD modeling. The median (range) number of IL-6 and IL-10 data 
points per neonate was 6 (4-6). The median IL-6 and IL-10 concentrations during the study were 
47.5 pg/mL (0-681.2) and 6.9 pg/mL (0.1-1125) across all infants, respectively. The median IL-6 and 
IL-10 baseline concentrations were 9.5 pg/mL (0.7-83.3) and 1.3 pg/mL (0.1-9.5) across all infants, 
respectively. Two subjects did not have any IL-6 or IL-10 concentrations measured and were therefore 
excluded from the PD analysis. There were no BQL samples. 
CPB effects on both IL-6 and IL-10 concentrations were best characterized by a separate CPB 
procedure effect on kin, in parallel with the methylprednisolone effect. Compared to a direct-effect model, 
the OFV of an indirect-effect model was significantly lower for IL-6 (∆OFV > 100) and IL-10 (∆OFV > 120). 
For IL-6, the indirect-response model with partial interaction between CPB effect and drug effect provided 
the best fit to the data. In addition, the simulated concentrations of IL-6 using the PK/PD parameters from 
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the indirect-response model with partial interaction after administration of either placebo or a single 
30-mg/kg dose of methylprednisolone were comparable to the concentrations of IL-6 reported in the 
literature for infants receiving the corresponding treatment (Figure 3-6).12 The indirect-response model 
with partial interaction between the CPB and drug effects was therefore selected as the base model for 
IL-6 (Figure 3-7). For IL-10, the indirect-response model with interaction between the CPB and drug 
effects provided the best fit to the data. The simulated concentrations of IL-10 using the EBE PK/PD 
parameters from the indirect-response model with interaction after administration of either placebo or a 
single 30-mg/kg dose of methylprednisolone were both lower compared to concentrations of IL-10 
reported in the literature for infants receiving the corresponding treatment previously reported in the 
literature. However, the fold change in IL-10 after 30-mg/kg methylprednisolone relative to that after 
placebo was comparable to prior literature reports (Figure 3-8). The indirect-response model with 
interaction between the CPB and drug effects was therefore selected as the base model for IL-10 (Figure 
3-9).  
 
The solid lines are the mean of population-predicted IL-6 after 30 mg/kg. The dashed lines are the mean population-
predicted IL-6 after placebo. The error bar is SD. Time point: 1 = presurgery day; 2 = pre-CPB; 3 = CPB end; 4 = 4h 
after CPB end; 5 = 12h after CPB end; 6 = 24h after CPB end. 
Figure 3-6. Structural population pharmacodynamic model for interleukin-6: without 
interaction (A); with partial interaction (B); with interaction (C) 
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The solid lines in A and B are the lines of identity. The solid lines in C and D are reference lines at y = 0. The dashed 
lines in A, B, C, and D are smooth lines. 
Figure 3-7. Base population pharmacodynamic model for interleukin-6 diagnostic plots: 
observed vs individual predictions (A) and population predictions (B), conditional weighted 
residuals vs population predictions (C) and time after last dose (D) 
 
 
The solid lines are the mean of population-predicted IL-10 after 30 mg/kg. The dashed lines are the mean population-
predicted IL-10 after placebo. The error bar is SD. Time point: 1 = presurgery day; 2 = pre-CPB; 3 = CPB end; 4 = 4h 
after CPB end; 5 = 12h after CPB end; 6 = 24h after CPB end. 
Figure 3-8. Structural population pharmacodynamic model for interleukin-10: without 
interaction (A); with partial interaction (B); with interaction (C) 
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The solid lines in A and B are the lines of identity. The solid lines in C and D are reference lines at y = 0. The dashed 
lines in A, B, C, and D are smooth lines. 
Figure 3-9. Base population pharmacodynamic model for interleukin-10 diagnostic plots: 
observed vs individual predictions (A) and population predictions (B), conditional weighted 
residuals vs population predictions (C) and time after last dose (D) 
 
Plots of EBEs from the IL-6 base model vs covariates suggested relationships between the CPB effect 
(CPBE) and RACHS-1, CPBE and DHCA (deep hypothermic circulatory arrest), IL-6 base concentration 
and PNA, as well as IL-6 base concentration and GA (Figure 3-10). During the univariable analysis, 
RACHS-1 (≤ 4 vs > 4) on CPBE resulted in the highest OFV drop, followed by DHCA on CPBE, PNA on 
IL-6 base concentration, and GA on IL-6 base concentration (Table 3-4). After incorporating RACHS-1 on 
CPBE in the model, PNA on IL-6 base concentration and GA on IL-6 base concentration caused further 
significant drop, but only RACHS-1 on CPBE was retained after backward elimination. No other 
significant covariates were identified. Incorporation of RACHS-1 as a covariate for CPBE reduced the 
interindividual variability (IIV) on CPBE by 13%. The final IL-6 model thus included RACHS-1 on CPBE: 
CPBE = 48.6*(2.59)RACHS-1 ≥4. The increase in kin from baseline by CPB effect in neonates with RACHS-1 
less than 4 was estimated to be 48.6-fold. The increase in kin from baseline by CPB effect in the neonate 
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with RACHS-1 of 4 or greater was estimated to be 2.59-fold higher compared to that in neonates with 
RACHS-1 less than 4. 
 
Each closed circle represents a subject. 
Figure 3-10. ETA for baseline interleukin-6 (ETA_base) vs postmenstrual age (A), gestational 
age (B), and ETA for CPBE (ETA_CPBE) vs RACHS-1 (RANK) (C) and DHCA (D) for the base 
pharmacodynamic model for IL-6 
 
Table 3-4. Summary of the covariate selection process for the interleukin-6 population 
pharmacokinetic/pharmacodynamics model 
Description Model OFV ΔOFVa 
Univariable analysis 
Base model BASE = θBASE 
CPBE = θCPBE 
2518.9 - 
RACHS-1 on CPBE CPBE = θCPBE  x (RACHS-1>=4)
θRACHS-1 
 2508.4 -10.5 
PNA on baseline BASE = θBASE  x (PNA/7)
θPNA 
 2513.4 -5.5 
GA on baseline BASE = θBASE x (GA/39)
 θGA  2513.7 -5.2 
DHCA on CPBE CPBE = θCPBE x θ
DHCA 2514.1 -4.8 
CPB time categorical on 
CPBE (CPB > 156.5 min) 
CPBE = θCPBE  x (CPB>156.5min)
θCPBC 
 2515.3 -3.6 
CROSCLAMP on CPBE CPBE = θCPBE x θ
CROSCLAMP
 2515.9 -3.0 
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Description Model OFV ΔOFVa 
CPB time categorical on 
CPBE (CPB > 120 min) 
CPBE = θCPBE  x (CPB>120min)
θCPBC 
 2516.0 -2.9 
CPB time on CPBE CPBE = θCPBE x θ
CPBTIME
 2516.3 -2.6 





PMA on baseline BASE = θBASE x (PMA/40)
 θPMA 
 2518.0 -0.9 
Multivariable analysis-first step 
    
RACHS-1 on CPBE  
PNA on BASE 
BASE = θ
BASE









RACHS-1 on CPBE 












RACHS-1 on CPBE 







 2508.4 -0.1 
Multivariable analysis-
second step 
   
RACHS-1 on CPBE  
PNA on BASE 
BASE = θ
BASE









RACHS-1 on CPBE  
PNA on BASE 
GA on BASE 
BASE = θ
BASE












RACHS-1 on CPBE  
PNA on BASE 
GA on BASE 
BASE = θ
BASE











- RACHS-1 on CPBE BASE = θ
BASE
  x (PNA/7)
θPNA 
x (GA/39)
 θGA  
2508.6 +10.3 











- GA on BASE BASE = θ
BASE
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Description Model OFV ΔOFVa 
BASE, baseline IL-6 model without CPB; CPB, cardiopulmonary bypass duration (minutes); CPBE, 
cardiopulmonary bypass effect; OFV, objective function value; DHC, 0 for subjects without deep hypothermic 
circulatory arrest and 1 for subjects with deep hypothermic circulatory arrest; DHCA, deep hypothermic circulatory 
arrest time; CRC, 0 for subjects without cross-clamp procedure and 1 for subjects with cross-clamp procedure; GA, 
gestational age (weeks); IL, interleukin; PMA, postmenstrual age (weeks); PNA, postnatal age (days); RACHS-1, 
Risk Adjustment for Congenital Heart Surgery 
 
Plots of EBE parameter estimates from the IL-10 base model vs covariates suggested 
relationships between the CPBE and PMA, IL-10 base concentration, and PNA, as well as IL-10 base 
concentration and GA (Figure 3-11). During the univariable analysis, inotrope score on Smax caused the 
highest OFV drop (20.1 points) but did not decrease IIV on Smax and was thus not included in the model 
(Table 3-5). We later tested the addition of inotrope score to the model including PMA, which still did not 
result in a drop of IIV on Smax and was therefore not retained. PMA on CPBE caused the second-highest 
OFV drop (14.5 points), followed by PNA on IL-10 base concentration (8 points) and GA on IL-10 base 
concentration (5 points). After incorporating PMA on CPBE in the model, only GA on IL-10 base 
concentration caused a further significant drop, but only PMA on CPBE was retained after backward 
elimination. No other significant covariates were identified. Incorporation of PMA as a significant covariate 
for CPBE reduced the IIV on CPBE by an absolute drop of 13%. The final IL-10 model thus included PMA 
on CPBE: CPBE = 45.7*(PMA/40)14.8. The increase in kin from baseline by CPB effect in the average 
neonate with PMA of 40 weeks was estimated to be 45.7-fold. 
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Each closed circle represents a subject. 
Figure 3-11. ETA for interleukin 10 base vs postnatal age (A) and gestational age (B), and ETA 
for cardiopulmonary bypass effect vs postmenstrual age for the base pharmacodynamic model 
for interleukin-10 (C) 
 
Table 3-5. Summary of the model covariate selection process for the interleukin-10 
population pharmacokinetic/pharmacodynamics model 
Description Model OFV ΔOFV 
Univariable analysis 
Base model BASE = θBASE 
CPBE = θCPBE 
SMAX = θSMAX 
1863.6  
Inoscore on SMAX SMAX = θSMAX x (INOSCORE/11.25)
 ΘINOSCORE
 1843.5 -20.1 
PMA on CPBE CPBE = θCPBE x (PMA/40)
 ΘPMA
 1849.1 -14.5 
PNA  on baseline BASE = θBASE  x (PNA/7)
θPNA 
 1855.6 -8 
GA on baseline BASE = θBASE x (GA/39)
 θGA  1858.6 -5.0 
CPB time categorical on 
CPBE (CPB > 120 min) 
CPBE = θCPBE  x θ 
CPB>120min
  1861.0 -2.6 
PMA on SMAX SMAX = θSMAX x (PMA/40)
 ΘPMA
 1861.1 -2.5 
CPB time on CPBE CPBE = θCPBE  x (CPB/156.5)
θCPBTIME 
 1861.3 -2.3 
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Description Model OFV ΔOFV 
Gender on baseline BASE = θBASE x θ 
Male 1861.4 -2.2 
CROSCLAMP on CPBE CPBE = θCPBE x θ
CROSCLAMP
 1861.9 -1.7 
CROSCLAMP time on 
CPBE 





GA on SMAX SMAX = θSMAX x (GA/39)
 θGA 
 1862.6 -1.0 
PMA on baseline BASE = θBASE x (PMA/40)
 θPMA
 1863.3 -0.3 
CPB time categorical on 
CPBE (CPB > 156.5 min) 
CPBE = θCPBE  x  θ 
CPB>156.5min
 1863.6 0 
Multivariable analysis 
PMA on CPBE 
GA on BASE 
CPBE = θCPBE x (PMA/40)
 ΘPMA
 




PMA on CPBE  
PNA on BASE 
CPBE = θCPBE x (PMA/40)
 ΘPMA
 




Backward elimination    
PMA on CPBE 
GA on BASE 
CPBE = θCPBE x (PMA/40)
 ΘPMA
 




-GA on BASE CPBE = θCPBE x (PMA/40)
 ΘPMA
 1849.1 +5.6 
-PMA on CPBE BASE = θBASE x (GA/39)
 θGA  1858.6 +15.1 
CPB, cardiopulmonary bypass; CRC, 0 for subjects without cross-clamp procedure and 1 for subjects with cross-
clamp procedure; DHC, 0 for subjects without deep hypothermic circulatory arrest and 1 for subjects with deep 
hypothermic circulatory arrest; DHCA, deep hypothermic circulatory arrest time, minutes; GA, gestational age, 
weeks; OFV, objective function value; PMA, postmenstrual age, weeks; PNA, postnatal age, days; RACHS-1, Risk 
Adjustment for Congenital Heart Surgery 
 
Diagnostic plots for the final IL-6 and IL-10 popPK/PD models showed no obvious bias for IL-6, and slight 
underprediction for IL-10 at high concentrations (Figure 3-12 and Figure 3-13). Population PD 
parameters, covariate effects, and variability, along with the standard error of these estimates and 
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bootstrap output, is shown in Table 3-6 and Table 3-7. 
 
The solid lines in A and B are the lines of identity. The solid lines in C and D are reference lines at y = 0. The dashed 
lines in A, B, C, and D are smooth lines. 
Figure 3-12. Final population pharmacodynamics model for interleukin-6 diagnostic plots: 
observed vs individual prediction (A) and population prediction (B) and conditional weighted 
residuals vs population predictions (C) and time after last dose (D). 
 




The solid lines in A and B are the lines of identity. The solid lines in C and D are reference lines at y = 0. The dashed 
lines in A, B, C, and D are smooth lines. 
Figure 3-13. Final population pharmacodynamic model for interleukin-10 diagnostic plots: 
observed vs individual predictions (A) and population predictions (B), conditional weighted 
residuals vs population predictions (C) and time after last dose (D) 
 
Table 3-6. Population pharmacodynamic parameters for interleukin-6 
Parameter 
Estimate RSE (%) Shrinkage (%) 
Bootstrap CI 
2.5% Median 97.5% 
Structural PK model 
Imax  1 FIX NA  NA NA NA 
IC50 (ng/mL) 14 48  0.48 13.0 25.7 
IL-6 base (pg/mL) 7.9 21  5.4 8.2 12.8 
kout (1/h) 0.171 12  0.125 0.172 0.222 
HILL 2.53 62  1.02 2.36 46.3 
CPBE  48.6 61  20.6 57.4 857.2 
Percent of CPB effect 
not interacting with MP 
(%) 
21.4 46  1.26 18.4 36.8 
CPB effect half-life (h) 9.08 18  6.09 9.02 14.1 
RACHS-1 > = 4 on 
CPBE  2.59 30  1.56 2.60 4.75 
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Parameter 
Estimate RSE (%) Shrinkage (%) 
Bootstrap CI 
2.5% Median 97.5% 
Inter-individual variability (%CV) 
IIV (IL-6 base) 100.5 33 11 58.7 97.3 124.5 
IIV (CPBE) 83.6 34 20 39.8 76.9 100.1 
Residual Variability 
Proportional error (%) 54.1 10 9 49.0 54.4 59.5 
Cl, clearance; CPB: cardiopulmonary bypass; IIV, Interindividual variability; MP, methylprednisolone; PK, 
pharmacokinetics; RACHS-1: Risk Adjustment for Congenital Heart Surgery; RSE, relative standard error 
Imax, maximum fold change in production of IL-6 as a response to drug exposure; IC50, methylprednisolone 
concentration that produces 50% of maximum attainable inhibition; IL-6base, model predicted IL-6 plasma 
concentration in subjects prior to the first dose of methylprednisolone; IL-6, interleukin-66 plasma concentration;  
kout: first order rate constant for decline of IL-6; HILL: Hill coefficient; CPBE: fold change in IL-6 as a response to 
CPB procedure  
Table 3-7. Parameter estimates for the final population pharmacodynamics model for 
interleukin-10  
Parameter 
Estimate RSE (%) Shrinkage (%) 
Bootstrap CI 
2.5% Median 97.5% 
Structural PK model 
Smax  2.28 24  1.34 2.44 4.41 
SC50 (ng/mL) 58.2 52  22.5 68.3 176.8 
IL-10 base (pg/mL) 1.52 12  1.25 1.54 1.91 
kout (1/h) 0.542 12  0.43 0.55 0.66 
HILL 3.58 90  1.12 3.65 9.09 
CPBE 45.7 16  30.9 44.7 63.5 
PMA effect on CPBE 14.8 29  6.76 15.2 26.7 
Interindividual variability (%CV) 
IIV (Smax) 110 33 20 62.9 106 141 
IIV (IL-10 base) 64.7 23 11 46.2 63.0 77.6 
IIV (CPBE) 88.1 32 16 50.9 81.2 111 
Residual variability 
Proportional error (%) 53.8 9 15 48.2 53.5 58.3 
Cl, clearance; IIV, interindividual variability; PK, pharmacokinetics; PMA, postmenstrual age; RACHS-1: Risk 
Adjustment for Congenital Heart Surgery; RSE, relative standard error 
Smax, maximum fold change in production of IL-10 as a response to drug exposure; SC50, methylprednisolone 
concentration that produces 50% of maximum attainable stimulation; IL-10base, model predicted IL-10 plasma 
concentration in subjects prior to the first dose of methylprednisolone; IL-10, interleukin-10 plasma concentration;  kout  
first order rate constant for decline of IL-6; HILL, Hill coefficient; CPBE, fold change in IL-6 as a response to CPB 
procedure 
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The final model was evaluated using a 1000-set bootstrap analysis. The percent of bootstrap that 
converged to greater than 3 significant digits was 81% and 77% for IL-6 and IL-10, respectively. The 
median of bootstrap fixed effects parameter estimates were within 18% of the original population 
estimates for all parameters. The SVPCs revealed a reasonable fit between the observed and predicted 
IL-6 and IL-10 concentrations: 3.5% of observed average IL-6 responses fell outside the 90% prediction 
interval; 6.5% of observed average IL-10 responses fell outside the 90% prediction interval (Figure 3-14 
and Figure 3-15). 
 
Open circles represent calculated percentiles. Dashed lines represent the 5th, 50th, and 95th percentiles (bottom, 
middle, and top, respectively) of model predicted data. Time point: 1 = presurgery day; 2 = pre-CPB; 3 = CPB end; 
4 = 4h after CPB end; 5 = 12h after CPB end; 6 = 24h after CPB end. 
Figure 3-14. Standardized visual predictive check of interleukin-6 observation percentiles vs 
time after last dose (A) and observation percentiles vs time point (B) 
 
 
Open circles represent calculated percentiles. Dashed lines represent the 5th, 50th, and 95th percentiles (bottom, 
middle, and top, respectively) of model predicted data. Time point: 1 = presurgery day; 2 = pre-CPB; 3 = CPB end; 
4 = 4h after CPB end; 5 = 12h after CPB end; 6 = 24h after CPB end. 
Figure 3-15. Standardized visual predictive check of interleukin-10 observation percentiles vs 
time after last dose (A) and observation percentiles vs time point (B) 
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Simulations 
No significant differences in simulated concentration time profiles of IL-6 and IL-10 were observed 
between the 30-mg/kg and 10-mg/kg dose groups (Figure 3-16 and Figure 3-17). Simulated IL-6 and 
IL-10 concentrations overall were more than 50% lower and more than 100% higher following 
methylprednisolone administration compared to placebo. Simulated IL-6 AUC0-24 was minimally lower 
following 2 doses of methylprednisolone compared to a single dose (median AUC0-24 2042.5 ng*hr/mL vs 
2147 ng*hr/mL, p < 0.01), and following 30 mg/kg compared to 10 mg/kg (1342 ng*hr/mL vs 
1489 ng*hr/mL, p < 0.01), but significantly lower when compared to placebo (4794 ng*hr/mL, p < 0.01 
when compared to all methylprednisolone dosing regimens). The magnitude of difference is shown in 
terms of AUC0-24 ratios in Table 3-8. Similarly, simulated IL-10 AUC0-24  was higher following any 
administration of methylprednisolone compared to placebo (median IL-10 AUC0-24 following placebo 
347 ng*hr/mL, p < 0.01 when compared to all methylprednisolone dosing regimens), but did not differ 
significantly between any of the methylprednisolone dosing scenarios simulated (Table 3-8 and Table 
3-9). Similar results were observed when simulations were stratified by subject and operative 
characteristics, including PMA, RACHS-1 score, CPB time—methylprednisolone administration reduced 
IL-6 AUC0-24 and increased IL-10 AUC0-24 when compared to placebo, without clinically significant 
differences between any of the dosing regimens simulated (Table 3-9 and Table 3-10). 
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Figure 3-17. Simulated interleukin-10 concentrations following different dosing regimens 
 
Table 3-8. Mean (95% CI) ratios of simulated area under the concentration–time curve from 
time 0 to 24 hours after cardiopulmonary bypass start of interleukin-6 and interleukin-10 following 
different dose regimens of methylprednisolone and placebo 
Ratios Interleukin-6 Interleukin-10 
2 vs 1 dose of methylprednisolone 0.92 (0.92, 0.95) 1.08 (1.08, 1.10) 
30 vs 10 mg/kg of methylprednisolone 0.89 (0.89, 0.89) 1.03 (1.03, 104) 
10 mg/kg of methylprednisolone vs placebo 0.27 (0.27, 0.27) 3.85 (3.79, 3.90) 
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Table 3-9. Summary of simulated area under the concentration–time curve from time 0 to 
























<=41 <120 30 1 454 20 5672 839 980 485 
41.1-42 <120 30 1 595 20 5556 1023 1081 618 
>42 <120 30 1 879 31 6339 1344 1249 864 
<=41 <120 10 1 422 18 5400 796 957 454 
41.1-42 <120 10 1 559 19 5746 966 1039 579 
>42 <120 10 1 835 29 5713 1276 1201 814 
<=41 <120 0 1 165 11 2696 268 318 168 
41.1-42 <120 0 1 222 11 4356 376 472 226 
>42 <120 0 1 339 16 5645 590 734 346 
<=41 <120 30 2 536 26 5462 923 1021 543 
41.1-42 <120 30 2 715 29 6328 1167 1207 706 
>42 <120 30 2 1027 33 7014 1527 1381 985 
<=41 <120 10 2 521 25 5393 902 999 530 
41.1-42 <120 10 2 711 29 6291 1151 1195 693 
>42 <120 10 2 1005 33 6842 1507 1364 970 
<=41 <120 0 2 165 11 2696 268 318 168 
41.1-42 <120 0 2 222 11 4356 376 472 226 
>42 <120 0 2 339 16 5645 590 734 346 
<=41 120-<180 30 1 698 25 6940 1212 1307 722 
41.1-42 120-<180 30 1 943 26 7414 1476 1440 928 
>42 120-<180 30 1 1357 45 7282 1929 1626 1300 
<=41 120-<180 10 1 674 23 6653 1173 1283 694 
41.1-42 120-<180 10 1 903 24 6930 1423 1394 892 
>42 120-<180 10 1 1306 43 7161 1873 1588 1258 
<=41 120-<180 0 1 252 13 4325 414 506 251 
41.1-42 120-<180 0 1 354 13 6549 595 758 348 
>42 120-<180 0 1 550 22 7410 922 1098 544 
<=41 120-<180 30 2 816 30 7401 1326 1380 799 
41.1-42 120-<180 30 2 1076 36 7557 1649 1554 1039 
>42 120-<180 30 2 1531 42 7452 2097 1716 1421 
<=41 120-<180 10 2 794 30 7375 1308 1363 786 
41.1-42 120-<180 10 2 1060 36 7473 1633 1540 1026 
>42 120-<180 10 2 1515 42 7364 2083 1708 1409 
<=41 120-<180 0 2 252 13 4325 414 506 251 

























41.1-42 120-<180 0 2 354 13 6549 595 758 348 
>42 120-<180 0 2 550 22 7410 922 1098 544 
<=41 >=180 30 1 930 30 8570 1600 1687 959 
41.1-42 >=180 30 1 1255 32 9241 1924 1800 1230 
>42 >=180 30 1 1838 59 8526 2492 2009 1714 
<=41 >=180 10 1 913 29 8267 1556 1648 930 
41.1-42 >=180 10 1 1227 30 8920 1880 1770 1198 
>42 >=180 10 1 1783 57 8267 2416 1945 1664 
<=41 >=180 0 1 337 15 5955 561 697 332 
41.1-42 >=180 0 1 475 16 8743 813 1046 469 
>42 >=180 0 1 754 29 8409 1198 1316 726 
<=41 >=180 30 2 1072 34 9202 1732 1755 1050 
41.1-42 >=180 30 2 1403 42 9048 2112 1920 1354 
>42 >=180 30 2 1950 52 8871 2663 2100 1840 
<=41 >=180 10 2 1060 34 9062 1716 1740 1038 
41.1-42 >=180 10 2 1394 42 8919 2097 1909 1343 
>42 >=180 10 2 1949 52 8849 2651 2093 1829 
<=41 >=180 0 2 337 15 5955 561 697 332 
41.1-42 >=180 0 2 475 16 8743 813 1046 469 
>42 >=180 0 2 754 29 8409 1198 1316 726 




Table 3-10. Summary of simulated area under the concentration–time curve from time 0 to 

























<4 <120 30 1 870 22 26353 1934 3133 875 
>=4 <120 30 1 2056 48 32421 4126 5391 2036 
<4 <120 10 1 988 26 32674 2245 3660 1012 
>=4 <120 10 1 2362 56 34966 4562 5739 2304 
<4 <120 0 1 3172 87 34357 5555 6275 3024 
>=4 <120 0 1 6375 194 35176 9827 8849 6091 
<4 <120 30 2 782 6 28224 1867 3221 791 
>=4 <120 30 2 1907 14 33817 3861 5041 1870 
<4 <120 10 2 890 6 29919 2109 3526 906 


























>=4 <120 10 2 2163 15 33343 4225 5283 2095 
<4 <120 0 2 3158 38 34002 5663 6458 3036 
>=4 <120 0 2 6538 75 34547 9645 8651 5973 
<4 120-<180 30 1 910 22 27991 2015 3281 907 
>=4 120-<180 30 1 2136 49 33432 4281 5561 2119 
<4 120-<180 10 1 1004 25 33909 2256 3616 1023 
>=4 120-<180 10 1 2393 55 35056 4663 5864 2352 
<4 120-<180 0 1 3403 94 33616 5864 6398 3248 
>=4 120-<180 0 1 6617 212 33818 9898 8649 6294 
<4 120-<180 30 2 815 6 29278 1959 3398 826 
>=4 120-<180 30 2 2000 15 32889 4032 5222 1959 
<4 120-<180 10 2 903 7 30314 2156 3630 920 
>=4 120-<180 10 2 2205 15 34952 4393 5580 2155 
<4 120-<180 0 2 3394 41 32793 5956 6577 3251 
>=4 120-<180 0 2 6789 81 33597 9639 8280 6147 
<4 >=180 30 1 948 23 30402 2126 3474 954 
>=4 >=180 30 1 2246 52 31986 4403 5572 2213 
<4 >=180 10 1 1037 25 35902 2344 3772 1059 
>=4 >=180 10 1 2479 55 32961 4757 5869 2426 
<4 >=180 0 1 3590 101 32200 6049 6302 3429 
>=4 >=180 0 1 6725 230 33460 9877 8335 6441 
<4 >=180 30 2 865 7 30971 2080 3617 875 
>=4 >=180 30 2 2129 16 32391 4258 5481 2077 
<4 >=180 10 2 950 7 31680 2248 3801 956 
>=4 >=180 10 2 2297 16 33663 4558 5745 2243 
<4 >=180 0 2 3674 43 32965 6246 6733 3457 
>=4 >=180 0 2 7238 86 33334 10081 8525 6497 
AUC0-24, area under the concentration–time curve from time 0 to 24 hours; CPB, cardiopulmonary bypass; 
RACHS-1, Risk Adjustment for Congenital Heart Surgery 
 
DISCUSSION 
We developed the first popPK/PD model of methylprednisolone in neonates undergoing CPB and 
leveraged our model to perform dosing simuations for methylprednisolone in this popuation.The PK of 
methylprednisolone has been previously characterized using 1-compartment models in both healthy 
adults and those undergoing CPB.18,20,24 A 2-compartment model better characterized the data in our 
 63  
 
study. This may be related to LLOQ of our methylprednioslone assay (1 ng/mL) compared to the one 
used in previous studies (5, 10, 25, 50 ng/mL), which allowed our model to better charaterize the terminal 
elimination phase of methylprednisolone compared to prior models hampered by a greated proportion of 
BLQ values. We estimated typical values of the apparent clearance (CL/F) and apparent volume of 
distribution (Vss/F as a sum of Vc/F and Vp/F) for an average infant with a WT of 3.2 kg at 3.8 L/h and 
26.3 L, respectively. To our knowledge, PK paramters of methylprednisolone have never been reported in 
infants. However, CL/F and Vd/F of methylprednisolone after IV administration of methylprednisolone 
hemisuccinate in pediatric subjects with inflammatory bowel disease (mean [SD] age: 11.3 years [2.5]) 
were 0.98 L/h/kg and 1.53 L/kg, respectively.25 While our estimate of CL/F was only slighlty higher 
(1.18 L/h/kg), our estimate of Vss/F (8.2 L/kg) of methylprednisolone in infants undergoing CPB was about 
5-fold greater than that in the pediatric subjects with inflammatory bowel disease. The higher V of 
methylprednisolone in infants undergoing CPB may be related to CPB effects, including inflammation and 
capillary leak, adsorption of drug by the CPB circuit, increased V resulting from the circuit tubing, and 
hypoalbuminemia with secondary increase in free-drug concentration (methylprednisolone is 78% protein 
bound).26 In addition, the formation of methylprednisolone from its prodrug in adults undergoing CPB has 
been shown to be reduced by factors such as decreased liver perfusion and reduced metabolic activity 
during CPB when compared to healthy volunteers.20 In our study, the estimated formation rate of 
methylprednisolone in infants on CPB was even lower compared to adults on CPB (0.4 1/h vs 0.7 1/h).20 
The greater value of CL/F and Vss/F of methylprednisolone in infants undergoing CPB may therefore be 
explained by the decreased formation of methylprednisolone from the prodrug during CPB.  
Pharmacodynamic models, including direct- and indirect-effect models, have been used to 
characterize the time course of inflammatory cell counts after methylprednisolone.27,28 This is the first PD 
model characterizing methylprednisolone effect on cytokines in subjects undergoing CPB. The indirect-
effect models characterized the plasma concentration time profiles of IL-6 and IL-10 better than direct-
effect models.This is consistent with the drug’s mechanism of action: methylprednisolone was reported to 
reduce complement-mediated activation of neutrophils and inhibit the secretion of proinflammatory 
cytokines, including IL-6.29–31 A previous study suggested the increase in antiinflammatory cytokine IL-10 
may be a part of compensation for increased proinflammatory cytokines.32 Both effects can be assumed 
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to be delayed relative to the time of plasma exposure. The half-maximal effective concentration (EC50) 
was estimated to be 58 ng/mL for methylprednisolone effect on IL-10,  and half-maximal inhibitory 
concentration was estimated to be 14 ng/mL for methylprednisolone effect on IL-6. To our knowledge, 
EC50 for methylprednisolone effect on cytokines has not been previoulsy reported. However, the EC50 and 
half-maximal inhibitory concentration for methylprednisolone effect on blood histamine concentrations 
estimated using different PD models ranged from 2.73 ng/mL17 to 113 ng/mL.33 This reported range, 
although wide, is consistent with our findings.  
The PD model without interaction failed to predict the reported fold change in IL-6 and IL-10 after 
30 mg/kg methylprednisolone relative to that after placebo in infants undergoing CPB. This may be 
related to the PD sampling in this study. Considering the relatively short half-life of methylprednisolone 
(2.4 hours in healty adult volunteers), the only sample following methyprednisolone administration and 
before CPB was collected at 8 hours and may not be sufficient to quantify the exclusive effect of 
methylprednisolone.5 Thus, it is difficult to adequately quantify relative contribution of methylprednisolone 
and CPB on the change of IL-6 and IL-10 using the model without interaction. Future studies with richer 
sampling after first methylprednisolose dose, and before and during CPB, may help better characterize 
the interplay between drug and CPB effect.  
CPB time was identified as a significant covariate on CL and longer CPB time was associated 
with lower CL of methylprednisolone. Because methylprednisolone is primarily metabolized in the liver 
with less than 10% excreted unchanged in urine, the relationsihp between CPB time and CL may be 
explained by decreased liver blood flow and metabolic activity due to hypothermia during CPB.34 In 
infants, these changes may be enhanced because of greater decrease in body termperature relative to 
adults during CPB, lower bypass flow rates, and the occasional use of complete circulatory arrest or 
regional cerebral perfusion (ie, period of no blood flow to organs other than the brain), which are 
infrequently employed in adults.35  
RACHS-1 was identified as a significant covariate for the CPB effect on IL-6. RACHS-1 is used 
as a predictor of mortality in subjects undergoing congenital heart surgery.36 A higher RACHS-1 score is 
indicative of higher surgical complexity and is associated with greater disease severity and longer CPB 
time during surgery. The model predicted a greater increase in IL-6 concentrations due to CPB in 
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subjects with higher RACHS-1, which may be related to the longer CPB time required for surgery in these 
subjects. 
 For IL-10, PMA was identified as a significant covariate on the CPB effect. When comparing the 
most premature infant included in our cohort (34 weeks GA) to a full-term infant (40 weeks GA), CPB 
effect on IL-10 production was approximately 10-fold higher in the full-term compared to the preterm 
infant. A positive monotonic trend in the expression of genes involved in immune-system development in 
preterm neonates has been previously reported.37 The greater magnitude of CPB effect in older infants 
may be explained by the maturation of the immune system in the early life stage. Because our model-
building steps were primarily guided by statistical considerations, PMA was not included as a covariate in 
the IL-6 model. While we can only speculate as to the biological reasons behind the observed statistical 
difference, the critical role played by antiinflammatory IL-10 in the maintenance of a state of relative 
immune tolerance between the fetus and the maternal organism before delivery may explain why it is 
more readily affected by early maturational changes. Conversely, IL-6 has shown rather robust 
expression in neonates, reaching or even exceeding adult levels.38   
Our simulation results suggest that both 10 mg/kg and 30 mg/kg of methylprednisolone produced 
significant antiinflammatory effect (as measured by IL-6 and IL-10 concentrations) compared to placebo. 
No substantial difference in the effect of methylprednisolone on IL-6 and IL-10 was observed between 
10-mg/kg and 30-mg/kg doses. This suggests that a 30-mg/kg dose is unlikely to provide significant 
additional benefit compared to 10 mg/kg. This finding is consistent with prior reports of clinical enpoints 
including intensive care unit and hospital length of stay and the occurrence of low cardiac output 
syndrome.11,12 No substantial difference in the effect of methylprednisolone on IL-6 and IL-10 
concentrations was observed following 1 vs 2 dose regimens. This finding suggests that an additional 
methylprednisolone dose given on the day before surgery may not be necessary. Again, this is consistent 
with previoulsy reported clinical assessments including inotropic requirement, duration of postoperative 
mechanical ventiation, and intensive care unit and hospital length of stay.39  
Limitations of our study include the relatively sparse PD data collected after methylprednisolone 
administration and before and during CPB, and the single-dose level (30 mg/kg) administered to all 
infants. A future study with richer PD sampling after methylprednisolone administration and before CPB, 
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PD measurements collected during CPB, longer sampling time after CPB (especially for IL-6) and 
additional dosing levels of methylprednisolone may help better characterize the PD of 
methylprednisolone. Sampling during CPB in particular may uncover significant changes in  
antiinflammatory effect resulting from altered methylprednisolone exposure, as has been previously 
shown for other drugs.40,41 It is important to note that while both IL-6 and IL-10 are known to be implicated 
in the inflammatory cascade induced by CPB infants, and have been previously studied in this population, 
other inflammatory biomarkers may be better suited to characterize methylprednisolone’s effect in this 
population. Finally, while it is reasonable to postulate that modulation of the inflammatory response would 
lead to improved clinical outcomes, it is important to point out that a clear relationship between 
methylprednisolone administration (vs placebo) and clinical endpoints has not yet been established.42 A 
large muticenter randomized controlled trial is currently underway to asssess the drug’s effect on a clinical 
compostive endpoint of cardiovascular outcomes.43  
In conclusion, we found that indirect-response PK/PD models characterized the effects of 
methylprednisolone administration on proinflammatory and antiinflammatory cytokines in infants 
undergoing surgery on CPB. Simulations suggested no additional benefit from dosing greater than 
10 mg/kg or multiple dosing, but significantly improved cytokine profile when compared to placebo. Our 
model, the first of its kind in this patient population, has important implications for the design of future 
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 A POPULATION PHARMACOKINETICS-ELECTRONIC HEALTH RECORD PLATFORM 
TO CHARACTERIZE DRUG EFFICACY AND SAFETY 
 
OVERVIEW 
Safety studies in infants are challenging, and evaluation of drug exposure adds to the 
complexity.1 Novel strategies are urgently needed to overcome limitations of traditional studies, including 
large sample sizes and the use of blood samples to measure drug concentrations.2 As a potential 
solution, we propose to develop pediatric population PK (popPK) models using opportunistically collected 
PK data and combine them with electronic health record (EHR) data from a large multicenter cohort of 
hospitalized children, to characterize exposure-safety relationships.  
In this chapter, we describe the key steps to this approach, including: (1) the creation of a 
comprehensive inpatient multicenter EHR-derived data repository that captures critical data, including 
date and time of drug dosing and of adverse events of interest; (2) the development of 2 popPK models 
for the probe drugs ketamine and milrinone, using opportunistically collected PK data following standard 
of care drug administration; and (3) the application of the popPK models to predict the drug exposures in 
the data repository and to characterize the relationship between simulated exposures and the occurrence 
of desaturation following ketamine exposure and hypotension following milrinone exposure. 
PART 1: DEVELOPMENT OF A MULTICENTER ELECTRONIC HEALTH RECORD-DERIVED 
INPATIENT DATA REPOSITORY3 
 
Introduction 
EHR systems hold great promise for pediatric clinical research.1,3–5 Primarily designed to improve 
safety, quality, and efficiency of clinical care, EHRs store vast amounts of routinely generated patient and 
provider data.6 Through dissemination and development of sophisticated clinical research informatics 
                                                     
3 This part 1 of chapter 4 previously appeared in a manuscript in press at Applied Clinical Informatics. 
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tools, it is increasingly feasible to reuse EHR data for research.7,8 This strategy is particularly attractive for 
the study of rare diseases, including those affecting children.9,10  
Despite the value of retrospective studies, prospective clinical trials remain essential to drug 
development.2 As part of the response to the gap in pediatric drug labeling, the Eunice Kennedy Shriver 
National Institute for Child Health and Human Development (NICHD) created the Pediatric Trials Network 
(PTN), tasked under the Best Pharmaceuticals for Children Act with the design and conduct of off-patent 
drug and device trials in children.11,12 Coordinated by the Duke Clinical Research Institute, the PTN has 
enrolled more than 7,000 children of all ages in 38 phase 1 through 4 studies across 18 therapeutic 
areas. All PTN studies are conducted under a US Food and Drug Administration (FDA) Investigational 
New Drug application, and all data are submitted to FDA for use in potential drug and device label change 
negotiations.  
From its inception, the PTN recognized the value of EHR data to support clinical trials. The 
network leveraged the Mednax Clinical Data Warehouse, the American Academy of Pediatrics–supported 
Comparative Effectiveness Research through Collaborative Electronic Reporting3 database, and 
individual site EHRs to identify target drugs and study populations, inform protocol development, and 
support findings from prospective trials.13–18 Most importantly, EHR data have been submitted by the PTN 
to the FDA for review in support of proposed labeling changes.  
Because of this initial positive experience with EHRs, and in order to take full advantage of data 
generated at participating sites, the PTN sought to develop an inpatient multicenter data repository. Data 
from this repository will be used in support of PTN trials and the labeling of drugs and devices for 
children. Herein, we describe the design and creation of this multicenter EHR-derived repository and 
share lessons learned in the process. 
 
Methods 
Coordinating center team 
The coordinating center team included a project leader, principal investigator, 2 clinical research 
informaticists, and an information technology (IT) team comprising a senior data modeler, a senior 
extract-transform-load developer, a quality-assurance tester, and a project manager. At each participating 
site, a site principal investigator and at least 1 site technical lead were identified.  
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Site selection 
The 30 highest-enrolling sites across the PTN were screened for participation. A feasibility survey 
concentrating on the following key capabilities was administered via web interface:  
a) Presence of an EHR system 
b) Availability of qualified site technical personnel to analyze EHR data and map them according to 
PTN specifications 
c) Accessibility of IT infrastructure to produce extract files 
d) General interest in the study 
Based on feasibility survey results, 15 sites completed a secondary survey by individual phone 
interviews, with the coordinating center leadership focused on a set of 21 additional technical factors. 
Sites were then ranked based on equally weighted scores assigned by all coordinating center team 
members, and the top 10 sites were selected. One site was not able to complete the contracting process 
within the time constraints of the study, resulting in 9 participating sites. The study was approved by the 
institutional review boards (IRBs) of Duke University (coordinating center) and each participating site. 
Data model 
After reviewing existing national standardization efforts of multiple EHR data systems (eg, Health 
Level Seven International Fast Healthcare Interoperability Resources, Health Level Seven International 
Domain Models, Clinical Data Interchange Standards Consortium-Biomedical Research Integrated 
Domain Group/Domain models, Patient-Centered Outcomes Research Institute, ClinicalTrials.gov), the 
coordinating team decided to pattern the first version of PTN repository data points using the National 
Patient-Centered Clinical Research Network (PCORnet) data model (version 2.0). To ensure utility of the 
developed repository, pediatric thought leaders were consulted to identify key data domains of interest. 
Whenever possible, the identified domains were aligned with PCORnet domains. After selection of the 
domains, all data points and their definitions were reviewed by pediatric thought leaders for completeness 
and applicability to the project. Following this review, a data master list was created and rules were 
developed for validation of each data point. These validation rules were added to the data master list 
together with coded value sets, data formats, a brief clinical description of the data point, and an indicator 
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of whether the field was mandatory or optional. The data master list was then released to sites to perform 
an initial inventory assessment.   
Repository design  
Each participating site was provided with an implementation guide with detailed instructions on 
how to perform EHR extractions, transformation, and testing and how to correctly package the data for 
submission. The transmissions were performed via secured file-transfer-protocol delivery method to the 
Duke Clinical Research Institute. Data were downloaded from the secured file-transfer-protocol drop site 
and processed using 15 Informatica extract-transform-load workflow processes and stored in an Oracle 
repository. All data were secured within a medium-level Federal Information Security Management Act-
compliant environment (Figure 4-1). 
 
Figure 4-1. Repository design and infrastructure 
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We a priori defined a set of 520 ules designed to detect errors or warning in the submitted data. 
Errors were generated and logged if a data point violated a critical rule (eg, invalid formats, required value 
not present, or nonunique primary key). Warnings were generated and logged if a data point violated a 
noncritical rule (eg, certain reasonable logical inconsistencies, nonrequired value missing, or dates 
outside of expected sequences for laboratory studies). Each new data submission was tested against all 
520 rules, and a warning and error report was generated and shared with the sites. For a data submission 
to be considered acceptable, 0% errors and less than 2% warnings were required across all records.   
The database and extract-transform-load logic were first created and tested within development 
and validation environments. After successful loads in both, the same logic was migrated to the 
production environment. All 3 environments were constructed in an identical manner. 
Results 
We included all children less than 17 years of age at the time of admission between June 1, 
2013, and June 30, 2017, whose admission source records were available in the EHR. The type of EHR 
used varied by site and represented 2 different platforms. We excluded outpatient encounters and 
inpatient admissions without an EHR record. Our final data model included 147 mandatory and 
99 optional data elements across 14 domains (Table 4-1). In addition to 10 PCORnet domains, we 
created 4 custom data domains because of their perceived importance to PTN trial design and execution: 
vital signs, fluids, flowsheet assessments, and respiratory support. All 10 PCORnet domains were 
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All data mapping was conducted by the sites using the implementation guide. The mapping 
process was iterative, with each site first completing a trial submission on a small subset of their records 
across all 14 domains. Following each data submission and testing against rules, a report of warnings 
and errors was generated and shared with the sites. Individual conference calls between each site and 
the PTN coordinating center technical team were then scheduled to review results of each submission 
and discuss strategies for resolution if needed. Over a 14-month period, 177 data submissions were 
received. Final transfer of a site file to the repository required approval of the entire PTN coordinating 
center team. 
An average of 20 submissions per site (range 13-29) were required before data were moved into 
the repository. Site participation from kickoff to final data submission ranged from 8 to 14 months. Time to 
process the final complete site files ranged from 30 to 36 hours.  
The complete repository includes 386,455 inpatient encounters from 264,427 children across the 
9 participating sites. The included encounters consist of 563,886,147 data points. Among the 14 data 
domains, 2 domains account for the majority of data points: “assessments” (33%) and “vital signs” (31%). 
Median (range) age at admission of children included in the repository was 2.3 years (0, 17), and 53% 
were female (Table 4-2). Encounters were evenly distributed across the study period, but varied by site 
as expected, based on hospital admission volume.  
Table 4-2. Summary of clinical data from participants in the repository 
Variables Median (range) or % 
Age 2.3 (0, 17) 
Female 53% 
Race 
American Indian or Alaska Native < 1% 
Asian 4% 
Black or African American 19% 
Native Hawaiian or other Pacific Islander < 1% 
White 58% 
Multiple races 2% 
Other 9% 
Unknown 6% 
Hispanic ethnicity 18% 
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We created a novel Federal Information Security Management Act-compliant EHR-based data 
repository of pediatric inpatient encounters at 9 US hospitals participating in the NICHD PTN. Our 
approach utilized a customized data model heavily influenced by the PCORnet format, site-based data 
mapping, a comprehensive set of data-testing rules, and an iterative process of data submission. Crucial 
to our success were the close-working relationships between dedicated teams with expertise in IT, 
informatics, and clinical medicine at both the coordinating center and participating sites.  
Since the launch of the National Institutes of Health’s Big Data 2 Knowledge initiative, much focus 
has been justifiably placed on this critical area of biomedical research.4–6 This importance is evidenced, 
among other indicators, by the exponential increase in publications discussing big data applications.19 
The progress of medical informatics as a tool to help make sense of health data has expanded the 
horizon of big data generation and applications in medicine.8,20 Today, biomedical big data encompasses 
(among other areas) health information management; computerized clinical decision support; sensor, 
signal, and imaging informatics; and EHR, and its reuse for research applications.6  
Multiple subspecialties, including cardiovascular medicine, emergency care, epidemiology, and 
pediatrics, have successfully leveraged clinical data from the EHR for research applications.9,10,18,21–26 The 
applications of EHR data to clinical research are diverse and include protocol design, participant 
selection, translational research efforts, safety analyses, and trial execution.27–30 In its effort to secure 
pediatric labeling of off-patent drugs and devices, the PTN has successfully reused EHR data collected 
by collaborating networks and individual participating sites. Analyzing EHR data, we described drug-
utilization practices and target molecules for study, reported on real-world drug safety, and performed 
comparative effectiveness studies.14,31–33 We have also leveraged EHR data as an innovative tool in 
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pharmacometric analyses, a critically important step in pediatric drug development, and submitted EHR 
data to the FDA.13,34–38 Despite these successes, more widespread application of EHR data within the 
PTN is contingent upon access to more detailed clinical information, including drug administration, 
laboratory results, vital sign changes, diagnoses and procedures, and clinical assessments. Data sources 
from previous PTN collaborating networks do not routinely capture this level of detail, and site-based 
collection of data from the EHR for a specific study is resource-consuming and inefficient. This multicenter 
repository provides access to detailed data, including new domains not routinely collected in registries, 
such as vital signs, fluid intake and outputs, flowsheet assessments, and respiratory support variables.  
This repository will create an opportunity to advance the PTN mission to design and conduct off-
patent drug and device trials in children. Specific applications made possible by the data include clinical 
trial simulation, cohort-enrichment strategies, synthetic control groups, retrospective safety assessments, 
and comparative-effectiveness studies. To meet these goals, a team of clinicians, IT and informatics 
experts, and biostatisticians has been assembled to design and implement appropriate analytics, quality 
control, and data curation tools. The team will also leverage the created repository to explore solutions to 
critical RWD issues, including record linkage, missingness, and data quality.39–41 To maximize the 
pediatric public health benefit of the repository while maintaining data privacy and confidentiality, PTN 
investigators will be offered the opportunity to propose studies and research questions through an easy-
to-use web-based interface (www.pediatrictrials.org). Further, we will explore the feasibility of opening the 
repository to participation by other PTN sites. We anticipate that through ongoing use of the repository, 
errors, discrepancies, and limitations of the data will become apparent. Whenever possible, we will 
remediate these with the assistance of our participating sites.  
At this stage, several limitations and important lessons have been identified. By design, this 
repository did not include textual data, which is challenging to collect, deidentify, and analyze. As new 
natural-language process methods become available, however, the importance of textual data reuse in 
clinical research will grow.42 The repository also focused on inpatient data only. Collection of ambulatory 
data may require additional considerations of its formats and linking to inpatient encounters. Site-based 
mapping, iterative submission and error reporting, and intense bidirectional communication was ultimately 
successful in creating a repository, but may be challenging to scale up to include a larger number of sites. 
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Finally, comprehensive high-quality analyses of these data will be performed by highly trained experts not 
traditionally involved in clinical research networks, including biostatistics, IT, informatics, machine learning 
and advanced analytics, and systems medicine. Integration of this workforce into clinical trial teams will 
help maximize the value of EHR data.   
PART 2: POPULATION PHARMACOKINETICS OF INTRAVENOUS AND INTRAMUSCULAR 
KETAMINE IN CHILDREN4 
 
Introduction  
Ketamine is an N-methyl D-aspartate receptor antagonist increasingly used off label to facilitate a 
dissociative anesthesia in children undergoing invasive procedures.43,44 Commercial preparations of 
ketamine are a racemic mixture of R- and S-enantiomers approved for use in adults as the sole 
anesthetic agent for diagnostic and surgical procedures and for the induction of anesthesia.45 Because 
administration of ketamine is associated with preservation of hemodynamics and laryngeal reflexes, it is 
frequently used in populations at risk for respiratory and hemodynamic compromise, such as 
children.43,46–48 The availability of a formulation for intramuscular (IM) administration makes it a common 
choice when vascular access is limited, such as in the emergency department.49 Label-recommended 
dosing for intravenous (IV) and IM ketamine to facilitate surgical anesthesia in adults ranges from 1 to 
4.5 mg/kg and 6 to 13 mg/kg, respectively.45 Ketamine is not approved for use in children under 18 years 
of age, but an observational study in 2007 found that when ketamine was administered to 60 children 1.5 
to 14 years of age in the emergency department, 1.5-mg/kg IV dosing provided adequate procedural 
sedation for up to 10 minutes.50  
In adults, ketamine exhibits low protein binding to both alpha-1 acid glycoprotein and albumin 
(10-30%) with high lipid solubility and extensive distribution.51 Central compartment volume (Vc) is 
70 liters, and the steady state volume of distribution (Vss) is around 200 liters.51 Ketamine elimination 
clearance (CL) is 12 to 20 mL/min/kg in adults, and it is hepatic-blood-flow limited.51 After IV 
administration, the distribution of ketamine undergoes alpha and beta phases. During the alpha phase, 
                                                     
4 This part 2 of chapter 4 previously appeared in a manuscript published in The Journal of Clinical 
Pharmacology. Population Pharmacokinetics of Intramuscular and Intravenous Ketamine in Children. 
Hornik CP, Gonzalez D, van den Anker J, Atz AM, Yogev R, Poindexter BB, Ng KC, Delmore P, Harper 
BL, Melloni C, Lewandowski A, Gelber C, Cohen-Wolkowiez M, Lee JH; Pediatric Trial Network Steering 
Committee. J Clin Pharmacol. 2018 Apr 20. doi: 10.1002/jcph.1116. [Epub ahead of print] 
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which has a half-life of about 10 to 15 minutes, the drug has initial anesthetic effect.52 Ketamine then 
undergoes redistribution from the central compartment and hepatic metabolism by CYP3A isoenzymes, 
CYP2B6, and CYP2C9.50 Approximately 80% of the dose is metabolized to active norketamine, which 
appears in the blood 2 to 3 minutes after an IV ketamine bolus and reaches peak plasma concentrations 
at approximately 30 minutes after administration.51 Norketamine persists in the plasma for more than 
5 hours after administration, and the half-life of the beta phase of ketamine is 2.5 hours.51,52  
Existing evaluations of ketamine PK in children are limited to smaller populations presenting to 
the emergency department or children with burn injuries or cardiac disease.43,53 Ketamine PK is most 
commonly described by 2-compartment models with linear elimination and CL increasing with age from 
26 L/hr/70 kg in infants less than 3 months old up to 90 L/h/70 kg, in older children.50,54 Ketamine steady-
state volume of distribution (Vss)  decreases with age, ranging from 242 L/70 kg in infants less than 
3 months old to 53 L/70 kg by adulthood. Subsequent analyses of pediatric data have contributed 
valuable information on optimal sampling times, oral bioavailability (45%), and absorption half-time 
following oral administration (59 minutes, 95% CI 29.4 to 109.2 minutes).43,55 Ketamine was also found to 
have a 36% bioavailability following intranasal administration in children weighing 10 kg or more.56 
Importantly, despite the frequent use of IM ketamine, its IM bioavailability has only been characterized in 
6 healthy adult volunteers to date.57 
In this population PK analysis, we leveraged a combined dataset from 2 prospective PK studies 
of ketamine in children, 1 with IM and the other with IV administration. In this analysis, we characterize 
the PK of ketamine in children, including its model estimated IM bioavailability.  
Methods 
Patient population 
Pharmacokinetics samples used to develop the model described in this report were collected 
through the PTN’s Pharmacokinetics of Understudied Drugs Administered to Children per Standard of 
Care trial (clinicaltrials.gov no. NCT01431326; protocol: NICHD-2011-POP01) and the Ketamine 
Pharmacokinetic Study in Healthy Children Aged 2 to 5 Years Old (KPSHC2011) study (Health Sciences 
Authority, Singapore: HPRG/CTB 78:10/11-086). Written informed consent (and assent when applicable) 
was obtained from the legal guardians of all study participants in both studies. The PTN POP01 study 
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protocol was reviewed and approved by the IRBs of each participating institution. The KPSHC2011 
protocol was reviewed and approved by the KK Women’s and Children’s Hospital IRB. 
The PTN POP01 trial is a multicenter, prospective, PK and safety study of understudied drugs 
administered to children (< 21 years old) per standard of care. Children who received IV ketamine per 
standard of care as administered by their treating caregiver were eligible for enrollment. Exclusion criteria 
included failure to obtain consent or assent, or a known pregnancy as determined by interview or testing. 
Pharmacokinetics samples were collected optimally with standard-of-care lab collections or at different 
times from standard-of-care collections if allowed per consent. Because this was a standard-of-care 
study, dosing and PK sample collection times varied between children. Standard-of-care laboratory 
assessments (eg, basic metabolic panel) were recorded if collected within 72 hours of a study dose of the 
drug. Gestational age (GA) was documented in infants with a postnatal age (PNA) of less than 120 days. 
Children were enrolled in the study for up to 90 days.  
The KPSHC2011 study is a single-center, prospective, PK, safety, and preliminary efficacy trial 
conducted at KK Women’s and Children’s Hospital, Singapore. Children up to 5 years old requiring IM 
ketamine for procedural sedation and analgesia in the emergency department were eligible for 
enrollment. Exclusion criteria included failure to obtain consent or assent and a history of anaphylaxis to 
ketamine. Children received IM ketamine per standard of care, and 3 timed venous PK samples were 
taken following administration.  
Drug dosing and sample collection 
Dosing information was collected for up to 8 doses before the sampling dose (last dose before 
first biological-sample collection) in the POP01 study and for all study doses in the KPSHC2011 study. 
Dosing in both studies was per standard of care, but limited to the IM administration route in the 
KPSHC2011 study. All children enrolled in the KPSHC2011 study received a single dose of IM ketamine, 
while all children enrolled in the POP01 study received 1 or more bolus doses or continuous infusions of 
IV ketamine. For the opportunistic POP01 study, the timing of blood-sample collection was dependent on 
standard-of-care laboratory assessments but suggested sampling times were provided (Table 4-3). For 
the KPSHC2011study, blood samples for PK analysis were collected at 10 minutes, 30 to 60 minutes, 
and 120 minutes after drug administration:. 
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Table 4-3. Suggested sampling times in the POP01 protocol 
Sample name Time points after start of continuous infusion or end of 
single-dose administration (hours) 
Sample #1 0-0.25 
Sample #2 0.15-0.5 
Sample #3 1-3 
Sample #4 4-8 
 
Analytical methods 
Blood was collected (0.2 mL in children < 1 year of age and 2 mL in children ≥ 1 year of age) in 
an EDTA-K2 microtainer and was processed into plasma immediately before freezing at the study sites. 
Pharmacokinetic samples from both studies were sent to a PTN-contracted commercial laboratory 
(Alturas Analytics, Inc., Moscow ID) for storage and analysis. Ketamine concentrations were quantified 
using validated liquid chromatography-tandem spectrometry assays.58 The chromatography system and 
mass spectrometer used for sample analysis were the Sciex API4000 triple Quadrupole mass 
spectrometer with a Synergi Polar-RP 80A 4u HPL Column from Phenomenex (Torrance CA) used to 
separate ketamine from the internal standard. The validation range for the assay was 10 to 2000 ng/L. 
The lower limit of quantification (LLOQ) was 10 ng/mL, and the validated dilution range was 50x. Both R- 
and S-ketamine were measured and the assay was not designed to differentiate between the 2 
enantiomers. Accuracy and precision assessed were within the FDA’s bioanalytical assay validation 
criteria (eg, ± 15%).  
Statistical analysis 
Using the value at the time of first recorded dose, the median and range were calculated and 
presented for demographic and dosing variables. Counts and percentages are calculated and presented 
for categorical variables. Distribution of study variables are compared using Wilcoxon rank sum, chi 
square, or Fisher’s exact tests where appropriate. With the exception of the PK modeling, all statistical 
analyses were performed using Stata (version 14.2, College Station TX). 
Population pharmacokinetics model development 
Ketamine plasma PK data collected after IV or IM administration (Figure 4-2) were analyzed with 
a nonlinear mixed effects modeling approach using the software NONMEM (version 7.2, Icon 
Development Solutions, Ellicott City MD). The first-order conditional estimation method with eta-epsilon 
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interaction was used for all model runs. Run management was performed using Pirana (version 2.8.2).59 
Bootstrap analyses were performed with Perl-speaks-NONMEM (version 3.7.6).60 Data manipulation and 
visualization were performed using the packages Xpose in the software R (version 3.0.3, R Foundation 
for Statistical Computing, Vienna, Austria), RStudio (version 0.97.551, RStudio, Boston MA), and Stata 
(version 14.2, College Station TX).61–63 
 
Figure 4-2. Concentration time plots of samples obtained in the POP01 (left) and the 
KPSHC2011 (right) study 
 
Using the combined datasets of both studies, 1- and 2-compartment PK models with first-order 
absorption for the IM administration were explored with assumed linear PK.64 Bioavailability of IM 
ketamine was estimated. Interindividual variability (IIV) was assessed for PK model parameters using an 
exponential relationship (equation 1).  
𝑃𝑃𝐴𝐴𝑆𝑆𝑖𝑖𝑗𝑗 = 𝜃𝜃𝑃𝑃𝑜𝑜𝑃𝑃,𝑗𝑗 ∗ exp (η𝑖𝑖𝑗𝑗)        (1) 
where PARij denotes the estimate of parameter j in the ith individual; θPop,j is the population value for 
parameter j; and ηij denotes the deviation from the average population value for parameter j in the ith 
individual with mean zero and variance ω2. The correlation between random effect parameters was 
calculated and the inclusion of a block covariance matrix in the model was evaluated but not retained in 
the final model.  
Proportional, additive, and combined (additive plus proportional) residual error models were 




Actual body weight (WT) was assumed to be a significant covariate for CL and V and was 
included in the base model. The relationship between WT and PK parameters was characterized using an 
allometric relationship for CL and V parameters (scaled to a 70-kg standardized WT), respectively. 
Allometric coefficients were estimated, but fixed exponents (0.75 for CL and 1 for V) were retained in the 
final model (equations 2 and 3).  





        (2) 





         (3) 
where CLstd and Vstd represent population estimates of CL and V in a 70-kg adult and WTi denotes WT for 
the ith subject.  
Other covariates were tested for model inclusion (Table 4-4). Determination of which covariates 
to test for model inclusion was based on physiological relevance and by visual inspection of scatter and 
box plots (continuous and categorical variables, respectively) of the individual deviations from the 
population-typical value PK parameters (ETAs) against covariates. The following covariates were 
explored:  
• Extracorporeal membrane oxygenation (ECMO) support at the time of PK sampling 
• Race 
• Ethnicity 
• Obese status (defined as body mass index ≥ 95th percentile per Centers for Disease Control 
reference values for children > 2 years of age) 
• Postmenstrual age (PMA) 
• PNA 
• Protocol under which subject was enrolled (binary variable: POP01 or KPSHC2011)  
Table 4-4. Stepwise covariate evaluation 
Description Population model OFV Change in  OFV 
Univariate analysis 


















Race on CL CL=46.6*(WT/70)**0.75 IF RACE=WHITE; 
CL=51.6*(WT/70)**0.75 IF RACE=BLACK 
CL=18.8*(WT/70)**0.75 IF RACE=ASIAN 
3033.358 2.505 
Race on Vc Vc=25.1*(WT/70)**1 IF RACE=WHITE; Vc=38.9*(WT/70)**1 IF 
RACE=BLACK 
Vc=22.8*(WT/70)**1 IF RACE=ASIAN 
3031.5 0.279 
ECMO on Vc Vc=34.7*(WT/70)**1*0.37**ECMO 3028.594 -2.627 
Obese on 
CL 
CL=48.7*(WT/70)**0.75*1.03**OBESE 3033.767 2.546 
Obese on Vc Vc=31.2*(WT/70)**1 *1.03**OBESE 3034.123 2.902 
PMAW on 
CL by 
FIXED MF  
THETA(2)*((WT/70)**0.75)*(PMAW/(59+PMAW)) 3048.58 17.359 
PMAW on 
CL by power 













CL by linear  
TVCL=THETA(2)*((WT/70)**0.75)*(PMAW*0.0012) 3131.961 100.7 
PMAW on 










CL by power 








CL by linear 
TVCL=THETA(2)*((WT/70)**0.75)*(PNAYR*0.045) 3153.844 122.6 
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Description Population model OFV Change in  OFV 
PNAYR on 





Vc by linear 
TVVc=THETA(3)*(WT/70)*(PNAYR*0.37) 3079.447 48.2 
PNAYR on 




CL, clearance; ECMO, extracorporeal membrane oxygenation; Ka, absorption rate constant; MF, maturation 
function; OFV, objective function value; PMAW, postmenstrual age in weeks; PNAYR, postnatal age in years; Q, 
intercompartmental clearance; Vc, central compartment of distribution; Vp, peripheral compartment of distribution; 
TV, typical value; WT, body weight 
 
The relationship between age and CL was characterized using linear, power, and sigmoidal maximum 
effect (Emax) maturation functions (equations 4-6). Maturation function parameters were both estimated 
and fixed to previously published values.65–67 As a measure of age, PNA and PMA were explored.  
𝐹𝐹𝑏𝑏𝑘𝑘𝑏𝑏 =  𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝑊𝑊𝐴𝐴𝑊𝑊𝐶𝐶𝐶𝐶𝐶𝐶 ∗ 𝐴𝐴𝑎𝑎𝐶𝐶 + 𝑊𝑊𝐶𝐶𝐶𝐶𝐶𝐶𝐴𝐴𝐴𝐴𝐶𝐶𝑖𝑖𝐶𝐶       (4) 
𝐹𝐹𝑏𝑏𝑘𝑘𝑏𝑏 =  𝐴𝐴𝑎𝑎𝐶𝐶𝐶𝐶𝑜𝑜𝑏𝑏𝐶𝐶𝐶𝐶𝑖𝑖𝐶𝐶𝑖𝑖𝑏𝑏𝑖𝑖𝑑𝑑         (5) 
𝐹𝐹𝑏𝑏𝑘𝑘𝑏𝑏 =  
𝑏𝑏𝑘𝑘𝑏𝑏𝐻𝐻𝐻𝐻𝐻𝐻𝐻𝐻
𝑊𝑊𝑇𝑇50𝐻𝐻𝐻𝐻𝐻𝐻𝐻𝐻+𝑏𝑏𝑘𝑘𝑏𝑏𝐻𝐻𝐻𝐻𝐻𝐻𝐻𝐻
         (6) 
For dichotomous categorical covariates (ECMO, obese status), a power relationship was used 
(equation 7).  
𝐹𝐹𝐶𝐶𝑜𝑜𝑐𝑐 =  𝐴𝐴𝐶𝐶𝑐𝑐𝐴𝐴𝐴𝐴𝑊𝑊𝐴𝐴𝐶𝐶𝐶𝐶𝐶𝐶𝑜𝑜𝑏𝑏𝐶𝐶𝐶𝐶𝑖𝑖𝐶𝐶𝑖𝑖𝑏𝑏𝑖𝑖𝑑𝑑        (7) 
For categorical variables with n distinct values (race, ethnicity), additive coding with n-1 indicator 
variables (1 = yes, 0 = no) was used (equation 8). 
𝐹𝐹𝐶𝐶𝑜𝑜𝑐𝑐 =  𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝑊𝑊𝐴𝐴𝑊𝑊𝐶𝐶𝐶𝐶𝐶𝐶1 ∗ 𝐶𝐶𝐶𝐶𝑐𝑐𝐴𝐴𝐴𝐴𝑊𝑊𝐴𝐴𝐶𝐶𝐶𝐶 𝐶𝐶𝐶𝐶𝑐𝑐𝐶𝐶𝐶𝐶1 + ⋯+  𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝑊𝑊𝐴𝐴𝑊𝑊𝐶𝐶𝐶𝐶𝐶𝐶𝑖𝑖−1 ∗ 𝐶𝐶𝐶𝐶𝑐𝑐𝐴𝐴𝐴𝐴𝑊𝑊𝐴𝐴𝐶𝐶𝐶𝐶 𝐶𝐶𝐶𝐶𝑐𝑐𝐶𝐶𝐶𝐶𝑖𝑖−1 (8) 
For all continuous covariates, missing data values were imputed by carrying forward or backward 
the most recent available value for each subject. 
A forward inclusion (p < 0.05 and change in objective function value [OFV] > 3.8) and backward 
elimination (p < 0.01 and change in OFV > 6.6) approach was used to evaluate statistical significance in 
the covariate analysis.  
Population pharmacokinetics model evaluation 
  Standard model diagnostic methods were used and included successful minimization, diagnostic 
plots, plausibility, and precision of parameter estimates, as well as OFV and shrinkage values. Generated 
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diagnostic plots included individual predictions (IPREDs) and population predictions vs observations, and 
conditional weighted residuals vs population predictions and time after first dose. 
Parameter precision for the final popPK model was evaluated using nonparametric bootstrapping 
(1000 replicates) to generate the 95% CIs for parameter estimates. Standardized visual predictive checks 
(SVPCs) were performed whereby the base and final models were used to generate 1000 Monte Carlo 
simulation replicates per time point of ketamine concentration measurements, and simulated results were 
compared with those observed in the study.69 An SVPC was preferred to the commonly used visual 
predictive check as the primary graphical representation because of the opportunistic design of the study, 
resulting in variable dosage and time of PK sampling across subjects.69 However, a more commonly used 
typical VPC was also performed with 10 bins selected to equally distribute observed concentrations over 
time after the last dose (Figure 4-3). The percentile of each subject’s observation in the marginal 
distribution of model-simulated endpoints (Pi,j) as a function of time and dosing was estimated, using the 
subject’s individual time and dosing. Observations outside the 95% prediction interval were then 
estimated (equation 9). 
𝑃𝑃𝑖𝑖𝑗𝑗 =  
1
1000
∑ 𝛿𝛿𝑖𝑖𝑗𝑗,𝑖𝑖1000𝑖𝑖=1          (9) 
where 𝑃𝑃𝑖𝑖𝑗𝑗 is the percentile of the jth observation for the ith subject; 𝛿𝛿𝑖𝑖𝑗𝑗,𝑖𝑖 =1 if 𝐶𝐶𝑜𝑜𝑏𝑏𝑏𝑏,𝑖𝑖𝑗𝑗 > 𝐶𝐶′𝑜𝑜𝑏𝑏𝑏𝑏,𝑖𝑖𝑗𝑗,𝑖𝑖 (otherwise, 
𝛿𝛿𝑖𝑖𝑗𝑗,𝑖𝑖=0); 𝐶𝐶𝑜𝑜𝑏𝑏𝑏𝑏,𝑖𝑖𝑗𝑗 is the jth observed concentration for ith individual; and 𝐶𝐶′𝑜𝑜𝑏𝑏𝑏𝑏,𝑖𝑖𝑗𝑗,𝑖𝑖 is the nth simulated 




8% of observations were outside the 90% prediction interval. The inset shows a cropped version of the plot to better 
illustrate the distribution of concentrations at earlier time points. 
Figure 4-3. Visual predictive check of the final model 
 
The dosing and covariate values used to generate the simulations in the SVPC were the same as 
those used in the study population. 
In addition to the SVPC, a numerical predictive check using 1000 simulations was also performed 
for the final model. We calculated the percentages of outliers for each selected prediction interval (0%, 
20%, 40%, 50%, 60%, 80%, 90%, 95%) in each simulation to obtain a CI for the percentages of outliers 
and compared the observed percentages to the empirical confidence interval.  
Dosing simulations 
Plasma concentrations of ketamine were simulated in virtual subjects at 25 time points after dose 
administration: every minute between 1 to 20 minutes, and at 25, 30, 40, 50, and 60 minutes. We chose 
5 virtual subjects whose WTs were approximately equal to the median WT of male children in the middle 
of 5 age brackets covering our study population based on Centers for Disease Control and Prevention 
growth charts:  
• Children < 6 months: 6 kg 
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• Children 6 months to < 2 years: 11 kg 
• Children 2 to < 6 years: 17 kg 
• Children 6 to < 12 years: 28 kg 
• Children ≥ 12 years: 56 kg 
  Intravenous bolus dosing simulations were performed for scenarios on and off ECMO. Single IM 
dose simulations were not performed on ECMO, as this route of drug administration is typically 
contraindicated in this setting due to the high risk of bleeding. Fixed effects and IIV parameters were fixed 
for inclusion in the simulation. A total of 1000 simulations in each virtual subject were performed per 
dosing scenario, and the 10th percentile of simulations presented in concentration time curves plotted 
over previously published plasma ketamine concentration cutoffs: 100 ng/mL corresponding to analgesic 
effect, 750 ng/mL corresponding to awakening from anesthesia, 1000 ng/mL corresponding to arousal 
with verbal stimulus, and 1500 ng/mL corresponding to arousal with painful stimulus.69–72 The ketamine 
plasma concentration associated with unwanted toxicities has not been reported; thus, an upper limit of 
concentrations was not targeted in the simulations.  
Safety analysis 
In the POP01 study, only adverse events associated with study procedures (phlebotomy) and 
suspected unexpected serious adverse reactions were collected. In the KPSHC2011 study, the following 
adverse events of special interest were collected:  
(1) Abnormal pulse rate 
(2) Low pulse oximetry 
(3) Need for airway interventions 
(4) Need for any other interventions presumed directly related to ketamine administration 
Results  
Patient characteristics 
One hundred and thirteen children, 63 from the POP01 study and 50 from the KPSHC2011 study, 
were included in the analysis (Table 4-5). Median WT and PNA did not differ between children enrolled in 
the 2 studies: 11 kg (range: 2-176) in POP01 vs 15 kg (10-34) in KPSHC2011, P = .08; and 1.6 years 
(0.02-17.6) in POP01 vs 3.7 years (1.8-5.9) in KPSHC2011, P = .06. However, 17 children (27%) in the 
92 
 
POP01 study were obese, compared to only 2 children (4%) in the KPSHC2011 study (P < .001). Thirty-
six children (32%) were under the age of 2 years at the time of PK sampling, and 14 children, all from the 
POP01 study, were supported with ECMO at the time of PK sampling. There was no significant difference 
in the median (range) PNA or WT between children supported with ECMO compared to those not 
supported with ECMO—2.0 years (0.02-17) vs 3.4 years (0.01-18), P = 0.40; 10.7 kg (2.7-85.6) vs 
14.1 kg (2.4-176), P = 0.37.  







Race    
   White 2 36 38 
   Black 0 17 17 
   Unknown/not reported 0 5 5 
   Asian 48 5 53 
Male sex 19 29 48 
Age, years 3.7 (1.8–5.9) 1.6 (0.02–17.6) 3.3 (0.02–17.6) 
Weight, kg 14.9 (10.2–33.8) 29.8 (2.4–176.1) 14 (2.39–176.1) 
Height, cm 101 (82–130) 80 (36–180) 98 (36–180) 
Body mass index (kg/m2) 15 (9–20) 17 (10–58) 16 (9–58) 
Obesity    
   Not obese 46 12 58 
   Obese (body mass index ≥ 95th percentile) 1 9 10 
   Morbidly obese (body mass index ≥ 99th 
percentile) 
1 8 9 
  Unknown 2 34 36 
On extracorporeal membrane oxygenation 0 14 14 
Administration route    
   Intramuscular 50 0 50 
   Intravenous 0 63 63 
Number of doses 1 (1–1) 3 (1–32) 1 (1–32) 
Dose, mg/kg 4.0 (3.0–5.1) 1.0 (0.3–205) 3.3 (0.3–205) 
Number of ketamine plasma concentrations:    









2 1 21 22 
≥ 3 49 18 67 
*Data shown are counts or median (range). 
 
 
All children in the POP01 study received IV ketamine at a median dose of 1 mg/kg (range 0.3-
205). This included both bolus dosing and continuous infusion of ketamine. The largest dose was 
administered as a continuous infusion over 114 hours. The median number of ketamine doses received 
by children in the POP01 study was 3 (1-32). Median infusion rate was 35 mg/kg/hr (0.05-250), and 
median duration of infusion was 1 minute (1 minute-136 hours). All children in the KPSHC2011 study 
received a single dose of IM ketamine at a median dose of 4 mg/kg (3-5).  
Pharmacokinetic specimens  
The median number of PK samples per subject was 2 (1-6) in the POP01 study and did not differ 
significantly in the subset of 14-children supported with ECMO (1.5 samples [1-4]). A single subject in the 
KPSHC2011 study contributed 2, while all of the other 49 children contributed 3 PK samples. From the 
275 plasma PK samples drawn, 5 were excluded due to incomplete sampling time or dosing data and 4 
due to dilutions greater than the validated range (50x). Of the remaining 266 samples, 12 (< 5%) were 
BQL and dropped from the analysis, leaving a total of 254 samples—105 from the POP01 and 149 from 
the KPSHC2011 study—for analysis. Imputation using LLOQ/2 was evaluated, but not retained in the final 
model given that BQL after the first drug dose represented < 5% of the dataset and given the lack of 
appreciable difference in model fit or estimation results.73  
Population pharmacokinetics model development and evaluation 
A 2-compartment model with first-order absorption and elimination described the ketamine 
concentration vs time data well (Figure 4-4 and Figure 4-5). For the base model, we included 
allometrically scaled WT, normalized to 70 kg, with a fixed exponent of 0.75 for CL and 
intercompartmental CL (Q) and 1 for central (Vc) and peripheral (Vp) volumes of distribution. Estimation of 
the allometric coefficients was also performed and yielded similar results to the fixed values (0.7 for CL 
and 0.8 for V parameters), but was not retained in the final model due to concerns about 
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overparameterization and lack of significant effect on model fit and parameter estimates. Inclusion of a 
lag time to the first-order absorption model did not improve the OFV or model fit compared to the model 
without lag time and was therefore not retained in the base model. Diagnostic plots identified several 
outliers, and the model was reestimated after their exclusion without any significant difference in results. 
All concentrations were therefore retained in the final model. The IIV for absorption rate constant (KA), Vp, 
and bioavailability could not be accurately estimated due to excessively high shrinkage values (> 50%), 
and these random-effect parameters were therefore fixed to zero. The covariance between IIV (CL) and 
IIV (Vc) was not estimated, as the inclusion of a block covariance matrix resulted in model instability with 







Observed concentrations vs. population predictions (A); individual predictions (B); conditional weighted residuals 
against population predictions (C); time after first dose (D) 





8% of observations are outside of the 90% prediction interval. 
Figure 4-5. Final model standardized visual predictive check plot 
 
After accounting for body size, use of linear, power, and Emax maturation functions for either PNA or 
PMA on CL did not significantly reduce the OFV. Similarly, inclusion of race or ethnicity using additive 
covariates on CL also did not reduce the OFV. However, inclusion of ECMO as a covariate on CL/F using 
a power relationship resulted in a significant drop in the OFV (-19.5). Thus the final model included WT 
and a power relationship of ECMO on CL (Table 4-6): 
• KA (h-1) = 2.51 
• CL (L/h) = (38.9)*(WT (kg)/70)0.75*2.35ECMO  
• Vc (L) = (32.8)*(WT (kg)/70) 
• Q (L/h) = (54.9)*(WT (kg)/70)0.75 
• Vp (L) = (152)*(WT (kg)/70) 
• F = 0.411 
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Table 4-6. Final model parameter estimates and bootstrap results 
 
Final model 
OFV = 3011.711 
Bootstrap (n = 1000)* 
Parameter Estimate RSE (%) 2.50% Median 97.50% 
KA (1/hr) 2.51 38 1.57 2.49 4.59 
CL (L/hr/70kg) 38.9 15 26.93 38.73 51.14 
Vc (L/70kg) 32.8 35 19.66 33.66 58.01 
Q (L/hr/70kg) 54.9 13 33.66 53.90 79.62 
Vp (L/70kg) 152 36 97.12 152.15 301.99 
F 0.411 16 0.31 0.41 0.57 
ECMO**  2.35 26 1.46 2.37 4.02 
IIV (% CV) 
IIV (CL)% 49.1 27 25.2 46.9 64.9 
IIV (Vc)% 80.7 19 55.6 79.4 100.3 
IIV (Q)% 57.7 24 17.3 53.8 81.1 
Residual variability 
Proportional error POP01 data % 49.29 41 30.7 48.9 66.8 
Proportion error KPSHC2011 data % 15.75 30 11.1 15.8 20.2 
CL, clearance; ECMO, extracorporeal membrane oxygenation; F, bioavailability; IIV, interindividual 
variability; KA, absorption rate constant; OFV, objective function value; Q, intercompartmental clearance; 
RSE, relative standard error; Vc, central compartment of distribution; Vp, peripheral compartment of 
distribution 
*77% of all bootstrap runs minimized successfully  
**TVCL=CL*(WT/70)0.75*ECMO for subjects supported with ECMO, TVCL=CL*(WT/70)0.75 for subjects 
not supported with ECMO 
 
Separate proportional residual errors for the POP01 and KPSHC2011 data characterized residual 
variability and were estimated at 48.3% for the former and 15.8% for the latter. This difference is likely 
due to the opportunistic sampling design and variable dosing of the POP01 study. Shrinkage estimates 
for CL, Vc, and Q IIV were 15%, 31%, and 40%, respectively. Shrinkage for the POP01 and KPSC2011 
proportional residual error parameters were 18% and 46%. The percentage difference between model 
and bootstrapped median parameter estimates was 4% or less for all parameters. Diagnostic plots for the 
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final model showed overprediction at higher concentrations (≥ 1800 ng/mL) (Figure 4-4). Only 8% of 
observed concentrations were outside of the SVPC and typical VPC 90% prediction interval, indicating 
good performance of the final model (Figure 4-5). A numerical predictive check computing prediction 
intervals ranging from 0% to 95% found an appropriate percentage of observed concentrations outside 
the CI above the prediction intervals, but slightly lower than expected percentage of observed 
concentrations outside the CI below the prediction intervals (Table 4-7). 















95% CI above 
PI: from (%) 
95% CI 
above PI: to 
(%) 
0% PI 45.66929 43.30709 57.08661 54.33071 42.91339 56.69291 
20% PI 30.70866 33.07087 46.85039 42.91339 33.07087 46.85039 
40% PI 19.68504 23.62205 36.61417 32.28346 23.62205 36.61417 
50% PI 17.32283 18.89764 31.49606 24.40945 19.29134 31.88976 
60% PI 12.59843 14.56693 25.98425 16.53543 14.56693 25.59055 
80% PI 4.724409 6.299213 14.17323 11.81102 5.905512 14.56693 
90% PI 0.7874016 2.362205 8.267717 6.299213 2.362205 8.267717 
95% PI 0.3937008 0.7874016 5.11811 4.330709 0.7874016 5.11811 
CL, clearance; PI, prediction interval 
 
Individual empirical Bayesian estimates (EBEs) for PK parameters based on the final model were 
compared between children supported with and those not supported with ECMO (Table 4-8). Median 
empirical Bayesian estimate of CL was significantly higher in children supported with ECMO compared to 
those not supported with ECMO (1.70 L/h/kg vs 0.82 L/h/kg, P < .05). As expected, median Vc and Q did 
not differ between both groups.  
Table 4-8. Individual empirical Bayesian estimates in subjects supported and not supported 
with extracorporeal membrane oxygenation  
CL (L/h/kg)* Vc (L/kg) Q (L/kg) 
On ECMO 1.70 (1.01 to 4.3) 0.49 (0.23 to 0.65) 1.15 (0.78 to 1.74) 
No ECMO 0.82 (0.13 to 2.23) 0.47 (0.11 to 2.61) 1.13 (0.12 to 2.53) 
CL, clearance; ECMO, extracorporeal membrane oxygenation; Q, intercompartmental clearance; Vc, central 




Simulated dose-exposure relationship 
Following IM administration of doses ranging from 2 to 10 mg/kg, plasma concentrations 
corresponding to analgesic effects (> 100 ng/mL) were reached after approximately 5 minutes and lasted 
for 60 minutes (Figure 4-6). To achieve plasma concentrations above the anesthesia awakening 
threshold of 750 ng/mL, doses of 8 mg/kg in children 6 and 11 kg, and 6 mg/kg in children 17, 28, and 
56 kg were necessary (Table 4-9). Even at these doses, approximately 10 and 15 minutes were required 
to reach plasma concentrations > 750 ng/mL in children 6 and 11 kg, and 17 to 56 kg, respectively. 
Concentrations were maintained above this threshold for 20 to 30 minutes. A single IM dose of 0.5 mg/kg 
failed to exceed the analgesic effect threshold (not shown), while a single IM dose of 1 mg/kg barely 
reached this threshold in all simulated cases. Following IV administration, all bolus dosing levels 
simulated rapidly exceeded the analgesic threshold, and doses 2 mg/kg or greater resulted in plasma 
concentrations above the anesthesia awakening threshold of 750 ng/mL within 2 minutes of 
administration (Table 4-9). Doses of 2 mg/kg maintained plasma concentrations above this threshold for 
approximately 10 minutes, while a dose of 5 mg/kg was necessary to maintain plasma concentrations 
greater than 750 ng/mL for 20 minutes (Figure 4-7). When the typical child was simulated as supported 
with ECMO, similar IV doses were required to reach the threshold except for the 56-kg child, where a 
1-mg/kg dose was sufficient. However, plasma concentrations fell more rapidly and were below 







(A) 6-kg child; (B) 11-kg child; (C) 17-kg child; (D) 28-kg child; (E) 56-kg child 
Figure 4-6. 10th percentile simulated plasma concentration time curve in 5 individual children 
after administration of ketamine doses ranging from 1 to 10 mg/kg via intramuscular route 
 
Table 4-9. Minimum simulated doses exceeding the anesthesia-awakening threshold (plasma 
concentration > 750 ng/mL) by weight and route of administration 
Weight-simulated 
child (kg) 
IM dosing (mg/kg) IV dosing (mg/kg) IV dosing on ECMO 
(mg/kg) 
6 8 2 2 
11 8 2 2 
17 6 2 2 
28 6 2 2 
56 6 2 1 







(A) 6-kg child; (B) 11-kg child; (C) 17-kg child; (D) 28-kg child; (E) 56-kg child 
Figure 4-7. 10th percentile simulated plasma concentration time curve in 5 individual children 
not supported with extracorporeal membrane oxygenation after administration of ketamine doses 
ranging from 0.5 to 5 mg/kg via intravenous route 
 
 
(A) 6-kg child; (B) 11-kg child; (C) 17-kg child; (D) 28-kg child; (E) 56-kg child 
 
 -104- 
Figure 4-8. 10th percentile simulated plasma concentration time curve in 5 individual children 
supported with extracorporeal membrane oxygenation after administration of ketamine doses 
ranging from 0.5 to 5 mg/kg via intravenous route 
 
Safety  
No study procedure-related adverse events were reported in the 63 children enrolled in the 
POP01 study. In the KPSHC2011 study, 1 of the 50 children required airway repositioning and suctioning 
following ketamine administration.    
Discussion 
We developed a pediatric population PK model combining plasma concentrations of ketamine 
measured after IV and IM administration. Similar to published population PK models of ketamine in 
children and adults, a 2-compartment model best characterized the data. Our model is the first to 
estimate the bioavailability of IM ketamine in children, and the first to report on the effect of ECMO on 
ketamine CL. Our model is applicable to pediatric clinical practice by simulating optimal ketamine dosing 
for IM and IV administration, and for children supported with ECMO. 
The population estimates for ketamine Vc and Vp scaled to a 70-kg adult WT (32.8 L and 152 L) 
and the resulting Vss (= Vc + Vp = 184.8 L) were 41% higher than previously reported in a cohort of 
54 children with a mean age of 8.3 years (range 1.5–14) receiving IV ketamine for procedural sedation in 
the emergency department.50 Vss of ketamine is known to decrease with age, ranging from 242 L/70 kg in 
infants less than 3 months old to 53 L/70 kg by adulthood. Our estimate (185 L/70 kg) is consistent with 
the younger median age of 3.3 years in our cohort.54,74  
The population estimate for ketamine CL scaled to a 70-kg adult WT (38.9 L/hr) was comparable 
to the value (38.7 L/hr) previously derived in a cohort of 10 infants 1 week to 30 months of age receiving 
ketamine via continuous infusion while recovering from cardiac surgery.69 Our estimate was lower (51%) 
than the CL previously reported in 54 children with a mean age of 8.3 years (range 1.5-14) receiving 
ketamine in the emergency department (90 L/h/70 kg), although the authors pointed out that the latter 
value may have been overestimated by the truncated sampling scheme of the study, which was shorter 
than the sampling scheme available in our study (especially for the POP01 study).50 Our estimate is also 
24% to 74% lower than CL estimated in adults, with the highest adult CL being reported in critically ill 
subjects.75,76 Ketamine CL is known to be decreased in infants less than 3 months of age (26 L/hr/70 kg), 
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but approaches adult values by 3 to 12 months (86 L/hr/70 kg).11 As a result, estimation of CL from a 
pediatric cohort that includes infants less than 3 months old would be expected to yield lower values, as 
was the case in our study and the study of infants recovering from cardiac surgery.69 An estimate of CL in 
an older pediatric cohort should in turn result in higher CL values, as was the case in the report from the 
emergency department or a subsequent reanalysis of the same dataset.43 
Ketamine CL was 2.3-fold higher among children supported with ECMO in our cohort, while V 
was not significantly affected. The IIV on CL was only modestly decreased following inclusion of ECMO 
as a covariate and remained high (51% to 49%), but the OFV was significantly lower.  
Our study is the first to report on the PK of ketamine in children supported with ECMO, but 
previous studies have identified PK alterations of multiple drugs in children during ECMO support.77,78 
Several potential pathophysiologic mechanisms responsible for these alterations have been described: 
drug extraction by the ECMO circuit, hemodilution, and physiological changes related to the support of 
critical illness.79 We can only postulate as to the mechanism responsible for the increased CL of ketamine 
during ECMO support observed in our study. Hepatic N-demethylation is the primary elimination pathway 
of ketamine, with CL limited by liver blood flow.51 ECMO may ameliorate hepatic function through 
improved organ blood flow, particularly when compared to other critically ill children. An increase in CL 
among children supported with ECMO has previously been reported for micafungin and was presumed to 
be related to lower albumin concentration following hemodilution on ECMO.80 This is less likely to be the 
case in our cohort, as albumin concentrations were generally high in all children (> 2.1 g/dL), ketamine 
exhibits low protein-binding, and its CL has been shown to be blood-flow limited.51 Higher ketamine 
elimination with ECMO may also be due to nonspecific and irreversible drug adsorption by the circuit if 
adsorption is an ongoing process.81,82 Significant drug adsorption typically results in increased V, and is 
most often seen with lipophilic drugs.82 Because ketamine is more hydrophilic, adsorption may be less 
severe and occur more gradually over time, resulting in increased CL without affecting V.  
Our analysis leveraged a combined dataset from 2 clinical trials to estimate the bioavailability of 
IM ketamine using a population PK model. To our knowledge, the previously published bioavailability 
estimate of IM ketamine was calculated from the ratio of the trapezoidal area under the concentration 
time curve after IM and IV injection of ketamine in 6 healthy adult volunteers.57 In this population, the 
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bioavailability ranged from 85.9% to 97.2%, with a mean of 93%. Our estimate derived in a larger 
pediatric population using a popPK modeling approach is significantly lower (41%). The value does, 
however, reflect current dosing recommendations for induction of anesthesia with IM ketamine, which are 
2 to 3 times higher than recommended IV doses for children age 3 months or more to less than 16 years: 
5 to 10 mg/kg IM or 1 to 3 mg/kg IV.83–85 A similar dosing ratio is recommended for procedural sedation 
without concomitant use of propofol: 4 to 5 mg/kg IM or 1 to 2 mg/kg IV.86,87 The majority of these dosing 
recommendations were derived primarily from evaluating the dose-response relationship rather than 
characterizing exposure.  
We applied our model to ketamine dosing simulations following IM and IV bolus dosing in children 
with and without ECMO support. We designed our simulations to primarily reflect ketamine use for 
procedural sedation, given the prevalence of this indication in multiple clinical settings (intensive care unit, 
emergency department), and because it was an inclusion criteria for participation in the KPSHC2011 
study. Our recommended doses for children not supported with ECMO are consistent with previous 
reports for both IV and IM administration of ketamine for procedural sedation and with the ketamine FDA 
label.45,83,86,88–90 These reports primarily recommended doses based on safety profiles and clinical 
success rates of sedation and achievement of adequate conditions to complete procedures. Our 
simulation complements these reports by confirming that doses of 8 mg/kg and 6 mg/kg IM in children 6 
to 11 kg and 17 to 56 kg, respectively, and 2 mg/kg IV exceed plasma threshold concentrations 
previously associated with analgesia and arousability. When compared to the most recent and largest 
pediatric study of IV ketamine for procedural sedation that measured plasma concentrations, our 
simulations yielded similar exposures, with doses of 2 mg/kg resulting in plasma concentration less than 
750 ng/mL (level associated with arousal) after 10 minutes, while doses greater than 3 mg/kg exceeded 
this level for 20 minutes. An important difference between our IM and IV dosing simulations is the time to 
achievement of plasma concentrations greater than 750 ng/mL. Our results suggest that for children not 
supported with ECMO, IM doses of 8 mg/kg in children 6 to 11 kg and 6 mg/kg in children 17 to 56 kg will 
provide adequate sedation approximately 10 and 15 minutes after administration for procedures lasting 
up to 20 minutes. Doses of 2 mg/kg and 3 mg/kg IV will provide adequate sedation after approximately 
2 minutes for up to 10 and 15 minutes, respectively. For children supported with ECMO, IV doses of 
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2 mg/kg will provide adequate levels of sedation (> 750 ng/mL), but for shorter duration. For procedures 
lasting 10 minutes or longer, doses of 5 mg/kg or more would be required to maintain plasma 
concentrations greater than 750 ng/mL. 
Despite its strengths, our study has several important limitations. Our model diagnostics suggest 
some model misspecification, specifically overprediction of higher ketamine plasma concentrations 
(mostly 1800 ng/mL or more). The limited number of PK samples with high concentrations likely 
contributed to this bias. While we believe our report of IM bioavailability to be of clinical relevance given 
the frequent use of the drug in this population, we note that it is estimated from a popPK model with 
variable, sparse sampling schemes of distinct IV and IM dosing cohorts, and not estimates of area under 
the concentration vs time curve calculated in the same subjects following both IV and IM administration. 
This includes a notable lack of sampling times greater than 120 minutes after IM dosing, which is 
particularly relevant given the potential for longer absorption time after IM administration, which may limit 
our ability to truly describe the elimination phase. In addition, we recognize that merging of PK datasets 
should be undertaken with caution, as unrecognized sources of systemic bias may exist. We have 
attempted to address this possibility by estimating separate residual errors models and have tested 
numerous covariate relationships (including age and race) that may have differed between datasets. We 
also attempted to fit a model with separate CL estimated for each study, but minimization problems likely 
related to individual study sample size and sampling scheme precluded the reporting of reliable 
estimates. Despite these limitations, we believe that the challenges associated with conducting a 
traditional bioavailability study of ketamine in children warrant the reporting of our results as long as 
sufficient caution is applied in their interpretation. The sparsity of our data also did not allow us to provide 
IIV estimates of the IM bioavailability, which is likely to be substantial in children. We acknowledge that 
inclusion of IIV in these terms would increase the clinical value of our simulation results. Further, the 
opportunistic design of our study resulted in a wide spectrum of indications and dosing regimens. In part 
because of this limitation, we focused our simulations on achieving lower plasma-concentration targets 
required for procedural sedation and believe our model is useful in optimizing ketamine dosing for this 
indication in children with and without ECMO support even though our study is not a true PK/PD design 
and sedation scores were not obtained. The higher concentrations observed after larger doses should be 
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interpreted cautiously. Other limitations of our model include the relatively large residual error, particularly 
for children in the POP01 study. Again, the opportunistic study design with variable PK sampling times 
and large dosing range likely contribute to this effect. In the KPSHC2011 data, where dosing and PK 
sampling times were specified by the protocol, residual variability was lower. IIV also remained high for all 
3 parameters for which it could be estimated, even after including ECMO as a covariate on CL in our final 
model. As previously noted by others, high IIV is a consistent feature across multiple pediatric popPK 
models of ketamine, although the exact reason remains unclear.50 In both studies used in our analysis, 
several clinical characteristics that may affect ketamine exposure were not collected, limiting our ability to 
test all potentially relevant covariates. This includes pharmacogenomic differences in enzymatic activity of 
ketamine-metabolizing enzymes, including CYP3A isoenzymes, CYP2C9, and CYP2B6. We evaluated 
race as a surrogate for pharmacogenomic differences, given previously described racial differences in 
allelic distribution particularly of CYP2B6, which was undetectable in 70% of Japanese adults in 
1 study.75,81 We were unable to identify a significant relationship between age and ketamine CL, despite 
the known ontogeny of CYP3A isoenzymes in children less than 2 years of age. The limited number of PK 
samples collected for this subpopulation may, at least in part, explain this finding. It is further possible that 
CYP2C9 and CYP2B6 may play a greater role in ketamine metabolism in our population. Ketamine has 
an important pharmacologically active metabolite, norketamine, which was not measured in the plasma 
samples of either study. We therefore cannot comment on how norketamine plasma concentrations may 
affect our dosing recommendations. Finally, our evaluation of ketamine safety was limited by the fact that 
only study procedure-related adverse events were collected in the POP01 study, and only 1 event was 
recorded in the KPSHC2011 study. The observed event (suctioning and repositioning) is consistent with 
previous reports that excessive salivation and the need for airway suctioning are the most common 
adverse effects of ketamine, occurring in 13 to 33% of children.91 Unfortunately, we are unable to 
comment on the prevalence of other important adverse events such as the occurrence of emergence 
delirium or any long-term consequences of ketamine use.92  
Conclusions 
In conclusion, we used combined data from 2 PK studies to develop a pediatric popPK model of 
IM- and IV-administered ketamine. Our model is the first to estimate the bioavailability of IM ketamine of 
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41%, consistent with the ratio of currently recommended IM-to-IV dosing of ketamine for multiple 
indications. We also identified ECMO exposure as a significant covariate associated with higher ketamine 
CL. Using our model for dosing simulations, we recommend that children not supported with ECMO 
receive IV and IM doses of 2 mg/kg and 6 or 8 mg/kg, respectively, for sedation for procedures lasting up 
to 20 minutes. An important difference between the 2 administration routes is the time to onset of 
sedation, which is up to 10 minutes after IM administration. For children supported with ECMO, doses of 
5 mg/kg or more are required for procedures lasting 10 minutes or longer. As with all PK models, 
additional ketamine PK samples collected in future studies may be used to iteratively improve our model 
performance and maximize its clinical value. 
PART 3. POPULATION PHARMACOKINETICS OF MILRINONE IN INFANTS, CHILDREN, AND 
ADOLESCENTS 
 
This part 3 of chapter 4 previously appeared in a manuscript in preparation for submission to 
Journal of Clinical Pharmacology. Population Pharmacokinetics of Milrinone in Infants, Children, and 
Adolescents.  Christoph P. Hornik, MD, MPH, Ram Yogev, Peter M. Mourani, Kevin M. Watt, Janice E. 
Sullivan, Andrew M. Atz, David Speicher, Amira Al-Uzri, Michelle Adu-Darko, Elizabeth Payne, Casey 
Gelber, Susan Lin, Barrie Harper, Chiara Melloni, Michael Cohen-Wolkowiez, Daniel Gonzalez; on behalf 
of the Best Pharmaceuticals for Children Act – Pediatric Trials Network Steering Committee. 
Introduction 
Milrinone is a type 3 phosphodiesterase inhibitor approved by the US FDA for up to 48 hours of 
IV treatment in adults with acute decompensated heart failure.93 Milrinone is not approved for use in 
subjects under 18 years of age, but is frequently administered off label to infants and children for the 
treatment of pulmonary hypertension, low cardiac output, and vasoconstricted shock.94–97 
Phosphodiesterase inhibition by milrinone raises intracellular cyclic adenosine monophosphate levels, 
which increases intracellular calcium concentrations and promotes contractile protein phosphorylation, 
resulting in improved systolic cardiac contractility, diastolic cardiac relaxation, and vascular relaxation.98,99 
Due to a lack of direct adrenoreceptor stimulation, milrinone does not raise myocardial oxygen 
consumption, a particularly favorable property in the setting of impaired myocardial oxygen delivery.   
In adults, milrinone displays 70% protein binding, predominantly to albumin, and has a V of 
approximately 30 L/70 kg.100,101 Milrinone is eliminated via the kidneys, with up to 90% of the drug 
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recovered in the urine after 8 hours, predominantly in the parent form (~80%) or as an O-glucuronidated 
metabolite (~10%). Milrinone elimination CL is 300 mL/min in adults, indicative of active tubular secretion, 
though the specific transporters involved are not known. Elimination CL is significantly reduced in adults 
with moderate-to-severe renal impairment and an estimated creatinine clearance (CrCl) of 30 to 
80 mL/min, including those with congestive heart failure.102–104 Plasma concentrations associated with 
therapeutic effects in adults range from 100 to 300 ng/mL.105,106 Higher concentrations (> 500 ng/mL) are 
associated with toxicity, primarily systemic hypotension resulting from excessive vasodilation.105 To limit 
the risk of toxic accumulation in the setting of impaired renal function and decreased milrinone 
elimination, the product label recommends reducing the continuous infusion rate by up to 66% in adults, 
based on estimated CrCl.93  
Milrinone PK has been previously studied in pediatric subjects, including premature infants and 
those with congenital heart disease.97,105,107–109 PopPK models have been developed in different pediatric 
populations with both WT and age as covariates relevant for characterizing CL. The effects of variable 
renal function on milrinone CL in children are complex, involving an interplay between maturation of organ 
function, underlying disease processes, therapeutic benefits of milrinone, and milrinone toxicity, all 
affecting renal CL.109–111 In a retrospective analysis of therapeutic drug monitoring data from a single 
center, a significant correlation between estimated CrCl and milrinone CL was observed, a popPK model 
was developed, and the need for dose individualization was highlighted.110 While dose individualization 
has the potential to improve therapeutic outcomes of milrinone, turnaround times of quantification assays 
may prohibit its widespread implementation in several settings of care. More recently, a popPK model 
incorporating renal dysfunction as measured by Kidney Injury Improving Global Outcomes (KDIGO) 
criteria was developed in infants less than 12 months of age receiving milrinone after cardiac surgery.112 
In this patient population, the authors recommended lower milrinone infusion rates in infants with KDIGO 
stage 3 renal insufficiency based on their model-derived dosing simulations. A popPK model that 
incorporates renal function parameters across a broader pediatric age range could be leveraged to 
perform similar dosing simulations that may a priori inform milrinone dosing in children with variable age 
and renal function.  
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In this PK analysis, we used opportunistically collected samples from infants and children, 
covering a wide range of ages and renal function, to develop a popPK model and characterize the effect 
of CrCl on milrinone CL. We then leveraged the model to conduct simulations across the pediatric age 
continuum, highlighting the need for dose reductions in the setting of renal impairment. 
Materials and methods 
Subject population 
Pharmacokinetics samples used to develop the popPK model described in this report were 
collected through the PTN’s Pharmacokinetics of Understudied Drugs Administered to Children per 
Standard of Care trial (ClinicalTrials.gov no. NCT01431326; protocol: NICHD-2011-POP01).  
The PTN POP01 trial is a multicenter, prospective, PK and safety study of understudied drugs 
administered to children (< 21 years of age) per standard of care. Subjects who received IV milrinone per 
standard of care as administered by their treating caregiver were eligible for enrollment. Exclusion criteria 
included failure to obtain consent or assent or a known pregnancy as determined by interview or testing. 
Standard-of-care laboratory assessments (eg, basic metabolic panel, including serum creatinine) were 
recorded if collected within 72 hours of a study dose of the drug. GA was documented in infants with a 
PNA of less than 120 days and height and WT measured around the time of the first PK sample 
collection. Subjects were enrolled in the study for up to 90 days. The POP01 study protocol was reviewed 
and approved by the IRB of each participating institution. 
Drug dosing and sample collection 
Dosing information was collected for up to 8 doses before the sampling dose (last dose before 
first biological sample collection). Dosing was per standard of care, but limited to the IV administration 
route. Pharmacokinetic samples were collected optimally with standard-of-care lab collections or at 
different times from standard-of-care collections if allowed per consent (Table 4-10). Because this was a 




Table 4-10. Stepwise covariate evaluation 
Description Population model OFV Change in  OFV 
Univariate analysis 





































PNA on CL (Power) CL=11*((WT/70)**0.75)*(PNA/2.9)**54.6 
V=32.2*(WT/70) 
1110.43 -18.21 
PNA on CL (Linear) CL=5.84*((WT/70)**0.75)*(1+PNA*0.162) 
V=57.9*(WT/70) 
1108.9 -3.99 












Description Population model OFV Change in  OFV 






















CrCl on CL (Power) CL=10.3*(WT/70)**0.75*((CrCl/117)**0.772) 
V=31.6*(WT/70) 
1089.92 +11.82 
CL, clearance; CrCl, creatinine clearance; ECMO, extracorporeal membrane oxygenation; Emax, maximum effect; 
MF, maturation function; OFV, objective function value; PMA, postmenstrual age; PMAW, postmenstrual age in 
weeks; V, volume of distribution; WT, body weight 
 
Analytical methods 
Blood was collected (0.2 mL in subjects less than 1 year of age and 2 mL in subjects 1 year or 
greater of age) in an EDTA-K2 Microtainer and was processed into plasma immediately before freezing at 
the study sites. Pharmacokinetic samples were sent to a PTN-contracted commercial laboratory 
(Frontage Laboratories, Exton PA) for storage and analysis. Milrinone concentrations were quantified 
using validated liquid chromatography-tandem spectrometry assays.105 Reversed-phase high-
performance liquid chromatography separation was achieved with a Phenomenex Synergi, Polar-RP 80A 
column (50 x 2.0 mm, 4 micron) (Phenomex, Torrance CA). The validation range for the assay was 1 to 
3800 ng/mL. Accuracy and precision assessed were within the FDA’s bioanalytical assay validation 
criteria (eg, ± 15%). Additional details of the bioanalytical method are provided in the supplementary 
materials.  
Statistical analysis 
Using the value at the time of first-recorded dose (bolus or continuous infusion), the median and 
range were calculated and presented for demographic and dosing variables. Counts and percentages are 
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calculated and presented for categorical variables. Distribution of study variables are compared using 
nonparametric Kruskal-Wallis, chi square, or Fisher’s exact tests, where appropriate. The distributions of 
individual EBEs calculated from the final popPK model were compared across covariates using Wilcoxon 
rank sum tests. With the exception of the PK modeling, all statistical analyses were performed using Stata 
(version 14.2, College Station TX). 
Population pharmacokinetic model development 
Milrinone plasma PK data collected after IV administration were analyzed with a nonlinear mixed 
effects modeling approach using the software NONMEM (version 7.4.3, Icon Development Solutions, 
Ellicott City MD). The first-order conditional estimation method with eta-epsilon interaction was used for all 
model runs. Run management was performed using Pirana (version 2.8.2).59 Bootstrap analyses were 
performed with Perl-speaks-NONMEM (version 3.7.6).60 Data manipulation and visualization were 
performed using the packages Xpose in the software R (version 3.0.3, R Foundation for Statistical 
Computing, Vienna, Austria), RStudio (version 0.97.551, RStudio, Boston MA), and Stata (Version 14.2, 
College Station TX).63 
One, 2-, and 3-compartment PK models with assumed linear PK were explored.112 IIV was 
assessed for PK model parameters using an exponential relationship (equation 1).  
𝑃𝑃𝐴𝐴𝑆𝑆𝑖𝑖𝑗𝑗 = 𝜃𝜃𝑃𝑃𝑜𝑜𝑃𝑃,𝑗𝑗 ∗ exp (η𝑖𝑖𝑗𝑗)        (1) 
where PARij denotes the estimate of parameter j in the ith individual; θPop,j is the population value for 
parameter j; and ηij denotes the deviation from the average population value for parameter j in the ith 
individual with mean zero and variance ω2. The apparent IIV was converted to percent coefficient of 
variation (CV) by taking the square root of ω2 and multiplying it by 100.  
Proportional, additive, and combined (additive plus proportional) residual error models were 
explored.  
Covariate analysis 
Actual WT was assumed to be a significant covariate for CL and V and was included in the base 
model. The relationship between WT and PK parameters was characterized using an allometric 
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         (3) 
where CLstd and Vstd represent population estimates of CL and V in a 70-kg adult and WTi denotes WT for 
the ith subject, and 𝜃𝜃𝑊𝑊𝑊𝑊,𝐶𝐶𝐶𝐶 and 𝜃𝜃𝑊𝑊𝑊𝑊,𝑉𝑉 denote the exponents for the effect of WT on CL and V parameters, 
respectively. Estimation of these exponents was compared to using fixed values of 0.75 and 1 for 𝜃𝜃𝑊𝑊𝑊𝑊,𝐶𝐶𝐶𝐶 
and 𝜃𝜃𝑊𝑊𝑊𝑊,𝑉𝑉, respectively. 
After accounting for differences in body size using WT, additional covariates were tested for 
model inclusion. Determination of which covariates to test for model inclusion was based on physiological 
relevance and by visual inspection of scatter and box plots (continuous and categorical variables, 
respectively) of the individual deviations from the population-typical value PK parameters (ETAs) against 
covariates. The covariates explored were gender, race, ethnicity, obesity, PMA and PNA, ECMO at any 
time during PK sampling, indication, surgery history, serum creatinine, and CrCl. To estimate CrCl, we 
used the updated bedside Schwartz equation.113–117 With the exception of WT, which was standardized to 
70 kg, all other continuous covariates were normalized to the population median value of the trial 
population. When covariates were missing at a specific time point, the last available value was carried 
forward. When covariates were entirely missing, the median value from the study population was 
imputed, except for GA, where a value of 40 weeks (term infant) was imputed when missing.  
The relationship between age and CL was evaluated using linear, power, and sigmoidal Emax 
maturation functions (equations 4-6). Maturation function parameters were both estimated and fixed to 
previously published values as published by Rhodin et al., Mahmood et al, and Mizuno et al.112,118,119 As a 
measure of age, PNA and PMA were explored.  
𝐹𝐹𝑏𝑏𝑘𝑘𝑏𝑏 =  𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝑊𝑊𝐴𝐴𝑊𝑊𝐶𝐶𝐶𝐶𝐶𝐶 ∗ 𝐴𝐴𝑎𝑎𝐶𝐶 + 𝑊𝑊𝐶𝐶𝐶𝐶𝐶𝐶𝐴𝐴𝐴𝐴𝐶𝐶𝑖𝑖𝐶𝐶       (4) 
𝐹𝐹𝑏𝑏𝑘𝑘𝑏𝑏 =  𝐴𝐴𝑎𝑎𝐶𝐶𝐶𝐶𝑜𝑜𝑏𝑏𝐶𝐶𝐶𝐶𝑖𝑖𝐶𝐶𝑖𝑖𝑏𝑏𝑖𝑖𝑑𝑑         (5) 
𝐹𝐹𝑏𝑏𝑘𝑘𝑏𝑏 =  
𝑏𝑏𝑘𝑘𝑏𝑏𝐻𝐻𝐻𝐻𝐻𝐻𝐻𝐻
𝑊𝑊𝑇𝑇50𝐻𝐻𝐻𝐻𝐻𝐻𝐻𝐻+𝑏𝑏𝑘𝑘𝑏𝑏𝐻𝐻𝐻𝐻𝐻𝐻𝐻𝐻
         (6) 
The relationship between CrCl and CL was evaluated using linear and power relationships. For 
dichotomous categorical covariates (eg, ECMO), a power relationship was used (equation 7).  
𝐹𝐹𝐶𝐶𝑜𝑜𝑐𝑐 =  𝐴𝐴𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝑊𝑊𝐴𝐴𝑊𝑊𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝑜𝑜𝑐𝑐𝑏𝑏𝑐𝑐𝑏𝑏𝑖𝑖𝑑𝑑𝑏𝑏        (7) 
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For categorical variables with n distinct values (race, ethnicity), additive coding with n-1 indicator variables 
(1 = yes, 0 = no) was used (equation 8). 
𝐹𝐹𝐶𝐶𝑜𝑜𝑐𝑐 =  𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝑊𝑊𝐴𝐴𝑊𝑊𝐶𝐶𝐶𝐶𝐶𝐶1 ∗ 𝐶𝐶𝐶𝐶𝑐𝑐𝐴𝐴𝐴𝐴𝑊𝑊𝐴𝐴𝐶𝐶𝐶𝐶 𝐶𝐶𝐶𝐶𝑐𝑐𝐶𝐶𝐶𝐶1 + ⋯+  𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝑊𝑊𝐴𝐴𝑊𝑊𝐶𝐶𝐶𝐶𝐶𝐶𝑖𝑖−1 ∗ 𝐶𝐶𝐶𝐶𝑐𝑐𝐴𝐴𝐴𝐴𝑊𝑊𝐴𝐴𝐶𝐶𝐶𝐶 𝐶𝐶𝐶𝐶𝑐𝑐𝐶𝐶𝐶𝐶𝑖𝑖−1 (8) 
A forward inclusion (p < 0.05 and change in OFV > 3.8) and backward elimination (p < 0.01 and change 
in OFV > 6.6) approach was used to evaluate statistical significance in the covariate analysis. 
Population pharmacokinetics model evaluation 
Standard model diagnostic methods were used and included successful minimization, diagnostic 
plots, and plausibility and precision of parameter estimates, as well as OFV and shrinkage values. 
Generated diagnostic plots included IPREDs and population predictions vs observations and conditional 
weighted residuals vs population predictions and time after first dose. 
Parameter precision for the final popPK model was evaluated using nonparametric bootstrapping 
(1000 replicates) to generate the 95% CIs for parameter estimates. A prediction-corrected visual 
predictive check (pcVPC) was performed using the final model (N = 1000 simulations). To generate the 
pcVPC plots, both the simulated and observed concentrations were normalized using the median 
prediction for each bin across time after dose.120 The dosing and covariate values used to generate the 
simulations in the VPC were the same as those in the study population. The number of observed 
concentrations outside of the 90% prediction interval for each time point was quantified.  
Dosing simulations 
Plasma concentrations of milrinone were simulated in virtual subjects with variable renal function 
as defined by the CrCl. Four virtual subjects with WTs of 3 kg with PMA of 40 weeks, 13 kg with PMA of 
144 weeks (2 years PNA), 40 kg with PMA of 664 weeks (12 years PNA), and 70 kg with PMA of 
1600 weeks (PNA 30 years) were created, and within each subject, estimated CrCl was imputed at 
4 different levels: 30 mL/min/1.73 m2, 60 mL/min/1.73 m2, 120-mL/min/1.73 m2, and 160 mL/min/1.73 m2, 
thereby creating a total of 16 virtual subjects. These scenarios were chosen to represent WTs and renal 
function of infants, children, and adolescents who may be exposed to milrinone in clinical practice and 
were within the range of observed values in our study cohort. The PNA and subsequently calculated PMA 
were chosen to represent approximately the 50th percentile on the Centers for Disease Control WT for 
age percentiles. For each virtual subject, 2 dosing scenarios frequently used in clinical practice were 
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evaluated: an IV loading dose of 25 mcg/kg/min administered over 30 minutes followed by a continuous 
IV infusion of 0.25 mcg/kg/min for 48 hours and an IV loading dose of 50 mcg/kg/min administered over 
30 minutes followed by a continuous IV infusion of 0.5 mcg/kg/min for 48 hours. Ten concentration time 
points were simulated, starting with the completion of the loading dose and at regular intervals up to 
48 hours. A total of 1000 simulations were performed for each virtual subject for each dosing scenario, 
and the median values are presented in concentration time curves plotted over the plasma milrinone 
concentration range associated with efficacy per the FDA label and prior publications—100 ng/mL 
to 300 ng/mL.93,105,106 To illustrate the effect of IIV on simulated milrinone exposures, plasma 
concentrations at steady state (Css) during continuous infusion, calculated as Css = infusion rate/CL, were 
determined and plotted as box plots stratified by virtual subject WT, estimated CrCl, and dosing regimen.  
Safety analysis  
In the POP01 study, only adverse events associated with study procedures (phlebotomy) and 
suspected unexpected serious adverse reactions were recorded.  
Results 
Patient characteristics 
Seventy-four subjects contributed 111 evaluable plasma samples for PK analysis (Table 4-11). All 
subjects received IV milrinone at a median infusion rate of 0.5 mcg/kg/min (range 0.1-41 mcg/kg/min) for 
a median duration of 12 hours (range 0.02-2647 hours). Fifty-four bolus doses, defined as infusions 
administered over 1 hour or less, were administered in 21 subjects. Median number of dose adjustments 
per subject, including bolus doses or changes in infusion rate, was 2.5 (1-17). The median serum 
creatinine was 0.5 mg/dL (0.1-3.1), and the median estimated CrCl was 117.2 mL/min/1.73 m2 (13.1-
261.3). A subset of 17 subjects (23%) were supported with ECMO. The median number of PK samples 
per subject was 2 (1-11). From the total of 125 plasma PK samples drawn, 14 (1%) were excluded for the 
following reasons:  
• 9 due to dilutions greater than the validated range (50x dilution) 
• 3 were BQL and were the only samples obtained in 3 subjects and were not imputed, 
given their low number 
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• 2 were significant outliers and were the only 2 samples obtained in 1 subject at 
> 1800 hours after the first milrinone dose 
Table 4-11. Clinical data from 74 subjects  
Median (range) or N (%) 
Age (years) 2.9  (0.01, 18) 
Gestational age (weeks) 39 (37, 41) 
Postmenstrual age (weeks) 192 (37, 977) 
Weight (kg) 13.1 (2.6-157.7) 
Male, n (%) 39 (53%) 










Ethnicity, n (%) 
Hispanic or Latino 




Serum creatinine (mg/dL) 0.5 (0.1-3.1) 
Creatinine clearance (mL/min/1.73 m2)* 117.2 (13.1-261.3) 
On ECMO, n (%) 17 (23%) 
Obese, n (%) 11 (15%) 
Infusion rate (mcg/kg/min) 0.5 (0.1-41) 
Number of pharmacokinetic samples per subject 2 (1-11) 
ECMO, extracorporeal membrane oxygenation 
 
Population pharmacokinetics model development and evaluation 
A 1-compartment model characterized the milrinone concentration vs time data well (Figure 4-9 
and Figure 4-10). For the base model, we included allometrically scaled WT, standardized to 70 kg, with 
fixed allometric coefficients for both CL and V at 0.75 and 1, respectively. Estimation of the allometric 
coefficients was also performed, but did not improve model fit or significantly reduce OFV compared to 
inclusion of other covariates as outlined below. The IIV for V could not be accurately estimated due to 
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excessively high shrinkage values (> 50%), and this random effect parameter was therefore fixed to zero 
in both the base and final models. 
A      B 
  
 
C      D 
 
The solid black line represents the line of unity; the dashed line is a linear regression line (A and B) or a Loess 
smoother (C and D). 
Figure 4-9. Final population pharmacokinetic model goodness-of-fit plots: observed 
concentrations vs population predictions (A) and individual predictions (B), and conditional 
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Seven percent of the observations are outside of the 90% prediction interval. The shaded area represents the 90% 
prediction interval, the dashed line the median predicted concentrations, and the solid line the median observed 
concentrations. 
Figure 4-10. Prediction corrected visual predictive check for the final population 
pharmacokinetic model 
 
After accounting for body size, use of Emax maturation functions for PMA on CL most significantly 
reduced the OFV (-24.02), followed by inclusion of estimated CrCl as a covariate on CL using a power 
relationship (-22.97). In the multivariable step, addition of CrCl as covariates to a model containing the 
Emax maturation function further significantly reduced the OFV (-10.77). In the backward elimination step, 
removal of either covariate increased the OFV by greater than 6.6. Thus, the final model included WT, a 
maturational function that characterized the relationship between CL and PMA, and a power relationship 
that characterized the relationship between CL and CrCl (Table 4-12): 
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• CL (L/h) = (15.9)*(WT [kg]/70)0.75*(PMA[weeks]1.12/(67.71.12+PMA[weeks]1.12)) 
*(CrCl [mL/min/m2]/117)0.522  
• V (L) = (32.2)*(WT [kg]/70) 
Table 4-12. Parameter estimates and bootstrap results for the final population 
pharmacokinetic model 
Parameters Estimate (RSE) Bootstrap median (5th, 95th percentile) 
CL
70kg
 (L/h) 15.9 (23%) 15.9 (12.2, 33.5) 
V
70kg 
(L) 32.2 (30%) 31.6 (12.4, 153.9) 
Exponent for power function characterizing 
the effect of CrCl on CL 0.522 (27%) 0.54 (0.30, 0.82) 
TM50 (weeks PMA) 67.7 (64%) 68.4  (39.5, 1158.6) 
Hill coefficient 1.12 (70%) 1.1 (0.44, 24.7) 
IIV CL (CV%) 70 (27%) 67 (48, 83) 
Residual proportional error (%) 32 (29%) 26 (20, 37) 
CL, clearance; CrCl, creatinine clearance; CV%, coefficient of variation percentage; IIV, interindividual variability; 
PMA, postmenstrual age; TM50, maturation half-life; V, volume of distribution 
 
A proportional error model with a value of 32% characterized the residual error well. The 
shrinkage estimate for the parameter estimating the IIV in CL was 6%. Shrinkage for the proportional 
residual error parameter was 27%. The percentage difference between model and bootstrapped median 
parameter estimates was 5% or less for all parameters.  
Diagnostic plots for the final popPK model showed under prediction at higher concentrations 
(≥ 400 ng/mL) (Figure 4-9). Six subjects had conditional weighted residuals greater than 2. These 
subjects ranged in WT and PMA from 3 to 16 kg and 0.7 to 5.4 years, 1 was supported with ECMO, and 
none were obese. Eight percent of observed concentrations were outside of the pcVPC 90% prediction 
interval, indicating slight overestimation of the IIV by the final popPK model (Figure 4-10). 
Individual EBEs of milrinone half-life were compared between subjects with variable estimated 
CrCl (Figure 4-11). As expected, the distribution differed significantly between groups of estimated CrCl 




Outer limits of the boxes are 25th and 75th percentiles, vertical lines inside the box the 50th percentile, while 
whiskers are 1.5 times the interquartile range. Outlier values are shown. 
Figure 4-11. Empirical Bayesian estimates of milrinone half-life by estimated creatinine 
clearance 
 
Simulated dose-exposure relationship 
A loading dose of 50 mcg/kg resulted in milrinone plasma concentrations at the end of the load 
within the therapeutic range of 100 ng/mL to 300 ng/mL except for the 40-kg adolescent (12 years of age) 
with an above normal CrCl of 160 mL/min/1.73 m2 (Figure 4-12). Following administration of a 50-mcg/kg 
loading dose, a continuous infusion of 50 mcg/kg/min resulted in therapeutic plasma concentrations in the 
virtual 3-kg newborn, 13-kg child (2 years of age), and 40-kg adolescent (12 years of age) when the CrCl 
was 60 mL/min/1.73 m2 or greater, except for the 40-kg adolescent (12 years of age) with an above-
normal CrCl of 160 mL/min/1.73 m2, where concentrations remained below the 100-ng/mL threshold. 
Most importantly, the 50-mcg/kg/min continuous infusion exceeded the upper limit of the therapeutic 
range for a 3-kg newborn, when the estimated CrCl was severely impaired at 30 mL/min/1.73 m2. When 
CrCl was 30 mL/min/1.73 m2, a continuous infusion of 0.25 mcg/kg/min maintained plasma 




























































continuous infusion support these conclusions, but also highlight the wide range of simulated exposures 
resulting from the significant IIV (Figure 4-13).  
 A 
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Following a 25-mcg/kg loading dose followed by a 0.25-mcg/kg/min continuous infusion in a 13-kg child 
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Following a 25-mcg/kg loading dose followed by a 0.25-mcg/kg/min continuous infusion in a 40-kg adolescent 
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Following a 50-mcg/kg loading followed by a 0.5-mcg/kg/min continuous infusion in a 40-kg adolescent (12 years of 
age). 
Figure 4-12. Median simulated milrinone plasma concentration time curve in individual subjects 
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Following a 0.25-mcg/kg/min continuous infusion (A); during a 0.5-mcg/kg/min continuous infusion (B). Dashed lines 
represent the upper and lower limit of the therapeutic range (100 ng/mL and 300 ng/mL, respectively). Outer limits of 
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the boxes are 25th and 75th percentiles, vertical lines inside the box the 50th percentile, while whiskers are 1.5 times 
the interquartile range. Outlier values are not shown. 
Figure 4-13. Simulated steady-state milrinone plasma concentration by weight, age, and 
creatinine clearance at different doses 
 
Safety 
No study procedure-related adverse events or serious adverse events were reported in the  
74 subjects enrolled in the POP01 study exposed to milrinone. 
 
Discussion 
We developed a pediatric popPK model using milrinone concentrations collected opportunistically 
following IV administration in a group of children of widely varying age and renal function. Similar to some 
previously published popPK models of milrinone in adults and children, a 1-compartment model best 
characterized the data.101,107,108 Our model incorporates the effect of PMA and estimated CrCl on 
milrinone CL. This feature makes it particularly applicable to pediatric clinical practice by simulating 
optimal milrinone dosing for children with variable renal function.  
Our population estimate for milrinone V scaled to a 70-kg WT (32.2 L) is comparable to values 
previously reported in adults and on the FDA drug label (26.6 L/70 kg) and to that reported in a pediatric 
populations 0 to 6 years of age after cardiac surgery (V = 33.7 L/70 kg).93,107 Interestingly, neither our 
study nor any previously published popPK study of milrinone has, to our knowledge, identified any 
significant covariates affecting V estimates beyond WT or related anthropomorphic measurements, such 
as body surface area. Plasma concentrations of albumin in particular could affect estimates of V, given 
the moderate degree of binding of milrinone to this protein.100,101 Unfortunately, we did not have access to 
plasma albumin concentrations in these opportunistically collected data to assess its effect on milrinone 
V. Our estimate of CL scaled to a 70-kg WT (15.9 L/h) falls within the wide range of adult estimates 
(18 L/h in healthy volunteers, 9.1 L/h in subjects with congestive heart failure, 1.4 L/h in subjects with 
congestive heart failure and CrCl < 30m L/min) and is similar to prior pediatric estimates.102,104,121 In a 
study of 19 children 0 to 13 years of age (3.5-40 kg WT) recovering from cardiac surgery, milrinone CL 
was estimated at 24 L/h/70 kg.122 In a more recent popPK model developed in infants less than 
12 months of age who received milrinone after cardiac surgery, milrinone CL was estimated at 
7.91 L/h/70 kg.112 Importantly, milrinone CL has been previously shown to increase with age in both infant 
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cohorts and in cohorts including children up to 6 years of age.107,110,112 In our covariate analysis, the effect 
of age on CL was best represented by an Emax maturation model using PMA. This is consistent with a 
recent popPK model developed in infants less than 12 months of age who received milrinone after 
cardiac surgery.112 In this study, the reported maturation half-life (TM50) of the maturation function was 
47 weeks. We observed a higher TM50 value of 68 weeks, which may be related to the wider age range 
and the lower number of subjects 1 year or less of age (N = 23) in our cohort. Maturational effects 
primarily responsible for milrinone CL likely include changes in renal function, in particular the ontogeny of 
renal transporters that may be responsible for active secretion, given that over 80% of the parent drug is 
recovered unchanged in the urine and that mean renal CL in healthy adults (300 mL/min) is in excess of 
glomerular filtration.110 Because the primary transporters that may be responsible for active secretion of 
milrinone are unknown, characteristics of the maturational function of milrinone CL remain speculative. 
Interestingly, acyclovir, a drug cleared through active renal secretion, likely organic anion transports 1 and 
3, exhibits maturational properties more similar to our observations, with a reported TM50 of 
58 weeks.123,124 This is significantly greater than the TM50 previously reported to characterize the 
maturation of GFR.118,119 Despite inclusion of these covariates, however, the IIV on CL remains high, 
suggesting that additional covariates beyond age and renal function may affect milrinone elimination.  
Based on our final popPK model, children with an estimated CrCl of 30 mL/min/1.73 m2, 
indicative of severe renal impairment as defined by the FDA, had a 65% lower milrinone CL than children 
with an estimated CrCl of 117 mL/min/1.73 m2 (5.9 L/h/70 kg vs 15.9 L/h/70 kg), the median estimated 
value in our study cohort.125 This decrease in CL is comparable to findings from a prior study of 
11 children 3 weeks to 20 years of age diagnosed with acute kidney injury with or without continuous 
renal replacement therapy requirement (estimated CrCl 2.5-103 mL/min), where the mean milrinone CL 
was 4.7 L/h/70 kg.110 In this prior study, milrinone CL was estimated using popPK modeling based on 
scavenged sampling, with only allometrically scaled WT tested as a covariate and CL being the only 
population parameter estimated. The authors reported a strong correlation (R2 = 0.7) between milrinone 
CL and CrCl estimated by bedside Schwartz equation, but did not leverage their model to perform dosing 
simulations at the population level. More recently, the same authors developed a popPK model in 
92 infants less than 12 months of age who received milrinone after cardiac surgery and reported a 
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population estimate for CL of 7.91 L/h/70 kg. In this analysis, renal insufficiency as measured by KDIGO 
criteria was included as a covariate on CL. Consistent with our findings, milrinone CL was significantly 
lower in infants with KDIGO stage 3 renal insufficiency. The overall higher population estimates of CL in 
our analysis are likely related to the difference in our study population, which included older children. 
Indeed, the median EBE for CL in the subset of infants less than 1 year of age included in our analysis 
(11 L/h/70 kg) is more comparable to the value reported in this recent publication. 
  We are able to leverage our model to perform dosing simulations that take into account various 
levels of renal impairment as quantified by estimated CrCl. Because we estimated CrCl with the bedside 
Schwartz equation, our model has applicability to daily clinical practice. Our simulations support the 
notion of dose reduction in children, particularly neonates, with renal impairment and an estimated CrCl of 
30 mL/min/1.73 m2 or less. This finding is comparable to a prior study of 16 neonates with complex 
single-ventricle congenital heart disease undergoing cardiac surgery on CPB who received milrinone in 
the immediate perioperative settings.109 While the popPK model developed in this study did not 
incorporate a measure of renal function as a covariate, the authors observed a gradual increase of 
milrinone CL over time, which correlated with improvements in renal function. Based on their model, the 
authors recommended an infusion rate of 0.2 mcg/kg/min for infants with postoperative renal dysfunction. 
In the previously mentioned recent study of infants after cardiac surgery, the recommended infusion rate 
for those with KDIGO stage 3 criteria was 0.2 mcg/kg/min.112 Our dosing simulations arrived at a similar 
conclusion for infants (3 kg WT, 40 weeks PMA). In a toddler (13 kg WT, 144 weeks PMA), an infusion of 
0.5 mcg/kg/min reached a median Css at the upper limit of the therapeutic concentration range 
(300 ng/mL), suggesting that this dosing may be adequate. In all simulation scenarios where estimated 
CrCl was 60 mL/min/1.73 m2 or greater, a bolus dose of 50 mcg/kg followed by a continuous infusion of 
0.5 mcg/kg/min achieved plasma concentrations below the upper limit of the therapeutic concentration 
range. Overall, our proposed doses are within the range commonly used in critically ill infants and 
children.94,126,127  
Side effects associated with higher milrinone plasma concentrations in children are mostly 
unknown. In adults, plasma concentrations greater than 500 ng/mL have been associated with adverse 
events, including hypotension, arrhythmias, and thrombocytopenia.122,128,129 The POP01 study that 
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generated the data used in this analysis is not designed to rigorously capture adverse events. However, 
our simulations suggested that at the proposed dosing regimens, most infants would maintain milrinone 
Css below the 500-ng/mL cutoff.  
Despite its strengths, our study has several important limitations. Our model underpredicts higher 
milrinone plasma concentrations. The limited number of PK samples with high concentrations likely 
contributed to this bias. Despite a comprehensive covariate assessment, IIV variability on CL remains 
high in our final model (70%). While this value is comparable to popPK models of other drugs developed 
using opportunistically collected PK data, overprediction of IIV is evidenced by the VPC. We draw 
attention to this limitation by plotting simulated Css that incorporate IIV to demonstrate the range of 
concentrations that may be anticipated at a specific infusion rate for a child of given WT and age and 
estimated CrCl. This wide range is comparable to the dosing simulation results recently reported in infants 
after cardiac surgery.112 Of note, the model used for dosing simulations in that study was developed from 
a rich dataset of more than 1000 plasma samples in 92 infants. We calculated estimated CrCl using the 
modified bedside Schwartz equation. The simplicity of this calculation lends greater applicability to our 
model in clinical practice, but does carry with it the limitations of CrCl estimation based on this method. 
These limitations may be more pronounced in pediatric subpopulations including infants less than 2 years 
of age, obese children, and those supported with ECMO, all of which were included in our study cohort.  
Newer renal biomarkers may be more accurate and timely in the diagnosis of renal insufficiency and 
better take into consideration effects of renal dysfunction on active secretion of drugs, rather than 
glomerular filtration alone. We chose target plasma concentrations based on previously published cutoffs, 
but acknowledge that these are based on limited PD and efficacy data in this population.130 We are also 
unable to definitively comment on exposures associated with adverse events, as safety data were not 
comprehensively collected in our study. While some of these limitations may be overcome in a 
prospective PK, PD/efficacy, and safety trial of milrinone, consideration should also be given to the use of 
therapeutic drug monitoring for the titration of milrinone in children with or at risk for renal impairments, as 




We used opportunistic PK data from a cohort of children with a wide range of age and renal 
function to develop a pediatric popPK model for IV-administered milrinone. Our model is the first to 
incorporate estimated CrCl as a covariate on CL. Using our model for dosing simulations, we recommend 
that infants and small children with estimated CrCl of 30 mL/min/1.73 m2 or less receive infusions of 
0.25 mcg/kg/min. Future studies of milrinone in critically ill children should incorporate markers of renal 
function to further elucidate the complex relationship between dynamically changing renal function, 
maturation and growth, and milrinone exposure. 
PART 4. POPULATION PHARMACOKINETIC MODELING AND SIMULATIONS TO CHARACTERIZE 
PREDICTED EXPOSURE RESPONSE RELATIONSHIPS IN THE ELECTRONIC HEALTH RECORD  
 
Introduction 
Drug dosing is typically selected with the objective of achieving exposure that maximizes the 
likelihood of a favorable drug response, while minimizing the risk for toxicity.131,132 When drug exposure is 
highly variable, dose-safety relationships are likely to be confounded, and assessments of exposure are 
necessary to identify safety signals. Infants and children exhibit significant variability in drug exposure 
resulting from maturation of drug disposition pathways that may be further altered by the effects of 
systemic illness.133 As a result, comprehensive pediatric safety studies should incorporate consideration 
of the impact of drug dosing and exposure. 
Performing large-scale safety studies in children with drug concentration measurements from 
blood samples to characterize exposure is challenging and largely impractical.2 Limited blood volume, 
increased risk of phlebotomy, and lower consent rates in studies with invasive procedures relative to 
adults all hinder the completion of such studies. Alternatives to traditional exposures measurements are 
therefore needed.12 Population PK models can be used to predict individual drug exposures by taking into 
account the effects of dosing, subject characteristics, and the extent of interindividual and intraindividual 
variability.134,135 Exposures predicted from popPK models are routinely used to inform dosing of pediatric 
drugs approved by the FDA and other regulatory agencies based on efficacy thresholds established in 
adult or other pediatric populations. Similarly, using popPK models developed in a similar population may 
offer an alternative to invasive exposure measurements in safety studies.59  
 
 -134- 
The feasibility of using simulated exposures to characterize drug safety in children would be 
further enhanced if data needed to perform exposure predictions from popPK models were readily 
available and did not need to be prospectively collected. EHRs increasingly offer the ability to access 
precisely this type of information, collected for clinical purposes, and leverage it for research.29,136 EHR 
data have been previously used to characterize dose-safety relationships of drugs in children, but 
exposure assessments remain limited predominantly to drugs undergoing routine therapeutic drug 
monitoring with invasive plasma concentration measurement.37  
Here we leverage the available dosing and clinical data from the newly created multicenter EHR-
derived registry (Chapter 4, Part 1) and the 2 pediatric popPK models created from opportunistically 
collected PK data (Chapter 4, Parts 2 and 3) to predict exposures in children treated with milrinone or 
ketamine. We then use these predicted exposures to characterize their relationship with safety data 
collected in the EHR. For each drug, we selected a clinically important safety signal collected in the EHR: 
systemic desaturation (hypoxia) following ketamine administration and systemic hypotension (systolic and 
diastolic) following administration of milrinone.51,137 
Methods 
Data source and formatting 
From the EHR-derived registry, we identified all children 17 years of age or younger treated with 
ketamine or milrinone IV. For each inpatient encounter, we recorded all IV doses of either ketamine or 
milrinone received for a period of 24 hours after the first recorded dose. Demographic data, including GA, 
gender, age, WT, and height at the time of dosing were recorded for all subjects. In addition, we recorded 
available values for relevant covariates included in the popPK models for each drug, including the closest 
serum creatinine value measured before each dose was recorded, for subjects who received milrinone, 
and the dates and time of support with ECMO, when applicable, for subjects administered ketamine. For 
each drug dose included in the analysis, we captured drug amount administered and start and stop date 
and time of the infusion. Subjects with missing demographics and those without an available serum 
creatinine value before dosing with milrinone were excluded from the analysis, and we did not impute any 
clinical data. We estimated CrCl using the modified Schwartz equation.113 
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We collected all oxygen saturation measurements (in %), for subjects who received ketamine, 
and all systolic and diastolic blood pressure measurements (in mm Hg), for subjects who received 
milrinone, performed for up to 24 hours after the first dose of ketamine or milrinone. Dates and times of 
measurement of oxygen saturation (for ketamine-exposed subjects) or blood pressure (for milrinone-
exposed subjects) recorded in the EHR were also captured and used as the time points for exposure 
simulation.   
Exposure simulation 
We used the popPK models developed for ketamine (Chapter 4, Part 2) and milrinone (Chapter 4, 
Part 3) to simulate exposures in the subjects identified from the EHR. For the purpose of simulation, fixed- 
and random-effect parameters from the previously developed ketamine and milrinone popPK models 
were fixed at the final model estimates. IPREDs of ketamine or milrinone concentrations at each time 
point of assessment of oxygen saturation or blood pressure, respectively, were chosen to represent drug 
exposure, as these simulated values incorporated both the effects of clinical characteristics included as 
covariates in the PK model and the effects of remaining IIV. A sensitivity analysis was also performed 
wherein population predictions (PREDs) rather than IPREDs were used. All exposures simulations were 
performed using the software NONMEM (version 7.4.3, Icon Development Solutions, Ellicott City MD) 
with run management performed using Pirana (version 2.3.8).59 Because area under the concentration 
curve (AUC) targets for safety have been previously reported for ketamine in adults (AUC0-inf 3 mcg*h/mL 
in 12 critically ill adult subjects with brain or spinal cord injury), we also calculated in NONMEM the 
cumulative AUC at each time point for the subject’s exposure to ketamine according to the equation: 
𝐴𝐴𝐴𝐴𝐶𝐶𝐶𝐶𝑜𝑜𝑐𝑐 =  ∫ 𝐶𝐶𝑃𝑃𝐶𝐶𝐶𝐶
𝑊𝑊
0 . 
where Cp is the plasma concentration of ketamine and dt represents change over time from ketamine 
administration to each assessment time point. This calculation was not performed for subjects exposed to 
milrinone because safety targets previously reported for milrinone were all based on plasma 
concentrations at steady state only, rather than AUC.  
Statistical analysis 
Standard summary statistics, including counts (percentages), medians (range), and graphing 
techniques were used to characterize all study variables. When applicable, chi square, Fisher’s exact, 
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and Wilcoxon rank sum tests were used to compare categorical and continuous variable distributions 
between groups. Oxygen saturation cutoffs of 92% and 85% were chosen to represent mild and 
significant desaturation, respectively, for all age groups.138,139 Hypotension was defined as systolic blood 
pressure less than 70 mm Hg if PNA was less than 1 year and systolic blood pressure less than 
(70 + 2*PNA [years]) mm Hg for older children.140 Changes from baseline values before drug exposure 
were also calculated at each assessment time point when baseline values were available. We defined 
minimal saturation and systolic and diastolic blood pressure as the lowest values recorded during the 
observation period. We stratified unadjusted analyses by age, time after dose, and clinically relevant 
variables, including level of respiratory support received at the time of drug administration and plasma 
lactate concentrations as surrogate markers for inadequate tissue oxygen delivery at the time of milrinone 
dosing. We performed linear and logistic regressions to evaluate subject-level relationships between 
exposure measurements and systolic or diastolic blood pressure, hypotension, oxygen saturation, and 




We included 2022 children with a median (interquartile range) PNA of 3.1 years (0.8, 8.9) who 
received 4904 IV doses of ketamine at a median dose of 1 mg/kg (0.5, 1.2) (Table 4-13). The median 
simulated plasma concentration of ketamine was 218.2 ng/mL (69.3, 682.3) at a median of 2.3 hours (0.5, 
5.6) after the first dose. The median value of the highest plasma concentration of ketamine achieved in all 
subjects was 1489.8 ng/mL (675.9, 2794.1). The median cumulative AUC over the entire observation 
period was 1.8 ng*h/mL (1, 3.3). ECMO support was provided to 25/2022 (1%) subjects at the time of 
ketamine administration. 
Median baseline oxygen saturation was 98% (89, 100), with 450/2022 (22%) subjects with a 
recorded saturation of less than 85% at the time of ketamine administration. Only 163/2022 (8%) subjects 
received noninvasive or invasive respiratory support at the time of ketamine administration. The median 
of the lowest recorded saturation for each subject over the study period was 93% (88, 96), of which 
339/2022 (17%) had at least 1 recorded saturation less than 85%. 
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Table 4-13. Clinical data* of subjects exposed to ketamine 
 N = 2022 
Postnatal age, years 3.1 (0.8, 8.9) 
Weight, kg 14 (8, 28) 
Female sex 904 (45%) 
Supported with ECMO 25 (1%) 
Ketamine dosing in mg/kg 1 (0.5, 1.12) 
Number of doses per subject 2 (1, 3) 
Simulated plasma concentration, ng/mL 218.2 (69.3, 682.3) 
Simulated cumulative plasma AUC, ng*h/mL 1.8 (1.0, 3.3) 
Baseline oxygen saturation 98 (89, 100) 
Baseline respiratory support 
None/room air 
Nasal cannula, face mask, tent, or oxyhood 
High-flow nasal cannula 
Other noninvasive ventilation 




10 (< 1%) 
37 (2%) 
78 (4%) 
Saturation shift from normal baseline 
Remain normal 
To mild desaturation 





AUC, area under the curve; ECMO, extracorporeal membrane oxygenation 
*Data shown are median (range) or counts (%). 
 
Unadjusted scatter plots did not show a significant association between simulated plasma 
ketamine concentrations and oxygen saturations (Figure 4-14). This includes plotting the oxygen 
saturation at the time of maximum simulated plasma ketamine concentration, evaluating changes from 
baseline oxygen saturation, and plotting cumulative AUC. Plots were similar when stratified by age 
(Figure 4-15) and time after first dose (Figure 4-16). Results were similar when plotting PRED instead of 
IPRED (data not shown). 
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A  All simulated ketamine concentrations vs concomitant saturation 
 
 





C All simulated ketamine concentrations vs concomitant absolute change in oxygen 






D Cumulative area under the ketamine concentration-time profile vs concomitant oxygen 
saturation 
 
Oxygen saturation cutoff values of 92%, 88%, and 85% are depicted with horizontal red dashed lines. Ketamine 
plasma concentrations cutoffs previously associated with efficacy are shown with horizontal grey dashed lines. 
Figure 4-14. Association between simulated ketamine exposure and systemic oxygen 
saturations 
 





B > 1 month to 2 years of age 
 
 










E > 12 years of age 
 
Oxygen saturation cutoff values of 92%, 88%, and 85% are depicted with horizontal red dashed lines. Ketamine 
plasma concentrations cutoffs previously associated with efficacy are shown with vertical grey dashed lines. 
Figure 4-15. Association between simulated ketamine exposure and systemic oxygen 
saturations stratified by age 
 




B > 5 to 15 minutes after first dose 
 





D > 30 to 60 minutes after first dose 
 
E > 60 minutes after first dose 
 
Oxygen saturation cutoff values of 92%, 88%, and 85% are depicted with horizontal red dashed lines. Ketamine 
plasma concentrations cutoffs previously associated with efficacy are shown with vertical grey dashed lines. 
Figure 4-16. Association between simulated ketamine exposure and systemic oxygen 
saturations stratified by time after first dose 
 
We observed higher maximum plasma concentrations of ketamine in subjects with normal 
baseline saturation (> 92%) who had at least 1 documented saturation of less than 85% (median 
1831 ng/mL [836, 3249]) compared to those who maintained normal saturations throughout (median 
1481 ng/mL [694, 2747], p = 0.03). However, this association did not retain statistical significance in a 
multivariable analysis controlling for PNA and baseline level of respiratory support (Table 4-14). In this 
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analysis, however, higher cumulative AUC was associated with increased odds of progression to 
significant desaturation (< 85%), though the magnitude of the effect was minimal (7% higher odds with 
increasing cumulative AUC).  
Table 4-14. Adjusted association between highest simulated plasma ketamine concentration 
or cumulative area under the concentration time curve, and drop in oxygen saturation from 
normal at baseline to < 85% during the observational period 
 
Odds ratio 
(95 % CI) 
Maximum plasma ketamine concentration (ng/mL) 1.00 (0.99, 1.01) 
Cumulative AUC over the study period (ng*hr/mL) 1.07 (1.02, 1.12) 
AUC, area under the curve 
 
Milrinone 
We included 399 children with a median (interquartile range) PNA of 1 year (0, 5) who received 
428 IV doses of milrinone. The median infusion rate of milrinone was 0.31 mcg/kg/min (0.29, 0.5) (Table 
4-15). The median simulated plasma concentration of milrinone was 80.3 ng/mL (35.8, 148.6) at a median 
of 10.5 hours (4.8, 17.3) after the first dose. The median value of the highest plasma concentration of 
milrinone achieved in all subjects was 110.8 (18.5, 206.1), and 16/399 (4%) subjects had simulated 
plasma concentrations greater than 500 ng/mL, a cutoff previously associated with increased risk of 
adverse events, including hypotension, in adults.104 Median serum creatinine was 0.41 mg/dL (0.3, 0.6), 
and median estimated CrCl was 107 mL/min/1.73m2 (50, 145). Only 6/399 (2%) subjects met the FDA 
definition of severe renal impairment and had an estimated CrCl of less than 30 mL/min/1.73m2.  
Table 4-15. Clinical data of subjects exposed to milrinone 
 N = 398 
Postnatal age, years 1.0 (0.0, 5.0) 
Postmenstrual age, weeks 92 (40, 300) 
Weight, kg 8 (4, 17) 
Female sex 212 (53%) 
Milrinone infusion rate in mcg/kg/min 0.3 (0.29, 0.49) 
Number of doses per subject* 1.1 (1, 2) 
Simulated plasma concentration (all time points), ng/mL 80.3 (35.8, 148.6) 
Baseline systolic blood pressure 94 (77, 105) 
Baseline diastolic blood pressure 55 (46, 72) 
Baseline plasma lactate concentration in mg/dL 1.8 (1.3, 2.7) 
 
 -147- 
 N = 398 
Systolic blood pressure shift from normal baseline 
Remain normal 






*Doses per subject include bolus doses or adjustments of infusion rates. 
Median baseline systolic and diastolic blood pressures were 92 mm Hg (74, 105) and 50 mm Hg 
(39, 61), and 8/399 (2%) subjects met the definition of hypotension at the time of milrinone initiation. The 
median of the lowest systolic and diastolic blood pressures recorded for each subject over the study 
period were 74 mm Hg (60, 85) and 35 mm Hg (25, 42). At least 1 episode of hypotension occurred in 
185/399 (46%) subjects.  
Unadjusted scatter plots did not show a significant association between simulated plasma 
concentrations of milrinone and systolic and diastolic blood pressure (Figure 4-17). Plots were similar 
when repeated in the subset of infants (1 year of age) (Figure 4-18). Results were similar when plotting 
PRED instead of IPRED (data not shown).  




B All simulated milrinone plasma concentrations vs concomitant diastolic blood pressure 
 
C All simulated milrinone plasma concentrations vs concomitant absolute change in systolic 






D All simulated milrinone plasma concentrations vs concomitant absolute change in 
diastolic blood pressure from baseline 
 
 
Milrinone plasma concentrations cutoffs previously associated with efficacy are shown with horizontal red dashed 
lines. 
Figure 4-17. Association between simulated milrinone plasma concentration and systolic and 
diastolic blood pressure 
 
 




B All simulated milrinone plasma concentrations vs concomitant diastolic blood pressure 
 
C All simulated milrinone plasma concentrations vs concomitant absolute change in systolic 





D All simulated milrinone plasma concentrations vs concomitant absolute change in 
diastolic blood pressure from baseline 
 
Milrinone plasma concentration cutoffs previously associated with efficacy are shown with vertical red dashed lines. 
Figure 4-18. Association between simulated milrinone plasma concentration and systolic and 
diastolic blood pressure in infants < 1 year of age 
 
Predicted milrinone plasma concentrations did not differ between times of hypotension relative to 
those without hypotension (Figure 4-19). We also did not observe a significant difference in measured 
systolic or diastolic blood pressure when predicted milrinone plasma concentration was above the 
therapeutic threshold of 300 ng/mL (Figure 4-20). We did not observe higher maximum plasma 
concentrations of milrinone in subjects without hypotension at baseline who became hypotensive (median 
113 ng/mL [54, 192]) compared to those who maintained normal blood pressure throughout (median 
110 ng/mL [47, 206]), p = 0.83). Similarly, the proportion of subjects with hypotension did not differ 
between those whose simulated milrinone concentrations ever exceeded the toxicity threshold of 
500 ng/mL and those who did not—9/16 (56%) vs 176/383 (46%), p = 0.45. In multivariable regression 
adjusted for PNA, the highest simulated milrinone plasma concentration was not associated with the 
occurrence of hypotension (odds ratio 0.99, 95%; CI 0.99, 1.01). Finally, we compared milrinone 
exposures between children with episodes of clinically significant hypotension, defined as concomitant 
hypotension and plasma lactate elevation greater than 3 mg/dL. This combination of findings occurred in 
only 9/399 (2%) subjects. However, the highest simulated milrinone plasma concentrations were 
generally higher (median 281 ng/mL [171, 235]) in subjects with clinically significant hypotension 
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compared to subjects with hypotension without concomitant lactate elevation (107 ng/mL [50, 178]) and 
subjects who did not suffer an episode of hypotension (110 ng/mL [47, 207], p = 0.02) from the Kruskal 
Wallis test. However, this significance was not retained in the multivariable analysis (odds ratio 1.01 [95% 
CI; 0.99, 1.02], p = 0.06).   
 
The box represents 25th and 75th percentiles of the distribution, with the median displayed as a solid line within the 
box. The whiskers are 1.5x the interquartile range of the distribution, and outliers outside of the whiskers are omitted 
from the plot to improve clarity. The horizontal solid red lines display milrinone plasma concentrations previously 
associated with efficacy. 
Figure 4-19. Distribution of simulated milrinone plasma concentrations by presence or absence 




A Measured systolic blood pressure 
 
B Measured diastolic blood pressure 
 
The box represents 25th and 75th percentiles of the distribution, with the median displayed as solid line within the 
box. The whiskers are 1.5x the interquartile range of the distribution, and outliers outside of the whiskers are omitted 
from the plot to improve clarity. The horizontal solid red lines display systolic and diastolic blood pressure cutoffs of 
70 mm Hg and 30 mm Hg, respectively, which will commonly represent clinically significant hypotension. 
Figure 4-20. Measured systolic and diastolic blood pressure during times with vs without 
simulated milrinone plasma concentrations above the therapeutic threshold of 300 ng/mL 
 
Discussion 
We successfully linked predicted ketamine and milrinone exposures with safety events in children 
by combining data from an EHR-derived inpatient data repository with predicted exposures from popPK 
models. We simulated ketamine and milrinone concentrations within the range and variability of values 
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previously reported in this population. While we did not find a statistically significant relationship between 
predicted exposures for either drug and the safety events of interest, our results support the feasibility of 
our proposed approach: develop popPK models using opportunistically collected PK data and apply them 
to routinely collected data captured in the EHR to study exposure-safety relationships. This novel study 
design is cost effective, efficient, and minimizes risk by applying models to existing data and reducing the 
need for prospective plasma sampling.  
Respiratory decompensation resulting in systemic desaturation, primarily because of upper 
airway compromise, is the most common pediatric adverse event associated with ketamine 
administration, reported in 13 to 33% of children.141 We observed a similar prevalence of significant 
desaturation (< 85%) in our cohort, with 17% of subjects affected. The relationship between ketamine 
exposure and desaturations has not been well characterized. However, because desaturation occurs 
primarily as a result of loss of upper airway control and ability to clear oral secretions, it may be 
reasonable to assume that concentrations associated with anesthetic effects of ketamine (> 1500 ng/mL) 
would also be associated with this unwanted adverse event, though this relationship has never been 
demonstrated.50,71 Prior prospective studies assessing ketamine exposures and safety have been limited 
by small sample sizes, with typically fewer than 50 subjects enrolled per trial. Our novel approach resulted 
in a greater sample size than prior prospective trials of ketamine in children combined.51,142–146 Despite 
this advantage, we were still unable to find an association between ketamine systemic exposure and 
desaturation. Though we can only speculate as to why this is the case, we have to assume that despite 
our efforts to control for respiratory support in our analyses, additional interventions known to prevent 
desaturation associated with upper airway obstruction were performed on children exposed to ketamine.  
Manual airway repositioning, airway suctioning of secretions, and increased supplemental oxygen, among 
others, may have masked the relationship between exposures and desaturation and were not readily 
captured in our data repository. Alternatively, it is also conceivable that central nervous system, rather 
than plasma, exposures are correlated with changes in innervation of the muscles controlling the upper 
airway and the salivary glands producing airway secretions, both of which may ultimately lead to lack of 
airway control, laryngospasm, and desaturation. However, modern magnetic resonance imaging 
techniques have confirmed that ketamine plasma concentrations around 200 ng/mL are associated with 
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changes in thalamic and suprathalamic function.51 Studies evaluating the relationship between central 
nervous system exposures and safety are challenging to conduct and have not been reported to date, but 
opportunities may exist when cerebral-spinal-fluid sampling procedures are being performed, during 
which ketamine is administered for analgesia or sedation.  
Systemic hypotension is a clinically significant and well described adverse event associated with 
milrinone administration in adults and children.93,122,146 The largest prospective pediatric trial of milrinone 
conducted to date enrolled 238 children 0 to 6 years of age receiving milrinone at either low 
(0.25 mcg/kg/min) or high dose (0.75 mcg/kg/min) or placebo for the prevention of postoperative low 
cardiac output syndrome for up to 36 hours.137 In this study, systolic blood pressure decreased by almost 
10% within the first 4 to 8 hours of milrinone infusion at both low and high doses. However, only 2.6% and 
1.3% of the children in the high-dose and low-dose arms, respectively, suffered clinically significant 
hypotension. This estimate is lower than the prevalence we observed in our cohort, where 46% of 
children had at least 1 systolic blood pressure consistent with systemic hypotension. This discrepancy 
most likely highlights the challenges of our data-collection approach. Within the context of the clinical trial, 
clinically significant hypotension was defined based on a combination of blood pressure measurement 
and need for intervention. This is much different than capturing all recorded systolic blood pressure 
measurements as was done in our EHR-derived data repository. Under the latter circumstances, 
erroneous measurements, chronically low blood pressures, or intermittent and self-resolved episodes of 
hypotension related to other patient interventions (eg, repositioning of critically ill patients or 
administration of bolus doses of sedation) are all captured. Future analysis could be performed to identify 
hypotensive episodes associated with interventions to raise blood pressure, such as IV fluid bolus or 
inotropic medication administration, to help identify instances of clinically significant hypotension. It is 
worth noting that studying drug safety based on real-word data, as is done in the context of postmarketing 
surveillance systems, is a worthwhile endeavor that can yield meaningful data in addition to that collected 
within a clinical trial.147 Despite the obvious differences in data collection and analysis strategies, neither 
our analysis nor any previously conducted pediatric trials were able to definitely characterize the 
relationship between milrinone exposure and the occurrence of systemic hypotension. In adult 
populations, plasma concentrations of greater than 500 ng/mL have been associated with increased risk 
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of adverse events, including systemic hypotension.104 However, particularly in populations with cardiac 
dysfunction, the interplay between milrinone therapeutic effect, milrinone side effects, and underlying 
systemic and cardiovascular physiology, including fluid status and preload, are complex.146,148–150 
Because milrinone is both a positive inotrope and systemic vasodilator, it may in fact improve cardiac 
output and subsequently blood pressure in subjects with abnormally high systemic vascular resistance or 
those with abnormal myocardial contractility.100,151,152 As a result, large interpatient variability in milrinone 
exposure, including plasma concentrations greater than 500 ng/mL, have been found in pediatric PK trials 
without a demonstrable effect on safety profiles.110,112 Our study confirms these findings, with several 
instances of predicted milrinone concentrations above the 500-ng/mL threshold occurring in the context of 
normal systemic blood pressure. While our analysis did not account for all sources of bias that may mask 
a relationship between higher exposures and hypotension, including concomitant therapy with other 
inotropes, fluid resuscitation, and others, our findings do not support a strict exposure target for the 
prevention of hypotension. However, it is worth noting that prior studies have characterized exposure 
targets associated with efficacy (100-300 ng/mL) and showed that additional exposure did not confer 
further benefit.105,106 In the absence of a comprehensive study evaluating the exposure-toxicity 
relationship of milrinone in children, targeting plasma concentrations in the 100- to 300-ng/mL range may 
be reasonable, but our data do not suggest that more aggressive monitoring of plasma exposures 
through therapeutic drug monitoring or other methods would result in improved safety of milrinone in 
children.110,112 
Given the potential generalizability of our approach to other drugs, it is important to highlight 
additional overall limitations. Current methods of extracting data from the EHRs are mostly restricted to 
objective data points captured in individual fields. We performed a simple analysis of 2 integrated data 
points (hypotension and plasma lactate elevation) to capture a potential safety event of clinically 
significant hypotension with evidence of tissue hypoxemia and subsequent plasma lactate elevation in 
children exposed to milrinone. However, more complex safety events, for example the occurrence of 
emergence delirium, known to occur in approximately 5% of children but up to 30% of adults after 
ketamine therapy, would require a more comprehensive analysis of multiple complex EHR data points, 
including diagnoses documented in progress notes, pharmacologic and other interventions to treat 
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delirium, vital sign changes to assess its severity, and others. The development of natural language 
processing and other advanced artificial intelligence strategies is expected to increase our capability to 
interpret EHR data, but mostly remain in the development stages at this time.10,153 While exposure 
simulation is an attractive approach, it is certainly not as robust as actual concentration measurements 
and relies on the assumption that the developed PK model will adequately characterize the drug 
characteristics in the simulated population. In particular, the significant IIV that remained in the popPK 
models used for exposure simulations could mask actual relationships between exposures and safety 
events by introducing excessive variability in the simulations. To address this limitation, we did repeat 
predicted exposure-safety relationship assessment using population rather than individual predictions, 
which do not incorporate IIV into the simulation. Results of these analyses did not differ from the findings 
shown here using IPRED values. The EHR approach is also constrained by the timing of safety 
assessments performed per standard of care, which may further limit its ability to characterize safety 
profiles.  
Conclusions 
In conclusion, we successfully leveraged popPK models and EHR data to confirm the absence of 
a relationship between simulated plasma concentration of ketamine and milrinone and the occurrence of 
oxygen desaturation and systemic hypotension, respectively. Despite several limitations, these findings 
are consistent with prospectively collected data from prior studies and support the broader applicability of 
our novel, efficient, and cost-effective study design for the study of drug exposure response and drug 
exposure-safety relationships. Despite the overall success of our approach, we uncovered several 
important limitations, including model predictive performance limitations and timing of safety assessments 
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 SUMMARY AND FUTURE DIRECTIONS 
 
INTRODUCTION 
Reversing the dangerous trend of off-label drug prescribing in critically ill infants will require 
conducting efficient and comprehensive clinical trials in this vulnerable population.1,2 For these trials to 
succeed, innovative approaches in study design, conduct, and data analysis will be paramount.3,4 This 
dissertation presented 3 innovative pharmacometric strategies to address 3 specific limitations affecting 
drug trials during the design, analysis, and study conduct phases (Figure 5-1). 
 
Figure 5-1. Challenges and proposed solutions to infant drug trials 
 
Each innovation provided a direct solution to a specific problem encountered during the conduct 
of an actual clinical trial of a drug in critically ill infants. In addition, each innovation was sufficiently flexible 
and pragmatic to allow for its generalizability throughout infant drug development. The cornerstones of all 
3 proposed solutions were the innovative use of modeling and simulation and the leveraging of electronic 
health record (EHR)-derived real-world data (RWD) in infant drug development. Despite the strengths of 




their planning and execution. This final chapter will briefly summarize each proposed solution and 
highlight its strengths, limitations, and applicability to future drug development. 
TRIAL-SPECIFIC SAMPLE SIZE ESTIMATION 
Optimal sample size selection is an essential consideration during the design phase of all clinical 
trials.5 Sample size selection is of particular relevance for trials with anticipated enrollment challenges, as 
is the case in infants and neonates.6,7 At its core, sample size selection balances the requirements of 
feasibility, cost, and certain ethical considerations, with the required or desired degree of certainty of a 
study’s findings. While guidance and appropriate methods for sample size selection are well described for 
numerous trial and analysis designs, estimation of pediatric and infant PK trial sample size remains more 
challenging due to the multiple number of patient and trial-design factors to be considered and the 
complexity of the analysis method.8,9  
Aim 1 of this dissertation presented a sample size estimation approach based on population 
pharmacokinetic (popPK) modeling and simulation. The approach relied on combining existing popPK 
models with real-world datasets to conduct simulations aimed at characterizing the precision with which 
PK parameters could be estimated. By varying characteristics of the participants, as well as trial-design 
considerations, the approach predicted optimal sample size for several scenarios known to affect popPK 
model performance. 
Table 5-1. Strengths, limitations and future applicability of innovation in Aim 1 






• Straightforward to 
implement 
• Generalizable 
approach, not results 
• Requires popPK model 
and known 
characteristics of the 
population 
• Comparison across 
models with covariate 
effects 




popPK, population pharmacokinetics 
 
The key strengths of the approach included its pragmatic and flexible design, which allowed for 
modifying several input factors. In addition, the approach is straightforward to implement and while 
somewhat computationally burdensome, utilizes software tools routinely employed in drug development 
and pharmaceutical sciences research.  
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The essential limitation of the approach is that the method, and not its results, are the 
generalizable feature. Because simulations were used to compute individual PK parameter estimates 
from an existing popPK model in a specific clinical trial population, the results of these simulations are 
applicable only to the simulated scenario. In other words, the sample sizes estimated for the probe drugs 
meropenem and clindamycin in neonates may not directly apply to other probe drugs or other 
populations. However, the method is easily replicated if both a virtual population and a reference popPK 
model can be identified during the trial-design stage.  
The method can be expanded to incorporate additional and more complex design features, 
including comparisons of covariate effects of different magnitude and greater variability in PK sampling 
strategies. For example, different reference popPK models could be used to compare simulated sample 
size requirement between models with and without covariates, or with and without covariates of different 
effect magnitude, or with different covariate parameterization. In addition, the characteristics of the 
reference population can be almost endlessly modified to simulate new and innovative trial scenarios. For 
example, combinations of opportunistic or scavenged sparse PK samples and rich, timed PK samples 
could be simulated by varying the number of samples and introducing some element of random error into 
the sampling times, as is often the case when using opportunistically collected or scavenged samples. 
POPULATION PHARMACOKINETIC/PHARMACODYNAMIC MODELING IN INFANTS UNDERGOING 
CARDIOPULMONARY BYPASS 
 
When pediatric drug development relies on partial extrapolation of drug efficacy from adult data, a 
key consideration of the drug development process is to establish the exposure-response relationship.10 
Unfortunately, these relationships may be especially challenging to uncover in critically ill infants, where 
developmental and disease-related changes in physiologic functions can affect both drug disposition and 
response to therapy.11  
Aim 2 of this dissertation presented the development and application of 2 popPK/PD models to 
characterize the exposure-response relationship of methylprednisolone in neonates undergoing cardiac 
surgery on cardiopulmonary bypass (CPB). Using 2 inflammatory biomarkers (the proinflammatory IL-6 
and the antiinflammatory IL-10), 2 separate indirect-response popPK/PD models that incorporated infant 
and CPB-conducted characteristics were developed. Dosing simulations were then performed to identify 
the methylprednisolone dose associated with optimal antiinflammation in the 24 hours after the initiation 
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of CPB based on maximizing antiinflammatory IL-10 plasma exposures and minimizing proinflammatory 
IL-6 plasma exposures. 
Table 5-2. Strength, weakness, and future applicability of innovation in Aim 2 





















application for pretrial 
dose optimization  
PopPK/PD, population pharmacokinetics/pharmacodynamics 
 
The key strength of this approach is the ability to identify an optimal dose of methylprednisolone 
based on its effect on biomarker profiles in an infant population experiencing extensive physiologic 
alterations as a result of CPB.12–16 When studying drugs in such a high-risk and complex population, 
optimizing dose through modeling and simulation is an attractive approach.17 Unfortunately, 
methylprednisolone exposure targets during CPB have not been previously identified in children or adults. 
popPK/PD models offer a tool for simulation to optimize dosing under such circumstances. For the 
specific population of infants receiving methylprednisolone while undergoing CPB, the findings from Aim 2 
can be used to select the optimal dose for future study in efficacy trials.  
The essential limitations of our approach for this example are related to the significant variability 
in model parameter estimates and subsequent uncertainty in simulated methylprednisolone and IL-6 and 
IL-10 exposures. This variability stems from the characteristics of the population studied and the relative 
lack of data to delineate all responsible features. Specifically, we lacked sampling during the CPB phase 
to model the effects of intraoperative procedures and manipulations, such as ultrafiltration and targeted 
organ perfusion, which may alter both drug distribution and overall levels of inflammation.18  
PopPK/pharmacodynamic (PD) modeling has broad applicability to future drug development in 
critically ill infants. In this population, dose optimization is essential to achieve study success and 
minimize harm associated with overdosing or underdosing. Because of the complexity of infant critical 
illness, exposure targets are rarely known, further enhancing the applicability of popPK/PD modeling. The 
key obstacle to more widespread use of this pharmacometric method is the availability of sufficient data to 
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develop the model. Therefore, systematic efforts to collect drug response biomarkers in critically ill infants 
are needed to achieve broader use of popPK/PD modeling and simulation and infant drug development. 
Fortunately, critically ill infants undergo extensive physiologic monitoring during the course of their 
hospitalization, which provides an opportunity for the collection of standard of care and potentially study-
specific biomarker sampling. 
ELECTRONIC HEALTH RECORD-POPULATION PHARMACOKINETIC MODELING PLATFORM FOR 
DRUG SAFETY 
 
Safety trials are an essential component of pediatric drug development. Even when efficacy can 
be fully extrapolated from adult studies, population-specific safety studies in infants and children are 
required by the Food and Drug Administration (FDA) to support labeling.10 To identify rare drug-safety 
events, large sample sizes are needed. Because of the challenges of enrolling infants in clinical trials, and 
because off-label drug use in infants is common, drug safety is often retrospectively extracted from RWD 
sources such as the EHR.19 A key limitation of EHR-based drug-safety assessments is the lack of 
available drug exposure data to characterize the exposure-safety relationship.  
Aim 3 of this dissertation presented a novel and efficient platform to study exposure-safety 
relationships of drugs in infants. Using popPK models developed from opportunistically collected PK data, 
we simulated drug exposures in a large infant dataset derived from EHRs. This approach allowed us to 
characterize the exposure-safety relationship not otherwise attainable through a traditional clinical trial 
approach, of 2 drugs, in large cohorts of infants. 
Table 5-3. Strengths, weaknesses, and future applicability of innovation in Aim 3 
Solution Strengths Weaknesses Future applications 
• PopPK & electronic 
health record 
platform 






• Reliance on 
clinical data  
• Exposure-efficacy 
relationships 
• Complex clinical data 
interpretation through 
machine learning 
• Systems biology modeling  
PopPK, population pharmacokinetics 
 
The key strengths of this approach include its efficiency, cost-effectiveness, practicality, and 
generalizability to the study of all drugs administered during routine clinical care and for which safety 
events of interest are captured in the EHR. Cost and other feasibility considerations would preclude the 
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conduct of a prospective safety trial of similar size. Further, the safety events collected within the EHR are 
RWD safety data, which may be more representative of an actual drug safety profile.  
The essential limitations of our approach are the reliance on exposure simulations, rather than 
actual measured drug concentrations and the limitations inherent to EHR-derived data. Exposure 
simulations were performed using popPK models and included between-subject and residual variability 
not otherwise attributable to infant characteristics. This variability may have masked underlying exposure-
safety relationships. Certain safety events are difficult to capture from the EHR, especially more complex 
causal relationships where drug overexposure leads to subsequent events, which ultimately results in an 
unwanted toxicity. We therefore focused our analysis on vital-sign changes, an objective measurement 
routinely captured in EHRs, but were unable to capture more complex safety events.  
The use of EHRs, and other sources of RWD, in drug development will continue to expand.20 As 
a vast and rich source of clinical data, EHRs have the potential to revolutionize trial design and conduct. 
The proposed platform links traditional PK studies to the EHRs. As more advanced methodologies based 
on artificial intelligence and machine learning continue to be developed and implemented, opportunities to 
study more complex predicted exposure-safety and exposure-efficacy relationships will arise.21–24 EHRs 
may also provide essential data to develop more complex disease and systems biology models, which 
could be linked to predicted drug exposures to enhance their utility in drug development. 
CONCLUSION 
The work presented in this dissertation presents 3 practical solutions to overcome infant drug-
development challenges based on advanced pharmacometric methods. Each proposed solution has both 
immediate impact and future application potential. In its totality, it illustrates the power of pharmacometric 
innovations to advance drug development toward the study of more complex and vulnerable populations. 
As drug development in both children and adults evolves towards the study of more targeted and 
powerful therapeutics in more complex and vulnerable populations, pharmacometric methods and 






1.  Laughon MM, Benjamin DK. Mechanisms to provide safe and effective drugs for children. 
Pediatrics. 2014;134(2):e562-563. doi:10.1542/peds.2014-1585 
2.  Ward RM, Benjamin DK, Davis JM, et al. The Need for Pediatric Drug Development. J Pediatr. 
2018;192:13-21. doi:10.1016/j.jpeds.2017.08.011 
3.  Gonzalez D, Paul IM, Benjamin DK, Cohen-Wolkowiez M. Advances in pediatric pharmacology, 
therapeutics, and toxicology. Adv Pediatr. 2014;61(1):7-31. doi:10.1016/j.yapd.2014.03.005 
4.  Abdel-Rahman SM, Reed MD, Wells TG, Kearns GL. Considerations in the rational design and 
conduct of phase I/II pediatric clinical trials: avoiding the problems and pitfalls. Clin Pharmacol Ther. 
2007;81(4):483-494. doi:10.1038/sj.clpt.6100134 
5.  Bagiella E, Chang H. Power analysis and sample size calculation. J Mol Cell Cardiol. January 2019. 
doi:10.1016/j.yjmcc.2019.01.006 
6.  van der Lee JH, Wesseling J, Tanck MW, Offringa M. Sequential design with boundaries approach 
in pediatric intervention research reduces sample size. J Clin Epidemiol. 2010;63(1):19-27. 
doi:10.1016/j.jclinepi.2009.07.005 
7.  Nikolakopoulos S, Roes KCB, van der Lee JH, van der Tweel I. Sample size calculations in 
pediatric clinical trials conducted in an ICU: a systematic review. Trials. 2014;15:274. 
doi:10.1186/1745-6215-15-274 
8.  Wang Y, Jadhav PR, Lala M, Gobburu JV. Clarification on precision criteria to derive sample size 
when designing pediatric pharmacokinetic studies. J Clin Pharmacol. 2012;52(10):1601-1606. 
doi:10.1177/0091270011422812 
9.  Salem F, Ogungbenro K, Vajjah P, Johnson TN, Aarons L, Rostami-Hodjegan A. Precision criteria 
to derive sample size when designing pediatric pharmacokinetic studies: which measure of 
variability should be used? J Clin Pharmacol. 2014;54(3):311-317. doi:10.1002/jcph.206 
10.  Dunne J, Rodriguez WJ, Murphy MD, et al. Extrapolation of adult data and other data in pediatric 
drug-development programs. Pediatrics. 2011;128(5):e1242-1249. doi:10.1542/peds.2010-3487 
11.  Zuppa AF, Barrett JS. Pharmacokinetics and pharmacodynamics in the critically ill child. Pediatr 
Clin North Am. 2008;55(3):735-755, xii. doi:10.1016/j.pcl.2008.02.017 
12.  van Saet A, de Wildt SN, Knibbe CAJ, Bogers ADJJC, Stolker RJ, Tibboel D. The effect of adult and 
pediatric cardiopulmonary bypass on pharmacokinetic and pharmacodynamic parameters. Curr Clin 
Pharmacol. 2013;8(4):297-318. 
13.  Tortorici MA, Kochanek PM, Poloyac SM. Effects of hypothermia on drug disposition, metabolism, 
and response: A focus of hypothermia-mediated alterations on the cytochrome P450 enzyme 
system. Crit Care Med. 2007;35(9):2196-2204. 
14.  Kagawa H, Morita K, Uno Y, et al. Inflammatory response to hyperoxemic and normoxemic 
cardiopulmonary bypass in acyanotic pediatric patients. World J Pediatr Congenit Heart Surg. 
2014;5(4):541-545. doi:10.1177/2150135114551029 
15.  Cavarocchi NC, Pluth JR, Schaff HV, et al. Complement activation during cardiopulmonary bypass. 
Comparison of bubble and membrane oxygenators. J Thorac Cardiovasc Surg. 1986;91(2):252-258. 
 
 -176- 
16.  Andersson LG, Bratteby LE, Ekroth R, et al. Renal function during cardiopulmonary bypass: 
influence of pump flow and systemic blood pressure. Eur J Cardio-Thorac Surg Off J Eur Assoc 
Cardio-Thorac Surg. 1994;8(11):597-602. 
17.  Zuppa AF, Nadkarni VM. Recent developments in the pharmacologic approach to pediatric critical 
care. Curr Opin Anaesthesiol. 2004;17(3):223-228. 
18.  Chew MS, Brix-Christensen V, Ravn HB, et al. Effect of modified ultrafiltration on the inflammatory 
response in paediatric open-heart surgery: a prospective, randomized study. Perfusion. 
2002;17(5):327-333. doi:10.1191/0267659102pf595oa 
19.  Mulugeta LY, Yao L, Mould D, et al. Leveraging Big Data in Pediatric Development Programs: 
Proceedings From the 2016 American College of Clinical Pharmacology Annual Meeting 
Symposium. Clin Pharmacol Ther. 2018;104(1):81-87. doi:10.1002/cpt.975 
20.  Sutherland SM, Kaelber DC, Downing NL, Goel VV, Longhurst CA. Electronic Health Record-
Enabled Research in Children Using the Electronic Health Record for Clinical Discovery. Pediatr 
Clin North Am. 2016;63(2):251-268. doi:10.1016/j.pcl.2015.12.002 
21.  Zhao J, Henriksson A, Asker L, Boström H. Predictive modeling of structured electronic health 
records for adverse drug event detection. BMC Med Inform Decis Mak. 2015;15 Suppl 4:S1. 
doi:10.1186/1472-6947-15-S4-S1 
22.  Velupillai S, Mowery D, South BR, Kvist M, Dalianis H. Recent Advances in Clinical Natural 
Language Processing in Support of Semantic Analysis. Yearb Med Inform. 2015;10(1):183-193. 
doi:10.15265/IY-2015-009 
23.  Richesson RL, Sun J, Pathak J, Kho AN, Denny JC. Clinical phenotyping in selected national 
networks: demonstrating the need for high-throughput, portable, and computational methods. Artif 
Intell Med. 2016;71:57-61. doi:10.1016/j.artmed.2016.05.005 
24.  Adam NR, Wieder R, Ghosh D. Data science, learning, and applications to biomedical and health 






APPENDIX 1: EXAMPLE NONMEM CODE USED FOR SAMPLE SIZE SIMULATION FOR 
MEROPENEM  
 
;; 1. Based on: merobasemodel 
;; 2. Description: Aim#1.1.1 Meropenem 'base' N=2 
;; x1. Author: user 
$PROB CPH DAim#1 Meropenem 'base' model on virtual population of term infants with 6-7 samples 
 
$INPUT CKEEP ID GA BWT SEX PNA CAT FCAT SCR ALB CWT TIME AMT
 RATE DV MDV BQL EVID DOSN 
 
 
$DATA mero_term111_v004.CSV IGNORE=C  
 






























































Y=W + W*ERR(1);+ERR(2) 






   (0.1,0.3); V 
      (0.001, 0.1); CL    
      ;(-1,0.5); COVAR2 
 
;$OMEGA  
; 0.50 ETA_V 
;$OMEGA 0.09; ETA_CL 
  
;$OMEGA BLOCK (2)  
;    0.50 ;ETA_V 
;    0.09 0.05 ;ETA_CL 
 
$OMEGA BLOCK (2)  
 0.01 ;ETA_V 







$SIML (123478) BOOTSTRAP=2 SUBP=1000  NOREPLACE STRAT=CAT STRATF=FCAT 






$TABLE ID TIME DV IPRED PRED CWRES CL V CLKG VKG ETA1 ETA2 KE HFLF GA SEX PNA 
NOPRINT NOAPPEND FILE=merobase_term111_dir1.csv 
 
 -179- 
$TABLE ID TIME DV WRES IPRED PRED CWRES NOPRINT ONEHEADER FILE=sdtab111 
$TABLE ID CL V CLKG VKG ETA1 ETA2 NOPRINT ONEHEADER FILE=patab111 
$TABLE ID WTKG PNA NOPRINT ONEHEADER FILE=cotab111 





APPENDIX 2: EXAMPLE NONMEM CODE USED FOR SAMPLE SIZE SIMULATION FOR 
CLINDAMYCIN   
 
;; 1. Based on: clindabase 
;; 2. Description: Aim#2.1.1 clindamycin base N=18 
;; x1. Author: user 




$INPUT C ID WTKG DV TIME AMT RATE
 GA PNA PMAW AAG ALB
 DOSEMGKG EVID EDUR DOSEN













$SUBROUTINE ADVAN1 TRANS2 
$PK  
 
;ALLOMETRICALLY SCALE CL 










;POWER FUNCTION WITH ALBUMIN 
;NEWALB=ALB 




;POWER FUNCTION - AAG  
;NEWAAG=AAG 




























(0, 10)     ;CL 
(0, 70)     ;V 
;(39.5)FIX    ;TM50 
;(0,3.1)     ;HILL 
;(-1.04)     ;EXP1 







0.0134 FIX ;  ETA_V 
 
$SIGMA  
1.13  ;RESID_CCV 
 
$SIML (12345)(67891) BOOTSTRAP=18 SUBP=1000  NOREPLACE STRAT=CAT STRATF=FCAT 




$TABLE ID TIME DV IPRED PRED CWRES CL V CLKG VKG ETA1 ETA2 KE HFLF GA SEX PNA 
NOPRINT NOAPPEND FILE=clindabase_term211_dir1.csv 
$TABLE ID TIME DV WRES IPRED PRED CWRES NOPRINT ONEHEADER FILE=sdtab211 
$TABLE ID CL V CLKG VKG ETA1 ETA2 NOPRINT ONEHEADER FILE=patab211 
$TABLE ID WTKG PNA NOPRINT ONEHEADER FILE=cotab211 





APPENDIX 3: NONMEM CODE FOR THE FINAL METHYLPREDNISOLONE POPULATION 
PHARMACOKINETIC MODEL 
 
;; 1. Based on: run79_002_003 
;; 2. Description: rerun79_002_003 + changed boundary 
;; x1. Author: user 
;Project Name: Methylprednisolone 
 
$PROB 79_002_005 CMP; SIZE ADJUSTMENT 
 
$INPUT  
KEEP ORDN=DROP ID TIMEPOINT=DROP OCC DAE=DROP TAFD=TIME TALD PERIOD=DROP DV 
MDV BQL=DROP DOSK=DROP DOSN=DROP WTKG AMT DUR=DROP RATE CMT EVID 
RACE=DROP SEX=DROP GAW PNADY PMAW STA1 STA2 STA3 CPBTIME LFLOW CROSTIME 























TVQ = THETA(3)*ASCL 
Q  = TVQ*EXP(ETA(3)) 
 
TVV3 = THETA(4)*LSV 
V3 = TVV3 
V3KG=V3/WTKG 
 
KA = THETA(5) 
 


















(0, 3) ; CL 
(0, 13); V2 
(0, 0.1) ; Q 
(3, 5, 20) ; V3 
(0, 2) ; KA 
(0, 0.75) ; WT on CL 















$TABLE ID TIME TALD DV WRES IPRED PRED CWRES IWRES NOPRINT ONEHEADER 
FILE=sdtab79_002_005 
$TABLE ID CL V2 CLKG V2KG ETA1 ETA2 ETA3 STA1 STA2 STA3 PNADY PMAW GAW CPBTIME 
LFLOW CROSTIME LFTIME DHCA T12 NOPRINT ONEHEADER FILE=patab79_002_005 





APPENDIX 4: NONMEM CODE FOR THE FINAL METHYLPREDNISOLONE/INTERLEUKIN-6 
POPULATION PHARMACOKINETIC/PHARMACODYNAMIC MODEL 
 
;; 1. Based on: run215_005_010_002 
;; 2. Description: rerun215_005_010_002 + RANK on CPBEFFECT noID25and31 
;; x1. Author: user 
;Project Name: Methylprednisolone PK/PD for IL6 
;Modeler:  
 
$PROB 215_005_024_002 CMP; SIZE ADJUSTMENT 
 
$INPUT  
KEEP ORDN=DROP ID POINT OCC DAE=DROP TAFD=TIME TALD PERIOD=DROP DVC=DRO 
PMDV BQL=DROP DOSK=DROP DOSN=DROP WTKG AMT DUR=DROP RATE CMT EVID 
RACE=DROP SEX=DRO PGAW PNADY PMAW STA1 STA2 STA3 CPBTIME LFLOW CROSTIME 
LFTIME DHCA CRGROUP STGROUP DV IL10 ET1 ET2 ET3 YNUM=DROP CPBSTART RANK 








$SUBR ADVAN6 TRANS1 TOL=5 
$MODEL COMP=(DEPOT) COMP=(CENTRAL) COMP=(PERIP1) COMP=(PD) 
 
$PK 




IF (CROSTIME.EQ.10000) CRC=0 
DHC=1 




IF (RANK.GE.4) RANKN=1 
 
 








TVQ = THETA(3)*ASCL 
Q  = TVQ*EXP(ET3) 
 
TVV3 = THETA(4)*LSV 





KA = THETA(5) 
 








;******Structural PD parameters*****/ 
STRT=1 
IF (POINT.LT.2.5) STRT=0 
ENDT=1 











IMAX = THETA(8)*EXP(ETA(1)) ;/(1+THETA(8)*EXP(ETA(1))) 












;set initial condition 
 








DADT(2)=KA*A(1)-CL*C2 + Q*C3 - Q*C2  









EFF = A(4) 
 










(3.888 FIX) ; CL 
(8.848 FIX); V2 
(0.0868 FIX) ; Q 
(11.58 FIX) ; V3 
(0.405 FIX) ; KA 
(1.245 FIX) ; WT on CL 
(-0.467 FIX) ; CPBTIME on CL 
(1 FIX)   ; IMAX THETA(8) as fraction 
(0, 1) ; IC50 THETA(9) in ng/mL 
(0, 10)   ; R0 THETA(10) 
(0, 0.462)   ; KOUT THETA(11) 
(0, 1)   ; HILL THETA(12) 
(1, 200) ; CPBEFFECT ON KIN 
(0, 50, 100) ;PERCENT 
(0, 9.6) ;CPBH 
(0, 1.5) ;RANK>=4 
 
$OMEGA  
0 FIX ;BSVEMAX 
0 FIX ;SC50 
0.2 ;BSVE0 
0 FIX ; KOUT 
0 FIX ; BSVHILL 
0.2 ; BSVCPB 





;$SIMULATION (12345678) ONLYSIM SUBPROBLEMS=1 




$TABLE ID EVID TIME POINT TALD AMT EFF IMAX IC50 BASE KOUT KIN HILL CPBEFFECT CP DV 
CPBV IPRED CWRES IRES IWRES CL V2 Q NOPRINT ONEHEADER FILE=sdtab215_005_024_002 
$TABLE ID TAFD POINT ETA3 ETA6 IMAX IC50 BASE KOUT KIN HILL CPBEFFECT PER PMAW 







APPENDIX 5: NONMEM CODE FOR THE FINAL METHYLPREDNISOLONE/INTERLEUKIN-10 
POPULATION PHARMACOKINETIC/PHARMACODYNAMIC MODEL 
 
;; 1. Based on: run206_007_015_003 
;; 2. Description: rerun206_007_015_003  + PMA on CPB effect 
;; x1. Author: user 
;Project Name: Methylprednisolone 
;Modeler:  
 





















































$SUBR ADVAN6 TRANS1 TOL=5 
$MODEL COMP=(DEPOT) COMP=(CENTRAL) COMP=(PERIP1) COMP=(PD) 
 
$PK 




IF (CROSTIME.EQ.10000) CRC=0 
STA4=STA2+STA3 
 








TVQ = THETA(3)*ASCL 
Q  = TVQ*EXP(ET3) 
 
TVV3 = THETA(4)*LSV 
V3 = TVV3 
V3KG=V3/WTKG 
 
KA = THETA(5) 
 








;******Structural PD parameters*****/ 
STRT=1 
IF (POINT.LT.2.5) STRT=0 
ENDT=1 






IF (TACPBS.GT.0.5) CPBES=1 
 
EMAX = THETA(8)*EXP(ETA(1)) 






















DADT(2)=KA*A(1)-CL*C2 + Q*C3 - Q*C2  
DADT(3)= -Q*C3 + Q*C2 







EFF = A(4) 
 






Y = EFF*EXP(ERR(1)) 
 
$THETA 
(3.888 FIX) ; CL 
(8.848 FIX); V2 
(0.0868 FIX) ; Q 
(11.58 FIX) ; V3 
(0.405 FIX) ; KA 
(1.245 FIX) ; WT on CL 
(-0.467 FIX) ; CPBTIME on CL 
(0, 1.47)   ; EMAX THETA(1) as fraction 
(0, 1) ; EC50 THETA(2)  
(0, 1.58)   ; BASE THETA(3) 
(0, 0.462)   ; KOUT THETA(11) 
(0, 2, 10) ; HILL 
(0, 40) ; CPB on KIN 
(0, 1.6) ; PMA on CPB effect 
 
$OMEGA 0.2 ;BSVEMAX 
$OMEGA 0 FIX ;BSVEC50 
$OMEGA 0.1 ;BSVE0 
$OMEGA 0 FIX ; BSVKOUT 
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$OMEGA 0 FIX ; BSVHILL 






;$SIMULATION (12345678) ONLYSIM SUBPROBLEMS=1 




$TABLE ID EVID TIME TALD POINT AMT CP EFF EMAX EC50 BASE DV CPBV IPRED CWRES IRES 
IWRES NOPRINT ONEHEADER FILE=sdtab206_007_015_003_002 
$TABLE ID TAFD POINT EMAX EC50 BASE KOUT HILL CPBEFFECT PMAW GAW PNADY CPBTIME 





APPENDIX 6: NONMEM CODE FOR THE FINAL KETAMINE POPPK MODEL   
;; 1. Based on: run36 
;; 2. Description: Run 41: run36 with ECMO on CL 
;; x1. Author: user 
$PROBLEM run41 Ketamine Combined 
  
$DATA ketamine_combined_20160615.csv IGNORE=C 
$INPUT C ORDN ID PROT WT BMI PBMI PNAYR PMAYR GAW SCR ALB AST ALT DBIL TBIL SEX 
OBESE RACE TIME TALD AMT DUR RATE CMT DV LNDV MDV BQL EVID ECMO SURG INDIC 
RACE2 RACEWH RACEB RACEA 
   








































IF (PROT.EQ.1) THEN 





IF (PROT.EQ.2) THEN 




(0, 2.23) ;POPKA 2.6 hour-1 (Brunette) 
(0, 51.8) ;POPCL CL=L/70kg/h  (Herd) 
(0, 32.2) ;POPV V2=L/70kg   (herd) 
(0, 61.9) ; POPQ = L/70kg/h (Herd) 
(0, 143) ; POPV3 = L/70kg    (Herd) 
(0, 0.49,1) ; POPF1  
(0, 1.2) ; ECMO 
 
$OMEGA 





 0 FIX  ; IIV (F1) 
 
$SIGMA 
 0.222 ;POPS data proportional error 
 0.026 ; SING data proportional error 
 







$TABLE ID PROT TIME DV WRES IPRED PRED CWRES NOPRINT ONEHEADER FILE=sdtab41 
$TABLE ID KA CL V2 V3 Q F1 CLKG V2KG V3KG ETA1 ETA2 ETA3 ETA4 ETA5 NOPRINT 
ONEHEADER FILE=patab41 
$TABLE ID PROT WT PNAYR BMI ECMO RACE NOPRINT ONEHEADER FILE=cotab41 
$TABLE ID PROT ECMO SEX OBESE RACE FILE=catab41 
$TABLE ID PROT TIME TALD AMT EVID DV MDV IPRED PRED CWRES KA CL V2 V3 Q F1 CLKG 
V2KG V3KG ETA1 ETA2 ETA3 ETA4 ETA5 K HFLF 






APPENDIX 7: NONMEM CODE FOR THE FINAL MILRINONE POPPK MODEL   
;; 1. Based on: run60 
;; 2. Description: 1-compartment final model drop outlier MF estimates + CRCL for BS 
;; x1. Author: user 
$PROBLEM run61 Milrinone POPS 
 
$INPUT C ORDN ID WT BMI PBMI PNAYR PMAYR GAW SCR CRCL ALB AST ALT DBIL TBIL SEX 
OBESE RACE TAFD=TIME TALD AMT DUR RATE CMT=DROP DV PKT LNDV MDV BQL EVID ECMO 




 IGNORE=(DV.GE.2000) ; outlier not solved despite query 
 IGNORE=(MATRIX.EQ.3) ; LPS only 
  






; IMPUTE CRCL  
NEWCRCL=CRCL 
IF (CRCL.LE.0) NEWCRCL=110 
 
































(0, 9.25) ; CL 2.42mL/kg/min  
(0, 30.2) ; V  
(0, 47.7) ; TM50 GFR maturation in PMAweeks Rhodin 
(0, 3.4)  ; Hill GFR Maturation in PMAweeks Rhodin 





 0, FIX  ; 
 
$SIGMA 
 0.101 ;data proportional error 
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